Tricyclopyrazole derivatives

ABSTRACT

Compounds which are tricyclopyrazole derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, viral infection, prevention of AIDS development in HIV-infected individuals, cell proliferative disorders, autoimmune and neurodegenerative disorders; also disclosed is a process under Solid Phase Synthesis conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.

CROSS REFERENCES TO RELATED APPLICATIONS

The present application is a divisional of a co-pending application having U.S. Ser. No. 13/512,904, filed on Jul. 17, 2012, which is a 371 of International application having Serial No. PCT/EP2010/068129, filed on Nov. 24, 2010, which claims benefit of European Patent Application No. 09178074.2, filed on Dec. 4, 2009, the contents of all of which are incorporated herein by reference.

The present invention relates to certain substituted derivatives of tricyclopyrazole compounds, which modulate the activity of protein kinases. The compounds of this invention are therefore useful in treating diseases caused by dysregulated protein kinase activity. The present invention also relates to methods for preparing these compounds, combinatorial libraries thereof, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

The malfunctioning of protein kinases (PKs) is the hallmark of numerous diseases. A large share of the oncogenes and proto-oncogenes involved in human cancers code for PKs. The enhanced activities of PKs are also implicated in many non-malignant diseases, such as benign prostate hyperplasia, familial adenomatosis, polyposis, neurofibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis.

PKs are also implicated in inflammatory conditions and in the multiplication of viruses and parasites. PKs may also play a major role in the pathogenesis and development of neurodegenerative disorders.

For general reference to PKs malfunctioning or disregulation see, for instance, Current Opinion in Chemical Biology 1999, 3, 459-465 and Carcinogenesis 2008, 29, 1087-191.

Substituted hexahydroarylquinolizine derivatives useful as antidiabetics, antidepressants, antihypertensives, and inhibitors of blood platelet aggregation, are disclosed in EP154142 A in the name of Merck and Co.

Synthesis of 1H-imidazo[1,2-a]pyrazolo[3,4-c]pyridine derivatives are described in Chemical & Pharmaceutical Bulletin (1990), 38(9), 2352-6, without reporting any biological activity.

Tricyclic 5,6-dihydro-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine derivatives as phosphodiesterase inhibitors useful for the treatment of an inflammatory condition, asthma, arthritis, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, dermatitis as well as AIDS, septic shock and other diseases, such as cachexia, are disclosed in WO9639408 in the name of Pfizer Inc.

Pyrrolo[2,1-a]isoquinolines, pyrrolo[1,2-a]quinolines, pyrrolo[2,1-a]isobenzazepines, and pyrrolo[1,2-a]benzazepines derivatives endowed with antineoplastic activity are described in Journal of Medicinal Chemistry (1988), 31(11), 2097-102.

Pyrrolo[2,1-a]isoquinolines as phosphodiesterase 10a inhibitors useful for treating cancer, are disclosed in WO2002048144 in the name of Bayer Aktiengesellschaft.

The present inventors have now discovered that the new compounds of formula (I), described below, are kinase inhibitors and are thus useful in therapy as antitumor agents.

Accordingly, a first object of the present invention is to provide a tricyclic compound represented by formula (I):

wherein n is 0 or 1; R1, R2 and R4, each independently one from the other, are selected from the group consisting of —R^(a), —COR^(a), —CONHR^(a), —SO₂R^(a) and —COOR^(a); R3 is a group —NR^(a)R^(b) or —OR^(a); wherein R^(a) and R^(b), the same or different, are each independently hydrogen or a group optionally substituted, selected from straight or branched C₁-C₆ alkyl, straight or branched C₂-C₈ alkenyl, straight or branched C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, cycloalkyl C₁-C₆ alkyl, heterocyclyl, heterocyclyl C₁-C₆ alkyl, aryl, aryl C₁-C₆ alkyl, heteroaryl and heteroaryl C₁-C₆ alkyl or, taken together with the nitrogen atom to which they are bonded, either R^(a) and R^(b), may form an optionally substituted 3 to 8 membered heterocycle, optionally containing one additional heteroatom or heteroatomic group selected from S, O, N or NH, and pharmaceutically acceptable salts thereof.

The present invention also provides methods of synthesizing the substituted compounds, represented by formula (I), prepared through a synthetic process comprising well known reactions carried out according to conventional techniques, as well as through an extremely versatile solid-phase and/or combinatorial process.

The present invention also provides a method for treating diseases caused by and/or associated with dysregulated protein kinase activity, particularly ABL, ACK1, AKT1, ALK, AUR1, AUR2, BRK, BUB1, CDC₇/DBF4, CDK2/CYCA, CHK1, CK2, EEF2K, EGFR1, EphA2, EphB4, ERK2, FAK, FGFR1, FLT3, GSK3beta, Haspin, IGFR1, IKK2, IR, JAK1, JAK2, JAK3, KIT, LCK, LYN, MAPKAPK2, MELK, MET, MNK2, MPS1, MST4, NEK6, NIM1, P38alpha, PAK4, PDGFR, PDK1, PERK, PIM1, PIM2, PKAalpha, PKCbeta, PLK1, RET, ROS1, SULU1, Syk, TLK2, TRKA, TYK, VEGFR2, VEGFR3, ZAP70.

A preferred method of the present invention is to treat a disease caused by and/or associated with dysregulated protein kinase activity selected from the group consisting of cancer, viral infection, prevention of AIDS development in HIV-infected individuals, cell proliferative disorders, autoimmune and neurodegenerative disorders.

Another preferred method of the present invention is to treat specific types of cancer including but not limited to: carcinoma such as bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage including leukaemia, acute lymphocytic leukaemia, acute lymphoblastic leukaemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkitt's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukaemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma neuroblastoma, glioma and schwannomas; other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer and Kaposi's sarcoma.

Another preferred method of the present invention is to treat specific cellular proliferation disorders such as, for example, benign prostate hyperplasia, familial adenomatosis polyposis, neurofibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and post-surgical stenosis and restenosis.

The compounds of this invention may be useful in inhibiting tumour angiogenesis and metastasis, as well as in the treatment of organ transplant rejection and host versus graft disease.

The present invention further provides a method of treatment comprising a compound of formula (I) in combination with radiation therapy or chemotherapy regimen for simultaneous, separate or sequential use in anticancer therapy. Moreover the invention provides an in vitro method for inhibiting protein kinase activity which comprises contacting the said protein kinase with an effective amount of a compound of formula (I).

The present invention also provides a pharmaceutical composition comprising one or more compounds of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, carrier or diluent.

The present invention also provides a pharmaceutical composition comprising a compound of formula (I) in combination with known cytostatic or cytotoxic agents, antibiotic-type agents, DNA damaging or intercalating agents, platin-based agents, alkylating agents, antimetabolite agents, hormonal agents, antihormonal agents such as antiestrogens, antiandrogens and aromatase inhibitors, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g. COX-2 inhibitors), matrixmetalloprotease inhibitors, tyrosine kinase inhibitors, other kinase inhibitors, anti-growth factor receptor agents, anti-HER agents, anti-EGFR agents, anti-angiogenesis agents (e.g. angiogenesis inhibitors), farnesyl transferase inhibitors, ras-raf signal transduction pathway inhibitors, cell cycle inhibitors, other cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors, topoisomerase II inhibitors, inhibitors of kinesins, therapeutic monoclonal antibodies, inhibitors of mTOR, histone deacetylase inhibitors, inhibitors of hypoxic response and the like, for simultaneous, separate or sequential use in anticancer therapy.

Additionally, the invention provides a product or kit comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, or pharmaceutical compositions thereof and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.

In yet another aspect the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, for use as a medicament.

Moreover the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, in the manufacture of a medicament with antitumor activity.

Finally, the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, for use in a method of treating cancer.

As used herein, a compound of formula (I) wherein n is 0 and R1, R2, R3 and R4 are as defined above, namely 4,5-dihydro-1H-pyrazolo[4,3-g]indolizine derivatives, may be represented by the general formula (I)A:

and a compound of formula (I) wherein n is 1 and R1, R2, R3 and R4 are as defined above, namely 1,4,5,6-tetrahydropyrazolo[3,4-c]pyrrolo[1,2-a]azepine derivatives, may be represented by the general formula (I)B:

Unless otherwise specified, when referring to the compounds of formula (I) per se as well as to any pharmaceutical composition thereof or to any therapeutic method of treatment comprising them, the present invention includes all the hydrates, solvates, complexes, metabolites, prodrugs, carriers, N-oxides and pharmaceutically acceptable salts of the compounds of this invention.

A metabolite of a compound of formula (I) is any compound into which this same compound of formula (I) is converted in vivo, for instance upon administration to a mammal in need thereof. Typically, without however representing a limiting example, upon administration of a compound of formula (I), this same derivative may be converted into a variety of compounds, for instance including more soluble derivatives like hydroxylated derivatives, which are easily excreted. Hence, depending upon the metabolic pathway thus occurring, any of these hydroxylated derivatives may be regarded as a metabolite of the compounds of formula (I).

Prodrugs are any covalently bonded compounds, which release the active parent drug according to formula (I) in vivo.

N-oxides are compounds of formula (I) wherein nitrogen and oxygen are tethered through a dative bond.

All forms of chiral isomers or other forms of isomers including enantiomers and diastereomers, are intended to be covered herein. Compounds containing a chiral center may be used as a racemic mixture or as an enantiomerically enriched mixture, or the racemic mixture may be separated using well-known techniques and an individual enantiomer may be used alone.

In cases wherein compounds may exist in other tautomeric forms, such as keto-enol tautomers, each tautomeric form is contemplated as being included within this invention whether existing in equilibrium or predominantly in one form.

As such, unless otherwise provided, when in compounds of formula (I) n, R1, R2 and R3 are as defined above, R4 is hydrogen and only one of the following tautomeric forms of formula (I)a or (I)b is indicated, the remaining one has still to be intended as comprised within the scope of the invention:

In the present description, unless otherwise indicated, with the term “straight or branched C₁-C₆ alkyl” we intend any group such as, for instance, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, and the like.

With the term “straight or branched C₂-C₆ alkenyl” or “straight or branched C₂-C₆ alkynyl” we intend any of the unsaturated alkenyl or alkynyl groups with from 2 to 6 carbon atoms for instance including vinyl, allyl, 1-propenyl, isopropenyl, 1-, 2- or 3-butenyl, pentenyl, hexenyl, ethynyl, 1- or 2-propynyl, butynyl, pentynyl, hexynyl, and the like. With the term “C₃-C₆ cycloalkyl” we intend, unless otherwise specified, 3- to 6-membered all-carbon monocyclic ring, which may contain one or more double bonds but does not have a completely conjugated π-electron system. Examples of cycloalkyl groups, without limitation, are cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene and cyclohexadiene.

With the term “heterocyclyl” we intend a 3- to 7-membered, saturated or partially unsaturated carbocyclic ring where one or more carbon atoms are replaced by heteroatoms such as nitrogen, oxygen and sulfur. Non limiting examples of heterocyclyl groups are, for instance, pyrane, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazolidine, pyrazoline, thiazoline, thiazolidine, dihydrofuran, tetrahydrofuran, 1,3-dioxolane, piperidine, piperazine, morpholine and the like.

With the term “aryl” we intend a mono-, bi- or poly-carbocyclic hydrocarbon with from 1 to 4 ring systems, optionally further fused or linked to each other by single bonds, wherein at least one of the carbocyclic rings is “aromatic”, wherein the term “aromatic” refers to completely conjugated π-electron bond system. Non-limiting examples of such aryl groups are phenyl, α- or β-naphthyl or biphenyl groups.

With the term “heteroaryl” we intend aromatic heterocyclic rings, typically 5- to 7-membered heterocycles with from 1 to 3 heteroatoms selected among N, O or S; the heteroaryl ring can be optionally further fused or linked to aromatic and non-aromatic carbocyclic and heterocyclic rings. Not limiting examples of such heteroaryl groups are, for instance, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, imidazolyl, thiazolyl, isothiazolyl, pyrrolyl, phenyl-pyrrolyl, furyl, phenyl-furyl, oxazolyl, isoxazolyl, pyrazolyl, thienyl, benzothienyl, isoindolinyl, benzoimidazolyl, quinolinyl, isoquinolinyl, 1,2,3-triazolyl, 1-phenyl-1,2,3-triazolyl, 2,3-dihydroindolyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothiophenyl; benzopyranyl, 2,3-dihydrobenzoxazinyl, 2,3-dihydroquinoxalinyl and the like.

According to the meanings provided to R^(a) and R^(b), any of the above groups may be further optionally substituted in any of their free positions by one or more groups, for instance 1 to 6 groups, selected from: halogen, nitro, oxo groups (═O), carboxy, cyano, C₁-C₆ alkyl, polyfluorinated alkyl, C₂-C₅ alkenyl, C₂-C₅ alkynyl, C₃-C₅ cycloalkyl, heterocyclyl, aryl, heteroaryl; amino groups and derivatives thereof such as, for instance, alkylamino, dialkylamino, arylamino, diarylamino, ureido, alkylureido or arylureido; carbonylamino groups and derivatives thereof such as, for instance, formylamino, alkylcarbonylamino, alkenylcarbonylamino, arylcarbonylamino, alkoxycarbonylamino; hydroxy groups and derivatives thereof such as, for instance, alkoxy, polyfluorinated alkoxy, aryloxy, alkylcarbonyloxy, arylcarbonyloxy, cycloalkenyloxy or alkylideneaminoxy; carbonyl groups and derivatives thereof such as, for instance, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, cycloalkyloxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl; sulfurated derivatives such as, for instance, alkylthio, arylthio, alkylsulfonyl, arylsulfonyl, alkylsulfinyl, arylsulfinyl, arylsulfonyloxy, aminosulfonyl, alkylaminosulfonyl or dialkylaminosulfonyl.

In their turn, whenever appropriate, each of the above substituents may be further substituted by one or more of the aforementioned groups.

In the present description, unless otherwise specified, with the term “cyano” we intend a —CN residue.

With the term “nitro” we intend a —NO₂ group.

With the term “halogen” we intend a fluorine, chlorine, bromine or iodine atom.

With the term “polyfluorinated alkyl or alkoxy” we intend a straight or branched C₁-C₆ alkyl or alkoxy group as above defined, wherein more than one hydrogen atom is replaced by fluorine atoms such as, for instance, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethyl, 2,2,2-trifluoroethoxy, 1,2-difluoroethyl, 1,1,1,3,3,3-hexafluoropropyl-2-yl, and the like.

From all of the above, it is clear to the skilled man that any group which name has been identified as a composite name such as, for instance, cycloalkylalkyl, arylalkyl, heterocyclylalkyl, alkoxy, alkylthio, aryloxy, arylalkyloxy, alkylcarbonyloxy and the like, has to be intended as conventionally construed from the parts to which it derives. So far, as an example, the terms heterocyclyl-alkyl and cycloalkyl-alkyl stand for a straight or branched alkyl group being further substituted by a heterocyclic or cycloalkyl group, respectively, as above defined.

The term “pharmaceutically acceptable salts” embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically acceptable. Suitable pharmaceutically acceptable acid addition salts of the compounds of the present invention may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric, and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, trifluoroacetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, salicylic, p-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxyethanesulfonic, sulfanilic, stearic, cyclohexylaminosulfonic, algenic, hydroxybutyric, galactaric and galacturonic acid. Suitable pharmaceutically acceptable base addition salts of the compounds of the present invention include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methyl-glucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding compounds of the present invention, for instance by reacting them with the appropriate acid or base.

A preferred class of compounds of formula (I) are the compounds wherein:

R1 is a group —CONHR^(a) wherein R^(a) is hydrogen or a group optionally substituted selected from straight or branched C₁-C₆ alkyl, straight or branched C₂-C₆ alkenyl, aryl and aryl C₁-C₆ alkyl.

Another preferred class of compounds of formula (I) are the compounds wherein:

R1 is a group —COR^(a) wherein R^(a) is hydrogen or a group optionally substituted selected from straight or branched C₁-C₆ alkyl, straight or branched C₂-C₆ alkenyl, aryl and aryl C₁-C₆ alkyl.

Another preferred class of compounds of formula (I) are the compounds wherein:

R1 is a group —SO₂R^(a) wherein R^(a) is hydrogen or a group optionally substituted selected from straight or branched C₁-C₆ alkyl, straight or branched C₂-C₆ alkenyl, aryl and aryl C₁-C₆ alkyl.

A further preferred class of compounds of formula (I) are the compounds wherein:

R2 is hydrogen.

A more preferred class of compounds of formula (I) are the compounds wherein:

R3 is a group —NR^(a)R^(b) wherein both of R^(a) and R^(b) are hydrogen or one of them is a hydrogen and the remaining one of R^(a) or R^(b) is a group optionally substituted selected from straight or branched C₁-C₆ alkyl, straight or branched C₂-C₆ alkenyl, aryl and aryl C₁-C₆ alkyl.

The most preferred class of compounds of formula (I) are the compounds wherein:

R4 is an hydrogen.

For a reference to any specific compound of formula (I) of the invention, optionally in the form of pharmaceutically acceptable salts, see the experimental section.

The present invention also provides a process for the preparation of a compound of formula (I) as defined above, characterized in that the process comprises the following steps:

a) reaction of the compound of formula (II):

with an alcohol of formula (III) R^(a′)—OH  (III) wherein R^(a′) is straight or branched C₁-C₆ alkyl group; b) acylation by Friedel-Craft reaction of the resultant compound of formula (IV):

wherein R^(a) is as defined above; c) reaction of the resultant compound of formula (V):

wherein R^(a′) is as defined above, with a suitable alcohol of formula (III) as defined above; d) alkylation of the resultant compound of formula (VI):

wherein both R^(a′) are independently as defined above, with suitable halo-cyanoalkane of formula (XXI):

wherein n is 0 or 1; e) intramolecular condensation of the resultant compound of formula (VII):

wherein n is as defined above and both R^(a) are independently as defined above; f) treatment with hydrazine or an hydrazine salt thereof, of the resultant compound of formula (VIII):

wherein n and R^(a) are as defined above, to give a compound of formula (I):

wherein n is 0 or 1; R1, R2 and R4 are hydrogen and R3 is —OR^(a), wherein R^(a′) is a straight or branched C₁-C₆ alkyl group; optionally separating the resultant compound of formula (I) into the single isomers; and/or converting the resultant compound of formula (I) into a different compound of formula (I) by replacing the group —OR^(a) with a different group which R3 represents, and/or introducing the R4 group, and/or derivatizing the amino moiety; and/or removing the R4 group, and/or converting it into a pharmaceutically acceptable salt if desired.

Said optional conversions of a compound of formula (I) are summarized in scheme A below.

wherein n, R1, R2, R3 and R4 are as defined above and R^(a) is straight or branched C₁-C₆ alkyl group.

The present invention further provides a process for the preparation of a compound of formula (I) as defined above, characterized in that the compound of formula (I) wherein n is as defined in formula (I);

R1, R2 and R4 are hydrogen, and R^(a′) is straight or branched C₁-C₆ alkyl group, is optionally converted into the corresponding compound of formula (I) by replacing the group —OR^(a) with a different group which R3 represents, said conversion is carried out in step g) by one or more of the following reactions: g.1) hydrolysis under basic condition to give the corresponding compound of formula (I) wherein R3 is OH, optionally followed by the coupling of the resultant compound with an amine of formula (IX): HNR^(a)R^(b)  (IX) wherein R^(a) and R^(b) are as defined in claim 1, to give the corresponding compound of formula (I) wherein R3 is —NR^(a)R^(b) and R^(a) and R^(b) are as defined in claim 1; g.2) transesterification by reactions with a compound of formula (III) as defined above, to give the corresponding compound of formula (I) wherein R3 is OR^(a′) and R^(a′) is a different C₁-C₆ alkyl; g.3) coupling with an amine of formula (IX): HNR^(a)R^(b)  (IX) wherein R^(a) and R^(b) are as defined in formula (I), to give the corresponding compound of formula (I) wherein R3 is —NR^(a)R^(b) and R^(a) and R^(b) are as defined in formula (I).

The present invention further provides a process for the preparation of a compound of formula (I) as defined above, characterized in that the compound of formula (I) wherein n and R3 are as defined in formula (I), and R1, R2 and R4 are hydrogen, is optionally converted into the corresponding compound of formula (I) by introducing the group R4, said conversion is carried out in step h) by one or more of the following reactions:

h.1) coupling with an equivalent of an halide of formula (X): R^(a)Z  (X) wherein R^(a) is as defined in formula (I) but not hydrogen and Z is a halogen, to give the corresponding compound of formula (I) wherein R4 is R^(a), and R^(a) is as defined in formula (I) but not hydrogen; h.2) coupling with an equivalent of an acyl halide of formula (XI): R^(a)COZ  (XI) wherein R^(a) and Z are as defined above, to give the corresponding compound of formula (I) wherein R4 is —COR^(a) and R^(a) is as defined above; h.3) coupling with an equivalent of an alcohoxycarbonyl halide of formula (XII): R^(a)OCOZ  (XII) wherein R^(a) and Z are as defined above, to give the corresponding compound of formula (I) wherein R4 is —OCOR^(a) and R^(a) is as defined above; h.4) coupling with an equivalent of a sulfonyl halide of formula (XIII): R^(a)SO₂Z  (XIII) wherein R^(a) and Z are as defined above, to give the corresponding compound of formula (I) wherein R4 is —SO₂R^(a) and R^(a) is as defined above; h.5) coupling with an equivalent of an isocyanate of formula (XIV): R^(a)NCO  (XIV) wherein R^(a) is as defined above, to give the corresponding compound of formula (I) wherein R4 is —CONHR^(a) and R^(a) is as defined above.

The present invention further provides a process for the preparation of a compound of formula (I) as defined above, characterized in that the compound of formula (I) wherein n and R3 are as defined in formula (I); R1 and R2 are hydrogen and R4 is as defined in formula (I) but not hydrogen, is optionally converted into the corresponding compound of formula (I) by derivatizing the amino moiety, said conversion is carried out in step i) by one or more of the following reactions:

i.1) coupling with an equivalent of an acyl halide of formula (XI): R^(a)COZ  (XI) wherein R^(a) is as defined in formula (I) but not hydrogen and Z is a halogen, to give the corresponding compound of formula (I) wherein one of R1 or R2 is hydrogen and the other one is —COR^(a) and R^(a) is as defined above; i.2) coupling with an equivalent of an alkoxycarbolyl halide of formula (XII): R^(a)OCOZ  (XII) wherein R^(a) and Z are as defined above, to give the corresponding compound of formula (I) wherein one of R1 or R2 is hydrogen and the other one is —OCOR^(a) and R^(a) is as defined above; i.3) coupling with an equivalent of a sulfonyl halide of formula (XIII): R^(a)SO₂Z  (XIII) wherein R^(a) and Z are as defined above, to give the corresponding compound of formula (I) wherein one of R1 or R2 is hydrogen and the other one is —SO₂R^(a) and R^(a) is as defined above; i.4) coupling with an equivalent of an isocyanate of formula (XIV): R^(a)NCO  (XIV) wherein R^(a) is as defined above, to give the corresponding compound of formula (I) wherein one of R1 or R2 is hydrogen and the other one is —CONHR^(a) and R^(a) is as defined above; i.5) coupling with an equivalent of a carbonyl compound of formula (XV): R^(a)COR^(b)  (XV) wherein R^(a) and R^(b) are as defined in formula (I), to give the corresponding compound of formula (I) wherein one of R1 or R2 is hydrogen and the other one is —COR^(a) and R^(a) is as defined above.

The present invention further provides a process for the preparation of a compound of formula (I) as defined above, characterized in that the compound of formula (I) wherein n and R3 are as defined in formula (I); one of R1 and R2 is hydrogen and the other is as defined in formula (I) but not hydrogen, and R4 is as defined in formula (I) but not hydrogen, is optionally converted into the corresponding compound of formula (I) by further derivatizing the amino moiety, said conversion is carried in step j) by one or more of the reaction described under steps i.1)-i.5) described above.

The present invention further provides a process for the preparation of a compound of formula (I) as defined above, characterized in that the compound of formula (I) wherein n, R1, R2 and R3 are as defined in formula (I) and R4 is as defined in formula (I) but not hydrogen, is optionally converted into the corresponding compound of formula (I) by removing the group R4 by treatment with a basic solution to give the corresponding compound of formula I wherein R4 is hydrogen, said conversion is carried out in step k).

The above process is an analogy process which can be carried out according to well-known methods.

The starting materials of the process object of the present invention, comprehensive of any possible variant, as well as any reactant thereof, are known compounds and if not commercially available per se may be prepared according to well-known methods.

For example, the compound of formula (II) and (XXI) are commercially available.

The compounds of formula (III), (IX), (X), (XI), (XII), (XIIII), (XIV), (XV) and (XXI) are either commercially available or known and easily obtained according to known methods, for a general reference see: Smith, Michael-March's Advanced Organic Chemistry: reactions mechanisms and structure—5^(th) Edition, Michael B. Smith and Jerry March, John Wiley & Sons Inc., New York (N.Y.), 2001.

According to step a) of the process the 2,2,2-trichloro-1-(1H-pyrrol-2-yl)ethanone is reacted with ethanol to obtain the ethyl 1H-pyrrole-2-carboxylate. This reaction can be conducted in a variety of ways and experimental conditions, which are widely known in the art for condensation reactions. For a general reference to the operative conditions see: Nishiwaki, E. et al, Heterocycles [HTCYAM] 1988, 27, 1945; Freedlander, R. S. et al, J Org Chem [JOCEAH] 1981, 46, 3519; Harbuck, J. W. et al, J Org Chem [JOCEAH] 1972, 37, 3618; and Booth, C et al, Tetrahedron Lett [TELEAY] 1992, 33 (3), 413. Preferably, the reaction is carried out in presence of a base like trialkyl amine, sodium or potassium carbonates, alkali hydroxide or alkali hydride. The solvent, in case is not the same ethanol, could be a suitable solvent such as THF, ACN, dioxane or mixture of them and the temperature raging from room temperature to reflux.

According to step b) of the process, the compound of formula (IV) is reacted with trichloroacetyl chloride in presence of strong lewis acid such as AlCl₃, ZnCl₂, Pyridine, FeCl₃ or Sm(OTf)₃ in a dry solvent as ether, DCM, THF. Preferably, the reaction is carried out at reflux temperature.

According to step c) of the process, the compound of formula (V) is reacted with ethanol and the reaction is carried out as described under step (a).

According to step d) of the process, the reaction of the compound of formula (VI) with the halo-cyanoalkane can be conducted in a variety of ways and experimental conditions, which are widely known in the art for condensation reactions. For a general reference to the operative conditions see: Stevens, C. V. et al, Tetrahedron Lett [TELEAY] 2007, 48 (40), 7108-7111 and Dumas, D. J., J Org Chem [JOCEAH] 1988, 53, 4650. Preferably, the reaction is carried out in presence of bases such as alkali carbonates, alkali hydride in a suitable solvent such as tetahydrofuran, dichloromethane, acetonitrile, 1,4-dioxane or dimethylamide.

According to step e) of the process, the intramolecular condensation of the compound of formula (VII) can be conducted in a variety of ways and experimental conditions, which are widely known in the art. For a general reference see: Crowley, J. I. et al, J Am Chem Soc [JACSAT] 1970, 92, 6363-6365. Preferably the reaction is carried out according to the conditions of the Dieckmann reaction with potassium or sodium alkoxide in acetonitrile, tetrahydrofuran, toluene or an alcoholic solvent.

According to step f) of the process, the reaction between the compound of formula (VIII) and hydrazine or an hydrazine salt, can carried out in a variety of ways and experimental conditions, which are widely known in the art. Preferably, the reaction is carried out in the presence of catalytic amounts of an acid, for instance hydrochloric, acetic or sulphuric acid; in a suitable solvent such as, for instance, tetrahydrofuran, 1,4-dioxane, acetonitrile, methanol or ethanol; at a temperature ranging from about room temperature to reflux and for a time varying from about 30 minutes to about 8 hours.

According to any one of steps g.1) to g.3) of the process, the conversion of the alkoxycarbonyl derivative of formula (I) obtained in step e) into a different compound of formula (I) by replacing the group —OR^(a′) with a different group which R3 represents, can be carried out in a variety of ways, according to conventional methods.

According to step g.1) of the process, the hydrolysis under acid or basic condition of the alkoxycarbonyl derivative for conversion into the corresponding carboxylic acid derivative, is conducted according to standard procedures as reported in The Chemistry of Carboxylic Acids and Esters, Saul Patai, Interscience Publisher (John Wiley&Sons 1969).

According to step g.2) of the process, the transesterification of the alkoxycarbonyl derivative is conducted according to standard procedures as reported in The Chemistry of Carboxylic Acids and Esters, Saul Patai, Interscience Publisher (John Wiley&Sons 1969).

According to step g.3) of the process, the coupling of the alkoxycarbonyl or the corresponding carboxylic acid derivative with an amine is conducted according to standard procedures as reported in The Chemistry of Amides, Saul Patai, Interscience Publisher (John Wiley&Sons 1970). Preferably, the reaction is carried out in the presence of a suitable condensing agent, for instance dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide (EDC), 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (HBTOH), O-benzotriazolyltetramethylisouronium tetrafluoroborate (TBTU), or benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), in an appropriate solvent such as dichloromethane or dimethylformamide, under the setting well-known to skilled person.

According to any one of steps h.1) to h.5) of the process, the introduction of the group R4 can be carried out in a variety of ways, according to conventional methods.

The selective introduction of the R4 group on the pyrazole nitrogen in position 1 or 2, due to the tautomeric equilibrium, could be obtained working with a stoichiometric amount of the akylating, acylating, carbonylating, sulphorilating agent or isocyanate of formula (X), (XI), (XII), (XIII), (XIV) respectively, so as to prevent the multi-derivatization even on the amino group in position 3. The reaction is conducted in a suitable solvent such as dichloromethane, dimethylformamide, tetrahydrofuran or dioxane without using a base that could cleave in situ the R4 substituent just inserted.

According to any one of steps i.1) to i.5) of the process, the derivatization of the amino moiety, can be carried out in a variety of ways, according to conventional methods. For reference see: The Chemistry of Amino Group, Saul Patai, Interscience Publisher (John Wiley&Sons 1968), or J. Am. Chem. or J. Am. Chem. Soc., 1971, 93, 2897, or Comprensive Organic Synthesis, Trost B. N., Fleming L. (Eds. Pergamon Press: New York, 1991; Vol. 8).

Preferably, according to any one of steps i.1) to i.4) of the process, the compound of formula (I) is dissolved in a suitable solvent such as dichloromethane, dimethylformamide, tetrahydrofuran, 1,4-dioxane or the like, and a suitable base such as pyridine, triethyilamine, diisopropylamine or sodium carbonate is added therein. The compound of formula (XI), (XII), (XIII) respectively, is then added and the mixture stirred for a time of about 2 hours to about 15 hours, at a temperature ranging from about 20° C. to about 80° C. In the case of isocyanate of formula (XIV) the use of the base is optional.

Preferably, according to step i.5) of the process, the compound of formula (I) is reacted with an aldehyde or ketone derivative of formula (XV) under reductive conditions. From the above, it is clear to the skilled man that by employing an aldehyde derivative of formula (XV) wherein one of R^(a) and R^(b) is hydrogen, the corresponding derivative wherein R1 is —CH2R^(a) is obtained. Likewise, by employing a ketone derivative, the corresponding derivative wherein R1 is —CHR^(a)R^(b), wherein R^(a) and R^(b) are as defined above but different from hydrogen, is obtained.

According to any one of steps j.1) to j.5) of the process, the further derivatization of the amino moiety, can be carried out in a variety of ways, according to conventional methods. It is clear to the person skilled in the art that the further derivatization of the amino moiety is carried out in the same conditions reported in the step i) described above, to obtain a bis-substitution on the nitrogen in position 3.

According to step k) of the process, the removal of the group R4, can be carried out in a variety of ways, according to conventional methods Preferably, the removal can be carried out reacting the compound of formula (I) with a basic solution such as hydrazine, ammonia, metal hydroxide and so on. With strongest base condition also the imides eventually present in position 3 can be hydrolyzed.

A compound of formula (I) can also be transformed into a pharmaceutically acceptable salt according to standard procedures that are known to those skilled in the art. Alternatively, a compound of formula (I) that is obtained as a salt can be transformed into the free base or the free acid according to standard procedures that are known to the skilled person.

In addition to the above, the compounds of formula (I) may be advantageously prepared according to combinatorial chemistry techniques widely known in the art, by accomplishing the aforementioned reactions between the intermediates in a serial manner and by working under solid-phase-synthesis (SPS) conditions.

The present invention also provides a process for the preparation of a compound of formula (I) as defined above, characterized in that the process comprises the following steps:

l) acylation of the alkoxycarbonyl derivative of formula (I) obtained in step f) described above, with trifluoroacetic anhydride;

m) removal from the resultant compound of the trifluoroacetyl group in position 1 or 2 of the pyrazolo ring;

n) loading of the resultant compound of formula (I) trifluoroacetylated in position 3 onto a resin as suitable solid support, wherein the resin is a commercially available polystyrenic resin such as for instance, Br-Wang resin, Trityl resin, Cl-trityl resin, Merriefield resin, MAMP resin or isocianate resin and derivatives thereof; o) hydrolyzing under acid or basic conditions the alkoxycarbonyl group and the trifluoroacetyl group of the resultant compound of formula (XVI); p) coupling the carboxyl group of the resultant compound of formula (XVII) with an amine of formula (IX) described above; q) derivatizing the amino moiety in position 3 of resultant compound of formula (XVIII); r) cleaving the resin from the resultant compound of formula (XIX), so as to obtain the desired compounds of formula I, optionally converting the resultant compound of formula (I) into a different compound of formula (I) and/or converting it into a pharmaceutically acceptable salt if desired.

Said solid-phase-synthesis (SPS) is summarized in scheme B below.

wherein the resin is a commercially available polystyrenic resin such as for instance, Br-Wang resin, Trityl resin, Cl-trityl resin, Merriefield resin, MAMP resin or isocianate resin and derivatives thereof; n, R1, R2 and R3 are as defined in formula (I) and R^(a′) is straight or branched C₁-C₆ alkyl group.

Any of the above reactions is carried out according to known methods, by working as formerly reported, and allows obtaining compounds of formula (I) as set forth above.

Step l) is carried out as described under step i.1).

Step m) is carried out as described under step k).

According to step n) the compound of formula (I) is loaded on the trityl chloride resin (copolystyrene-1% DVB) to obtain the compound of formula XVI. The loading reaction may be carried out in a suitable solvent such as dichloromethane or tetrahydrofuran and in the presence of a base such as trethylamine, pyridine, diisopropylamine and so on. The reaction is shacked in a time between 18 and 24 h at room temperature. For references see: M. A. Youngman, et al. Tetrahedron Lett., 1997, 38, 6347; K. Barlos, et al. Poster P316, 24th European Peptide Symposium, Edinburgh, 1996.

Step o) is carried out as described under step g.1).

Step p) is carried out as described under step g.3).

Step q) is carried out as described under step i) and j).

According to step (r), the cleavage of the resin is performed under acidic conditions in the presence of suitable acids such as, for instance, hydrochloric, trifluoroacetic, methanesulfonic or p-toluensulfonic acid. Preferably the reaction is carried out using trifluoroacetic acid in dichloromethane as solvent.

Clearly, by working according to combinatorial chemistry techniques as formerly indicated, a plurality of compounds of formula (I) may be obtained.

Hence, it is a further object of the present invention a library of two or more compounds of formula (I), according to a preferred embodiment of the invention,

wherein n is 0 or 1; R1, R2 and R4, each independently one from the other, are selected from the group consisting of —R^(a), —COR^(a), —CONHR^(a), —SO₂R^(a) and —COOR^(a); R3 is a group —NR^(a)R^(b) or —OR^(a); wherein R^(a) and R^(b), the same or different, are each independently hydrogen or a group optionally substituted, selected from straight or branched C₁-C₆ alkyl, straight or branched C₂-C₆ alkenyl, straight or branched C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, cycloalkyl C₁-C₆ alkyl, heterocyclyl, heterocyclyl C₁-C₆ alkyl, aryl, aryl C₁-C₆ alkyl, heteroaryl and heteroaryl C₁-C₆ alkyl or, taken together with the nitrogen atom to which they are bonded, either R^(a) and R^(b), may form an optionally substituted 3 to 8 membered heterocycle, optionally containing one additional heteroatom or heteroatomic group selected from S, O, N or NH, and pharmaceutically acceptable salts thereof.

For a general reference to the above libraries of compounds of formula (I) see the experimental section.

From all of the above, it is clear to the skilled person that once a library of such derivatives is thus prepared, for instance consisting of about a thousands of compounds of formula (I), the said library can be very advantageously used for screening towards given kinases, as formerly reported.

See, for a general reference to libraries of compounds and uses thereof as tools for screening biological activities, J. Med. Chem. 1999, 42, 2373-2382; and Bioorg. Med. Chem. Lett. 10 (2000), 223-226.

Pharmacology

The inhibiting activity of putative kinase inhibitors and the potency of selected compounds is determined through a method of assay based on the use of the Kinase-Glo® Luminescent Kinase Assay (commercially available from Promega corporation and described in Koresawa, M. and Okabe, T. (2004) High-throughput screening with quantitation of ATP consumption: A universal non-radioisotope, homogeneous assay for protein kinase. Assay Drug Dev. Technol. 2, 153-60).

The depletion of ATP as a result of kinase activity can be monitored in a highly sensitive manner through the use of Kinase-Glo® or Kinase-Glo® Plus Reagent, which uses luciferin, oxygen and ATP as substrates in a reaction that produces oxyluciferin and light.

The short forms and abbreviations used herein have the following meaning:

ACN acetonitrile

BSA bovine serum albumine

Tris 2-Amino-2-(hydroxymethyl)-1,3-propanediol

Hepes N-(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid)

DTT threo-1,4-Dimercapto-2,3-butanediol

THF tetrahydrofuran

TertBuOK potassium tertbuthoxy

MTBE methyl tertiary butyl ether

DIPEA diisopropylethylamine

PyBOP benzotriazol-1-yloxytris(pyrrolidino)phosphonium exafluorophosphate

EDC 1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide

DHBTOH 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine

TEA triethylamine

TFA trifluoroacetic acid

TFAA trifluoroacetic anhydride

TMOF trimethyl orto formate

DCE dichloroethane

DCM dichloromethane

DMF dimethylformammide

DMSO dimethylsulfoxide

HOBT hydroxybenzotriazole

KDa kiloDalton

mg milligram

μg microgram

ng nanogram

L liter

mL milliliter

μL microliter

M molar

mM millimolar

μM micromolar

nM nanomolar

Kinase reaction conditions are target (enzyme) dependent and thus undergo individual adaptations. The Kinase-Glo® Luminescent Kinase Assay can be used with virtually any kinase and substrate combination.

Also the buffer conditions may vary depending on the kinase of interest (e.g for PKA a composition of 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/ml BSA, in 50 μl final volume is used). Typically the range of ATP titration is 0.1 μM to 10 μM.

The optimal kinase substrate results in the greatest change in luminescence when comparing kinase reaction wells with no kinase wells.

The optimal amount of kinase is determined by making two fold serial dilutions across plates using the optimal amount of ATP and optimal kinase substrate. The optimal amount of kinase to use in subsequent compound screens and IC50 determinations is the amount required for luminescence to be within the linear range of the kinase titration curve (sigmoidal dose response).

Robotized Kinase-Glo® Assay

This assay was set up for the measurement of kinase activity and/or inhibition.

It is homogeneous, quick, radioactivity-free and suitable for all type of protein kinases, such as PLK family, ABL, ACK1, AKT1, ALK, AUR1, AUR2, BRK, CDC7/DBF4, CDK2/CYCA, CHK1, CK2, EE2FK, EGFR1, ERK2, FAK, FGFR1, FLT3, GSK3beta, IGFR1, IKK2, IR, JAK2, JAK3, KIT, LCK, LYN, MAPKAPK2, MELK, MET, MPS1, MST4, NEK6, NIM1, P38alpha, PAK4, PDGFR, PDK1, PERK, PIM1, PIM2, PIM3, PKAalpha, PKCbeta, PLK1, RET, SULU1, SYK, TRKA, VEGFR2, VEGFR3 or ZAP70.

We established the assay in 384 well-plates: the test mix consisted of:

1) 3× Enzyme mix (done in Kinase Buffer 3×), 5 μl/well

2) 3× substrate and ATP mix (done in ddH₂O), 5 μl/well

3) 3× compound of formula (I) (diluted into ddH₂O-3% DMSO)-5 μl/well)

As an outcome, the percentage of inhibition at 10 μM was evaluated for each compound tested: see below for compound dilution and assay scheme. Each enzyme had its own buffer constitution, substrate type and concentration. Incubation time instead was 90 min for all targets.

Test compounds were received as a 1 mM solution in 100% DMSO into 96 well plates. The plates were diluted to 30 μM in ddH₂O, 3% DMSO; 4 plates are reorganized in 384 well plate by dispensing 5 μl of each 96 wp into the four quadrants of a 384 wp. In well P23 and P24 the internal standard inhibitor staurosporine was added.

Assay Scheme Test plates were first added with 5 μl of the compound dilution (30 μM, corresponding to 3× dilution) and then loaded onto a robotized station together with one reservoir for the Enzyme mix (3×) and one for the ATP mix (3×), specific for each target under study.

To start the assay, the robot aspirated 5 μl of ATP/Substrate mix, made an air gap inside the tips (5 μl) and aspirated 5 μl of Enzyme mix. The subsequent dispensation into the test plates allowed the kinase reaction to start after 3 cycles of mixing, done by the robot itself by up and down pipetting. At this point, the correct concentration was restored for all reagents.

The robot incubated the plates for 90 minutes at room temperature, and then stopped the reaction by pipetting 15 μl of Kinase-Glo® reagent into the reaction mix. Three cycles of mixing were done immediately after the addition of the reagent.

The principle of the Kinase-Glo® technique is the presence in the reagent mixture of oxygen, luciferin and luciferase enzyme: in the presence of ATP, remaining from the kinase reaction, oxi-luciferin is produced with the emission of light, directly dependent on the amount of ATP. For optimal performances of this technique, the kinase reaction should utilize at least 15-20% of the available ATP.

After another 60 minutes of incubation to stabilize the luminescent signal, the plates were read on a ViewLux® instrument. Data were analyzed using the software package Assay Explorer® that provided percent inhibition data. As example herein are reported the assay conditions used for testing the compounds of formula (I) against ALKtide YFF APCo kinase;

ATP concentration: 1 μM

Enzyme concentration: 100 nM

Reaction buffer: Hepes 50 mM pH 7.5, MgCl₂ 5 mM, MnCl₂ 1 mM, DTT 1 mM, Na₃VO₄ 3 uM, 0.2 mg/ml BSA.

Assay procedure: add 5 ul compound of formula (I) (3×), add 5 μl ATP/S mix(3×) in buffer1×; add 5 μl enzyme in buffer 2×+3×BSA; for the blank, add 5 μl buffer2×+3×BSA without enzyme. After 90 minutes of incubation, add 15 μl/well of Kinase-Glo reagent. After 60-90 minutes of incubation to stabilize the luminescent signal, the plates are read on a ViuwLux instrument.

The inhibitory activity of putative kinase inhibitors and the potency of selected compounds were also determined using a trans-phosphorylation assay.

Specific peptide or protein substrates are trans-phosphorylated by their specific ser-thr or tyr kinase in the presence of ATP traced with ³³P-γ-ATP, and in the presence of their own optimal buffer and cofactors. At the end of the phosphorylation reaction, more than 98% unlabeled ATP and radioactive ATP is captured by an excess of the ion exchange dowex resin; the resin then settles down to the bottom of the reaction plate by gravity. Supernatant is subsequently withdrawn and transferred into a counting plate, then evaluated by β-counting.

Reaction conditions are target (enzyme) dependent and thus undergo individual adaptations. Also the buffer conditions may vary depending on the kinase of interest. The assay can be used with virtually any kinase and substrate combination and is suitable for all type of protein kinases, such as ABL, ACK1, AKT1, ALK, AUR1, AUR2, BRK, BUB1, CDC7/DBF4, CDK2/CYCA, CHK1, CK2, EEF2K, EGFR1, EphA2, EphB4, ERK2, FAK, FGFR1, FLT3, GSK3beta, Haspin, IGFR1, IKK2, IR, JAK1, JAK2, JAK3, KIT, LCK, LYN, MAPKAPK2, MELK, MET, MNK2, MPS1, MST4, NEK6, NIM1, P38alpha, PAK4, PDGFR, PDK1, PERK, PIM1, PIM2, PKAalpha, PKCbeta, PLK1, RET, ROS1, SULU1, Syk, TLK2, TRKA, TYK, VEGFR2, VEGFR3, ZAP70.

As example herein are reported the assay conditions used for testing the compounds of formula (I) against cdc7 and cdk2 kinase.

Inhibition Assay of Cdc7 Activity

The inhibiting activity of putative Cdc7 inhibitors and the potency of selected compounds is determined through a method of assay based on the use of Dowex resin capture technology.

The assay consists of the transfer of radioactivity labeled phosphate moiety by the kinase to an acceptor substrate. The resulting 33P-labeled product is separated from unreacted tracer, transferred into a scintillation cocktail and light emitted is measured in a scintillation counter.

The inhibition assay of Cdc7/Dbf4 activity is performed according to the following protocol.

The MCM2 substrate is trans-phosphorylated by the Cdc7/Dbf4 complex in the presence of ATP traced with γ³³-ATP. The reaction is stopped by addition of Dowex resin in the presence of formic acid. Dowex resin particles capture unreacted γ³³-ATP and drag it to the bottom of the well while ³³P phosphorylated MCM2 substrate remains in solution. The supernatant is collected, transferred into Optiplate plates and the extent of substrate phosphorylation is evaluated by β counting.

The inhibition assay of Cdc7/Dbf4 activity was performed in 96 wells plate according to the following protocol.

To each well of the plate were added:

-   -   10 μl test compound (10 increasing concentrations in the nM to         uM range to generate a dose-response curve). The solvent for         test compounds contained 3% DMSO. (final concentration 1%)     -   10 μl substrate MCM2 (6 M final concentration), a mixture of         cold ATP (2 M final concentration) and radioactive ATP (1/5000         molar ratio with cold ATP).     -   10 μl enzyme (Cdc7/Dbf4, 2 nM final concentration) that started         the reaction. The buffer of the reaction consisted in 50 mM         HEPES pH 7.9 containing 15 mM MgCl₂, 2 mM DTT, 3 uM NaVO₃, 2 mM         glycerophosphate and 0.2 mg/ml BSA.     -   After incubation for 60 minutes at room temperature, the         reaction was stopped by adding to each well 150 l of Dowex resin         in the presence of 150 mM formic acid. After another 60 min         incubation, 50 L of suspension were withdrawn and transferred         into 96-well OPTIPLATEs containing 150 l of MicroScint 40         (Packard); after 5-10 minutes shaking the plates were read for 1         min in a Packard TOP-Count radioactivity reader.

IC50 determination: inhibitors were tested at different concentrations ranging from 0.0005 to 10 M. Experimental data were analyzed by the computer program Assay Explorer using the four parameter logistic equation: y=bottom+(top-bottom)/(1+10^((log IC₅₀-x)*slope)) where x is the logarithm of the inhibitor concentration, y is the response; y starts at bottom and goes to top with a sigmoid shape. Inhibition Assay of Cdk2/Cyclin A Activity

Kinase reaction: 1.5 μM histone H1 substrate, 25 μATP (0.2 μCi P33-ATP), 30 ng of baculovirus co-expressed Cdk2/Cyclin A, 10 M inhibitor in a final volume of 100 l buffer (TRIS HCl 10 mM pH 7.5, MgCl₂ 10 mM, 7.5 mM DTT) were added to each well of a 96 U bottom well plate. After 10 min at 37° C. incubation, reaction was stopped by 20 l EDTA 120 mM.

Capture: 100 μl were transferred from each well to MultiScreen plate, to allow substrate binding to phosphocellulose filter. Plates were then washed 3 times with 150 l/well PBS Ca⁺⁺/Mg⁺⁺ free and filtered by MultiScreen filtration system.

Detection: filters were allowed to dry at 37° C., then 100 I/well scintillant were added and 33P labeled histone H1 was detected by radioactivity counting in the Top-Count instrument.

Results: Data are analysed by an internally customized version of the SW package “Assay Explorer” that provides either % inhibition for primary assays or sigmoidal fittings of the ten-dilutions curves for IC₅₀ determination in the secondary assays/hit confirmation routines.

As an example, in Table A are reported some compounds of the present invention which showed IC₅₀ of less 10 μM when tested against different kinases.

TABLE A IC₅₀ (uM) IC₅₀ Entry Code (uM) Enzyme 190 A20-M1-B8 2.43 ABL 193 A21-M1-B8 4.94 ABL 200 A35-M1-B8 3.50 ABL 10 A5-M1-B8 2.23 ABL 390 A21-M1-B34 5.34 ABL 397 A35-M1-B34 4.31 ABL 400 A5-M1-B34 0.82 ABL 434 A21-M1-B36 3.23 ABL 467 A5-M1-B37 5.10 ABL 561 A5-M1-B41 0.40 ABL 578 A5-M1-B42 1.79 ABL 615 A5-M1-B43 0.54 ABL 10 A5-M1-B8 1.86 ABL 619 A38-M1-B41 2.29 ABL 619 A38-M1-B41 0.92 ABL 100 A5-M1-B25 1.92 ACK1 120 A5-M1-B26 3.04 ACK1 141 A5-M1-B27 2.40 ACK1 163 A5-M1-B28 4.33 ACK1 190 A20-M1-B8 1.04 ACK1 193 A21-M1-B8 0.63 ACK1 196 A6-M1-B8 1.89 ACK1 200 A35-M1-B8 0.49 ACK1 10 A5-M1-B8 0.63 ACK1 221 A35-M1-B10 3.13 ACK1 224 A5-M1-B10 3.25 ACK1 238 A21-M1-B17 1.41 ACK1 246 A5-M1-B17 2.16 ACK1 263 A35-M1-B30 6.56 ACK1 266 A5-M1-B30 4.71 ACK1 307 A35-M1-B7 5.91 ACK1 310 A5-M1-B7 1.43 ACK1 331 A5-M1-B31 3.16 ACK1 342 A20-M1-B32 3.06 ACK1 351 A35-M1-B32 1.21 ACK1 354 A5-M1-B32 1.38 ACK1 390 A21-M1-B34 0.89 ACK1 397 A35-M1-B34 1.08 ACK1 400 A5-M1-B34 0.36 ACK1 434 A21-M1-B36 3.34 ACK1 443 A5-M1-B36 4.12 ACK1 467 A5-M1-B37 1.00 ACK1 480 A21-M1-B38 2.04 ACK1 489 A5-M1-B38 2.16 ACK1 509 A35-M1-B39 2.85 ACK1 512 A5-M1-B39 1.94 ACK1 536 A5-M1-B40 1.73 ACK1 552 A21-M1-B41 2.45 ACK1 559 A35-M1-B41 2.87 ACK1 561 A5-M1-B41 0.96 ACK1 576 A35-M1-B42 2.20 ACK1 578 A5-M1-B42 0.44 ACK1 615 A5-M1-B43 1.01 ACK1 680 A5-M2-B26 4.84 ACK1 855 A5-M2-B31 3.51 ACK1 894 A35-M2-B33 3.82 ACK1 897 A5-M2-B33 2.47 ACK1 918 A33-M2-B34 1.44 ACK1 957 A35-M2-B36 3.98 ACK1 959 A5-M2-B36 0.74 ACK1 1020 A35-M2-B39 1.41 ACK1 1023 A5-M2-B39 0.55 ACK1 1024 A27-M2-B39 3.17 ACK1 1051 A21-M2-B41 1.56 ACK1 1055 A5-M2-B41 0.44 ACK1 10 A5-M1-B8 0.48 ACK1 619 A38-M1-B41 2.48 ACK1 1100 A38-M2-B41 2.82 ACK1 1055 A5-M2-B41 0.24 ACK1 619 A38-M1-B41 1.00 ACK1 200 A35-M1-B8 0.30 ACK1 397 A35-M1-B34 1.58 ACK1 620 A39-M1-B8 0.75 ACK1 621 A39-M1-B34 5.54 ACK1 397 A35-M1-B34 4.91 ALK 400 A5-M1-B34 5.81 ALK 615 A5-M1-B43 3.40 ALK 390 A21-M1-B34 5.06 BRK 397 A35-M1-B34 4.35 BRK 400 A5-M1-B34 0.86 BRK 467 A5-M1-B37 5.77 BRK 480 A21-M1-B38 6.30 BRK 561 A5-M1-B41 4.35 BRK 578 A5-M1-B42 3.64 BRK 615 A5-M1-B43 4.68 BRK 63 A16-M1-B18 2.99 CDC7/DBF4 63 A16-M1-B18 1.90 CDK2/CYCA 615 A5-M1-B43 7.87 EGFR1 397 A35-M1-B34 5.76 FGFR1 615 A5-M1-B43 7.27 FGFR1 63 A16-M1-B18 1.92 GSK3beta 190 A20-M1-B8 2.02 KIT 200 A35-M1-B8 3.52 KIT 400 A5-M1-B34 4.13 KIT 434 A21-M1-B36 5.03 KIT 561 A5-M1-B41 1.83 KIT 578 A5-M1-B42 6.61 KIT 615 A5-M1-B43 1.31 KIT 54 A8-M1-B16 2.68 KIT 26 A9-M1-B13 5.85 KIT 56 A9-M1-B16 0.85 KIT 58 A11-M1-B16 2.66 KIT 10 A5-M1-B8 5.98 KIT 63 A16-M1-B18 2.61 KIT 64 A16-M1-B19 4.47 KIT 397 A35-M1-B34 3.50 LCK 400 A5-M1-B34 3.99 LCK 434 A21-M1-B36 5.14 LCK 561 A5-M1-B41 1.15 LCK 615 A5-M1-B43 0.59 LCK 619 A38-M1-B41 4.13 LCK 200 A35-M1-B8 2.13 LYN 709 A32-M2-B28 3.09 MELK 752 A30-M2-B8 2.57 MELK 918 A33-M2-B34 1.23 MELK 976 A24-M2-B37 3.00 MELK 63 A16-M1-B18 6.33 MELK 397 A35-M1-B34 4.17 PKCbeta 709 A32-M2-B28 1.63 Syk 752 A30-M2-B8 2.10 Syk 1151 A42-M2-B33 3.15 Syk 918 A33-M2-B34 0.48 Syk 976 A24-M2-B37 2.78 Syk 397 A35-M1-B34 3.98 VEGFR3 400 A5-M1-B34 4.94 VEGFR3 665 A1-M2-B25 1.56 ZAP70 709 A32-M2-B28 0.80 ZAP70 752 A30-M2-B8 0.59 ZAP70 1151 A42-M2-B33 1.83 ZAP70 918 A33-M2-B34 0.72 ZAP70 976 A24-M2-B37 1.15 ZAP70

The compounds of the present invention can be administered either as single agents or, alternatively, in combination with known anticancer treatments such as radiation therapy or chemotherapy regimen in combination with cytostatic or cytotoxic agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g. COX-2 inhibitors), matrixmetalloprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-growth factor receptor agents, anti-HER agents, anti-EGFR agents, anti-angiogenesis agents (e.g. angiogenesis inhibitors), farnesyl transferase inhibitors, ras-raf signal transduction pathway inhibitors, cell cycle inhibitors, other cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors, topoisomerase II inhibitors, and the like.

If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described below and the other pharmaceutically active agent within the approved dosage range.

Compounds of formula (I) may be used sequentially with known anticancer agents when a combination formulation is inappropriate.

The compounds of formula (I) of the present invention, suitable for administration to a mammal, e.g., to humans, can be administered by the usual routes and the dosage level depends upon the age, weight, conditions of the patient and administration route.

For example, a suitable dosage adopted for oral administration of a compound of formula (I) may range from about 10 to about 500 mg per dose, from 1 to 5 times daily. The compounds of the invention can be administered in a variety of dosage forms, e.g., orally, in the form tablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally in the form suppositories; parenterally, e.g., intramuscularly, or through intravenous and/or intrathecal and/or intraspinal injection or infusion.

The present invention also includes pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable excipient, which may be a carrier or a diluent.

The pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a suitable pharmaceutical form. For example, the solid oral forms may contain, together with the active compound, diluents, e.g., lactose, dextrose saccharose, sucrose, cellulose, corn starch or potato starch; lubricants, e.g., silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g., starches, arabic gum, gelatine methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disintegrating agents, e.g., starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. These pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating, or film-coating processes.

The liquid dispersions for oral administration may be, e.g., syrups, emulsions and suspensions. As an example, the syrups may contain, as carrier, saccharose or saccharose with glycerine and/or mannitol and sorbitol.

The suspensions and the emulsions may contain, as examples of carriers, natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g., sterile water, olive oil, ethyl oleate, glycols, e.g., propylene glycol and, if desired, a suitable amount of lidocaine hydrochloride.

The solutions for intravenous injections or infusions may contain, as a carrier, sterile water or preferably they may be in the form of sterile, aqueous, isotonic, saline solutions or they may contain propylene glycol as a carrier.

The suppositories may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g., cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.

With the aim of better illustrating the present invention, without posing any limitation to it, the following examples are now given.

EXPERIMENTAL SECTION

General Methods

Flash Chromatography was performed on silica gel (Merck grade 9395, 60A). The high-pressure liquid chromatography retention times (HPLC: r.t. values) were determined by:

HPLC Method 1A and 1B:

A Waters Alliance LC mod. 2795 equipped with a variable UV detector mod 2487, a Chemiluminescence Nitrogen detector (CLND, Antek 8060) and a Waters ZQ2000 mass detector (ESI interface) was used in this application. The total flow was splitted and distributed to the three detectors at a fixed ratio (64:15:21 UV:MS:CLND). The liquid chromatograph was equipped with a 30×3.0 mm I.D. column (Waters xBridge C₁₈, 3.5 um particles), thermostated at 50° C. Two mobile phases were used: phase A was 0.05% w/v formic acid (1 mL/L of 50% formic acid Fluka 09676 in highly purified water) and phase B was 70/25/5 (v/v/v) MeOH/iPrOH/H2O containing 0.035% w/v of formic acid (700 uL/L of 50% formic acid Fluka 09676).

A 5 μL volume of 1 mM nominal sample solution in DMSO was injected (sequential, partial loop mode with no air gaps) and a generic reversed phase gradient analysis was carried out at 0.8 ml/min into either a fast variant (method 1A) or a slower one (method 1B), as indicated in the following table:

Method 1A Method 1B tR (min) phase B (%) tR (min) phase B (%) 0.00 0 0.00 0 5.00 100 8.00 100 5.70 100 9.00 100 5.71 0 9.01 0 6.3 stop time 9.6 stop time 7.9 total analysis time (*) 11.2 total analysis time (*) (*) between consecutive injections

The UV detector was operated at 220 nm, 5 Hz sampling rate. The MS device was operated at 3.2 kV capillary voltage, 30 V cone, 2 V extractor, 0.5 V RF lens, 400 L/hr desolvation flow, 100 L/hr cone flow, 100° C. source temperature, 150° C. desolvation temperature, ESI(+) full scan 120-1200 amu acquisition, at 1.7 Hz sampling rate. The CLND detector was operated at 1050° C. furnace temp, 280 mL/min inlet oxygen flow, 80 mL/min inlet argon, 25 mL/min make-up argon, 30 mL/min ozone, 28 torr vacuum, 750 V PMT voltage, PMT chamber at +10° C., sensitivity high, select 5, 4 Hz sampling rate.

HPLC Method 2:

HPLC-MS analyses were performed on a Finnigan MAT mod. LCQ ion trap mass spectrometer, equipped with an ESI (Electrospray) ion source, the mass spectrometer is directly connected to a HPLC SSP4000 (Thermo Separation) equipped with an autosampler Lc Pal (CTC Analytics) and an UV6000LP PDA detector.

HPLC Conditions:

Column: Phenomenex Gemini C₁₈, 3 μm, 50×4.6 mm (default)

Temperature 40° C.

Mobile phase A: Acetate Buffer 5 mM pH 4.5: acetonitrile 95:5 (v:v)

Mobile phase B: Acetate Buffer 5 mM pH 4.5: acetonitrile 5:95 (v:v)

Elution Gradient:

Time (min) % Mobile Phase A 0 100 7 0 9 0 11 100 13 100 Flow rate: 1 mL/min Injection volume: 10 μL Column temperature: 40° C. MS Conditions:

The LCQ mass spectrometer operates with an electrospray ionization (ESI) interface in positive and negative ion mode following the operation parameters reported in table 1. MS/MS experiments are performed on the most intense ion of each scan automatically by Xcalibur software. A 45% collision energy was used for the fragmentation of the precursor ions.

TABLE 1 Mass Spectrometer Instrument parameters Parameter Value Capillary Temperature (° C.) 255 Source Voltage (kV) 4.00 Capillary Voltage (V) 21.0 Tube Lens Offset (V) −5.0 Multipole RF Amplifier (Vp-p) 400.0 Multipole 1 Offset (V) −3.00 Multipole 2 Offset (V) −6.50 InterMultipole Lens Voltage (V) −16.00 Trap DC Offset Voltage (V) −10.00 Full Micro scans 3 Full AGC Target Ions 5 * 10⁷ Full Max Ion Time (ms) 150 MSn Micro scans 3 MSn AGC Target Ions 2 * 10⁷ MSn Max Ion Time (ms) 200 Electron Multiplier (V) −950.0 HPLC Method 3:

HPLC-MS analyses were performed on a Finnigan MAT mod. LCQ ion trap mass spectrometer, equipped with an ESI (Electrospray) ion source, the mass spectrometer is directly connected to a HPLC SSP4000 (Thermo Separation) equipped with an autosampler Lc Pal (CTC Analytics) and an UV6000LP PDA detector.

HPLC Conditions:

Column: Phenomenex Gemini C18, 3 μm, 50×4.6 mm (default)

Temperature 40° C.

Mobile phase A: Acetate Buffer 5 mM pH 4.5: acetonitrile 95:5 (v:v)

Mobile phase B: Acetate Buffer 5 mM pH 4.5: acetonitrile 5:95 (v:v)

Elution Gradient:

Time (min) % Mobile Phase A 0 100 2 80 9 60 10 0 12 0 12.10 100 Flow rate: 1 mL/min Injection volume: 10 μL Column temperature: 40° C. MS Conditions:

The LCQ mass spectrometer operates with an electrospray ionization (ESI) interface in positive and negative ion mode following the operation parameters reported in table 1. MS/MS experiments are performed on the most intense ion of each scan automatically by Xcalibur software. A 45% collision energy was used for the fragmentation of the precursor ions.

TABLE 1 Mass Spectrometer Instrument parameters Parameter Value Capillary Temperature (° C.) 255 Source Voltage (kV) 4.00 Capillary Voltage (V) 21.0 Tube Lens Offset (V) −5.0 Multipole RF Amplifier (Vp-p) 400.0 Multipole 1 Offset (V) −3.00 Multipole 2 Offset (V) −6.50 InterMultipole Lens Voltage (V) −16.00 Trap DC Offset Voltage (V) −10.00 Full Micro scans 3 Full AGC Target Ions 5 * 10⁷ Full Max Ion Time (ms) 150 MSn Micro scans 3 MSn AGC Target Ions 2 * 10⁷ MSn Max Ion Time (ms) 200 Electron Multiplier (V) −950.0

Retention times (HPLC r.t.) are given in minutes at 220 nm or at 254 nm. Mass is given as m/z ratio.

When necessary, the compounds have been purified by preparative HPLC on a Waters X-Bridge Prep Shield RP18 (19×100 mm, 5 μm) column or a Phenomenex Gemini C18 (21.2×250 mm, 10 μm) column, using a Waters FractionLynx Autopurification System equipped with a 996 Waters PDA detector and a Micromass mod. ZQ single quadrupole mass spectrometer, electron spray ionization, positive mode. Mobile phase A was water 0.05% NH3/acetonitrile 95:5, and Mobile phase B was acetonitrile. Gradient from 10 to 90% B in 8 min or 15 min. Flow rate 20 ml/min.

¹H-NMR spectrometry was performed on a Bruker AVANCE 400 MHz single bay instrument with gradients. It is equipped with a QNP probe (interchangeable 4 nuclei probe—¹H, 13C, 19F and 31P) (NMR method 1) or on a Mercury VX 400 operating at 400.45 MHz equipped with a 5 mm double resonance probe [1H (15N-31P) ID_PFG Varian] (NMR method 2).

The compounds of formula (I), having an asymmetric carbon atom and obtained as racemic mixture, were resolved by HPLC separation on chiral columns. In particular, for example, preparative columns CHIRALPACK® AD, CHIRALPACK® AS, CHIRALCELL® OJ can be used.

As formerly indicated, several compounds of formula (I) of the invention have been synthesized, according to solution and combinatorial chemistry techniques.

In this respect, some compounds thus prepared have been conveniently and unambiguously identified, as per the coding system of tables III together with HPLC retention time (methods 1A, 1B, 2 and 3) and mass.

Each code, which identifies a single specific compound of formula (I), consists of three units A-M-B.

A represents any substituent R1 and R2-[see formula (I)] and is attached to the M central core through the nitrogen in position 3; each A substituent is represented in the following table I.

B represents any substituent R3 [see formula (I)] and is attached to the rest of the M central core through the carbon atom of the carbonyl group; each B substituent is represented in the following table II.

M refers to the central core, more precisely M1 represent 4,5-dihydro-1H-pyrazolo[4,3-g]indolizine core [see formula (I)A] whereas M2 represent 1,4,5,6-tetrahydropyrazolo[3,4-c]pyrrolo[1,2-a]azepine core [see formula (I) B]; each cores being substituted in position 3 by groups A and at the carbonyl group by groups B, substantially as follows:

For ease of reference, each A and B groups of tables I and II has been identified with the proper chemical formula also indicating the point of attachment with the rest of the molecule M1 or M2.

Just as an example, the compound A1-M1-B1 (entry 1 of table III) represents a 4,5-dihydro-1H-pyrazolo[4,3-g]indolizine (central core M1), being substituted at the nitrogen in 3-position by the group A1 and at the carbonyl group by the group B1; likewise, the compound A44-M2-B28 (entry 1116 of table III) represents a 1,4,5,6-tetrahydropyrazolo[3,4-c]pyrrolo[1,2-a]azepine (central core M2), being substituted at the nitrogen in 3-position by the group A44 and at the carbonyl group by the group B28.

TABLE I A groups FRAGMENT CODE

A1

A2

A3

A4

A5

A6

A7

A8

A9

A10

A11

A12

A13

A14

A15

A16

A17

A18

A19

A20

A21

A22

A23

A24

A25

A26

A27

A28

A29

A30

A31

A32

A33

A34

A35

A36

A37

A38

A39

A40

A41

A42

A43

A44

A45

A46

A47

A48

A49

A50

A51

A52

A53

A54

TABLE II B groups FRAGMENT CODE

B1

B2

B3

B4

B5

B6

B7

B8

B9

B10

B11

B12

B13

B14

B15

B16

B17

B18

B19

B20

B21

B22

B23

B24

B25

B26

B27

B28

B29

B30

B31

B32

B33

B34

B35

B36

B37

B38

B39

B40

B41

B42

B43

Preparation 1 Preparation of ethyl 1H-pyrrole-2-carboxylate (IV, wherein Ra′ is —CH₂—CH₃)

A solution of 2,2,2-trichloro-1-(1H-pyrrol-2-yl)-ethanone (25 g, 0.12 moli) in ethanol (200 mL) was treated with potassium carbonate (5 g). The mixture was then heated to reflux for 1 hour. After this time the residue solid was filtered off, and the solution concentrated under reduced pressure. Ethyl acetate (200 mL) was added and washed 2 times with water. The organic phase was dried with anhydrous sodium sulphate to obtain a pale yellow solid (18 g).

HPLC (Method 2): m/z 140.12 [M+H]+@ Rt=4.01 min. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.29 (t, J=7.07, 3 H) 4.23 (q, J=7.07, 2 H) 6.04-6.25 (m, 1H) 6.65-6.86 (m, 1H) 7.00-7.06 (m, 1H) 11.83 (br. s., 1H)

Preparation 2 Preparation of ethyl 4-(trichloroacetyl)-1H-pyrrole-2-carboxylate (V, wherein Ra′ is —CH₂—CH₃)

To ethyl 1H-pyrrole-2-carboxylate (18 g, 0.12 mol) dissolved in DCM (200 mL), was added anhydrous AlCl3 (40 g). After 10 minutes of vigorous stirring was added drop wise a solution of trichloro-acetyl chloride (20 mL) in DCM (100 mL). The reaction was heated to reflux for 3 hours. The mixture was then allowed to reach room temperature and poured in a 2 L backer with iced HCl 6N left stirring for 2 hours. The DCM was extract and washed 2 times with NaHCO3 and water. A dark solid was obtained which was not purified. HPLC (Method 2): m/z 282.45 [M−H] @ Rt=6.55 min. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.32 (s, J=7.07 Hz, 3H) 4.30 (s, J=7.07 Hz, 2H) 7.26-7.40 (m, 1H) 7.85-8.09 (m, 1H) 13.06 (br. s., 1H).

Preparation 3 Preparation of diethyl 1H-pyrrole-2,4-dicarboxylate (VI, wherein both of Ra′ are —CH₂—CH₃)

To a solution of ethyl 4-(trichloroacetyl)-1H-pyrrole-2-carboxylate (30 g, 0.12 moli) in ethanol (250 mL) was added potassium carbonate (7 g). The mixture was then heated to reflux for 1 hour. After this time the residue solid was filtered off, and the solution concentrated under vacuum. Ethyl acetate (200 mL) was added and washed 2 times with water. The organic phase was dried with anhydrous sodium sulphate to obtain a brown solid (28 g).

HPLC (Method 2): m/z 212.34 [M+H]+@ Rt=4.79 min. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.26 (t, J=7.07 Hz, 3H) 1.28 (t, J=7.07 Hz, 3H) 4.19 (q, J=7.11 Hz, 2H) 4.25 (q, J=7.07 Hz, 2H) 7.06 (dd, J=2.50, 1.65 Hz, 1H) 7.54 (dd, J=3.35, 1.65 Hz, 1H) 12.50 (br. s., 1H)

Preparation 4 Preparation of diethyl 1-(3-cyanopropyl)-1H-pyrrole-2,4-dicarboxylate (VII, wherein n is 0 and both of Ra′ are —CH₂—CH₃)

To diethyl 1H-pyrrole-2,4-dicarboxylate (28 g, 0.13 mol) dissolved in ACN was added 30 g of potassium carbonate (0.21 mol) and 17 mL of 4-bromo-butyronitrile(0.14 mol, d=1.3). The reaction was refluxed over night. The solvent was then evaporated under reduced pressure, the residue dissolved in ethyl acetate and washed 2 times with water. The crude was purified with a silica column (10p silica) eluent cycloesane/ethyl acetate 7:3. 20 g of a white solid was obtained.

HPLC (Method 2): m/z 296.51 [M+NH4+]+@ Rt=5.88 min. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.24 (t, J=7.07 Hz, 3H) 1.27 (t, J=7.07 Hz, 3H) 2.03 (m, 2H) 2.48 (t, J=7.19 Hz, 2H) 4.19 (q, J=7.07 Hz, 2H) 4.24 (q, J=7.07 Hz, 2H) 4.38 (t, J=7.19 Hz, 2H) 7.16 (d, J=1.95 Hz, 1H) 7.80 (d, J=1.83 Hz, 1H)

Preparation 5 Preparation of ethyl 7-cyano-8-oxo-5,6,7,8-tetrahydroindolizine-2-carboxylate(VIII, wherein n is 0 and Ra′ is —CH₂—CH₃)

To the diethyl 1-(3-cyanopropyl)-1H-pyrrole-2,4-dicarboxylate (7 g) dissolved in anhydrous THF (150 mL), under nitrogen atmosphere, a solution of TertBuOK 1N in THF (50 mL) was added drop wise. The reaction was left stirring. After 15 minutes water and citric acid were added (pH≅5), after 30 minutes of vigorous stirring the solution was extract with 100 mL of ethyl acetate. The organic phase was then washed with water and NaHCO3 (pH≅7.10) dried on anhydrous Na2SO4. 5 g of a white solid were obtained (yield 87%). HPLC (Method 2): m/z 250.31 [M+NH4+]+@ Rt=4.23 min. 1H NMR (400 MHz, DMSO-d6) (mixture of tautomers cheto/enolic form ratio 56:44) δ ppm 1.26 (t, J=7.07 Hz, 3H 56%) 1.28 (t, J=7.07 Hz, 3H 44%) 2.62 (m, 2H) 4.06 (t, J=6.83 Hz, 2H 44%) 4.17 (q, J=7.07 Hz, 2H 56%) 4.20 (q, J=7.07 Hz, 2H 44%) 4.38 (dt, J=12.19 J=4.02 Hz, 2H 56%) 4.51 (dd, J=11.24 J=5.08 Hz, 1H 56%) 7.00 (d, J=1.59 Hz, 1H 44%) 7.23 (d, J=1.71, 1 H 56%) 7.65 (d, J=1.59, 1H 44%) 7.85 (d, J=1.59, 1H 56%) 10.96 (s, 1H 44% OH enolic)

Example 1 Preparation of the ethyl 3-amino-4,5-dihydro-1H-pyrazolo[4,3-g]indolizine-8-carboxylate (I, wherein n is 0, R1, R2 and R4 are hydrogen, and R3 is —O—CH₂—CH₃)

To ethyl 7-cyano-8-oxo-5,6,7,8-tetrahydroindolizine-2-carboxylate (12 g, 52 mmol) in ethanol a solution of hydrazine monohydrate (6.5 g, 130 mmol) and acetic acid (9 g, 150 mmol) was added. The reaction was refluxed for 62 hours and concentrated under reduced pressure. The residue was dissolved in ethyl acetate and washed with water and NH3. The organic phase was dried on Na2SO4. 10 g of a pale yellow solid were obtained (yield 78%).

HPLC (Method 2): m/z 247.25 [M+H]+@ Rt=3.17 min. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.25 (t, J=7.13 Hz, 3H) 2.69 (t, J=6.71 Hz, 2H) 4.05 (t, J=6.71 Hz, 2H) 4.17 (q, J=7.07 Hz, 2H) 4.40-5.13 (m, 2H) 6.48 (br. s., 2H) 7.49 (s, 1H) 11.49 (br. s., 1H)

Example 2 Preparation of compound ethyl 3-[(trifluoroacetyl)amino]-4,5-dihydro-1H-pyrazolo[4,3-g]indolizine-8-carboxylate (I, wherein n is 0, R1 is —COCF3, R2 and R4 are hydrogen, and R3 is —O—CH₂—CH₃)

To the compound ethyl 3-amino-4,5-dihydro-1H-pyrazolo[4,3-g]indolizine-8-carboxylate (5 g, 20.3 mmol) in DCM, was added TEA (11 g, 110 mmol) and TFAA (21 g 100 mmol). The reaction mixture was stirred at room temperature for 3 hours and then concentrated in vacuo. To the residue diluted NH3 and MeOH were added and stirred for 1 hour. The solution was then concentrated. 100 mL of water was added and extracted with ethylacetate (3×100 mL). The organic phase was dried with anhydrous sodium sulphate to obtain a pale yellow solid (6.5 g, 92%).

LCMS (HPLC Method 2): m/z 343 [M+H]+@ Rt 4.75 min (100% by ELS detection).

1H NMR (400 MHz, DMSO-D6) δ ppm 13.13 (s, 1H) 11.61 (s, 1H) 7.62 (s, 1H) 6.68 (s, 1H) 4.21 (q, J=7.07 Hz, 2H) 4.13 (t, J=6.83 Hz, 2H) 2.81 (t, J=6.77 Hz, 2H) 1.28 (t, J=7.13 Hz, 3H)

Preparation 6 Preparation of solid supported 3-amino-4,5-dihydro-1H-pyrazolo[4,3-g]indolizine-8-carboxylic acid (XVII, wherein n is 0)

To polystyrene trityl chloride resin (Aldrich, loading 1.73 mmol/g) swelled in DCM a solution of ethyl 3-[(trifluoroacetyl)amino]-4,5-dihydro-1H-pyrazolo[4,3-g]indolizine-8-carboxylate (1.5 eq) and TEA (2 eq) in DCM (10 ml/g) was added. The mixture was shaken for 24 hrs at room temperature. The resin was filtered off, washed with DMF (3×), DCM (3×), MeOH (3×), DCM, MeOH, DCM, MeOH, DCM (3×) and the unreacted chlorides were capped washing the resin with a solution of TEA/MeOH/DCM (1:2:7) (2×). Then the resin was washed with DCM (3×), MeOH (3×), DCM (3×) and dried under vacuum. Usually loading is over 90%: Calculated loading with increase of weight was 1.00 mmol/g The resin was then used in the next step.

The resin obtained from the first step was then treated with a solution of NaOH (40 eq), H2O (1 ml/12 mmol NaOH), THF (2 ml/12 mmol NaOH) and minimal amount of MeOH to give a homogeneous solution.

The reaction was left shaking for 72 hrs at 50 C.°. Then was filtred off and washed sequentially with DMF (3×), MeOH (3×), Water, MeOH, DCM, MeOH, DCM (3×).

After a check cleavage (40% TFA in DCM r.t. 30 min) the LCMS (HPLC Method 2) m/z 219 [M+H]+@ Rt 1.02 min (100% by ELS detection), the title compound was obtained.

Preparation 7 Preparation of diethyl 1-(4-cyanobutyl)-1H-pyrrole-2,4-dicarboxylate (VII, wherein n is 1 and both of Ra′ are —CH₂—CH₃)

To diethyl 1H-pyrrole-2,4-dicarboxylate (28 g, 0.13 mol) dissolved in ACN was added 30 g of potassium carbonate (0.21 mol) and 16.5 mL of 5-bromo-pentanenitrile (0.14 mol, d=1.377). The reaction was refluxed over night. The solvent was then evaporated under reduced pressure, the residue dissolved in ethyl acetate and washed 2 times with water. The crude was purified with a silica column (10p silica) eluent cycloesane/ethyl acetate 7:3. 20 g of a white solid was obtained. HPLC (Method 2): m/z 293.51 [M+H+]+@ Rt=5.61 min. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.23-1.34 (m, 6H), 1.42-1.56 (m, 2H), 1.73-1.85 (m, 2H), 3.27-3.28 (m, 2H), 4.16-4.30 (m, 4H), 4.36 (t, J=7.0 Hz, 2H), 7.17 (d, J=2.0 Hz, 1H), 7.83 (d, J=2.0 Hz, 1H).

Preparation 8 Preparation of ethyl 8-cyano-9-oxo-6,7,8,9-tetrahydro-5H-pyrrolo[1,2-a]azepine-2-carboxylate (VIII, wherein n is 1 and Ra′ is —CH₂—CH₁₃)

To the diethyl 1-(4-cyanobutyl)-1H-pyrrole-2,4-dicarboxylate (7 g) dissolved in anhydrous THF (150 mL), under nitrogen atmosphere, a solution of TertBuOK 1N in THF (50 mL) was added drop wise. The reaction was left stirring. After 15 minutes water and citric acid were added (pH 5), after 30 minutes of vigorous stirring the solution was extract with 100 mL of Ethyl acetate. The organic phase was then washed with water and NaHCO3 (pH≅10) dried on anhydrous Na2SO4. 5 g of a white solid were obtained (yield 87%). HPLC (Method 2): m/z 264 [M+NH4+]+@ Rt=4.6 min. 1H NMR (400 MHz, DMSO-d6) (mixture of tautomers cheto/enolic form ratio 55:45) ppm 1.35 (t, J=7.07 Hz, 3H) 1.91-2.23 (m, 6H) 2.35 (m, 2H) 3.95 (t, J=6.83 Hz, 2H 45%) 4.21 (q, J=7.07 Hz, 2H 55%) 4.23 (q, J=7.07 Hz, 2H 45%) 4.51 (dt, J=12.19 J=4.02 Hz, 2H 55%) 4.57 (m, 1H 55%) 7.12 (d, J=1.59 Hz, 1H 45%) 7.17 (d, J=1.71, 1 H 55%) 7.31 (d, J=1.59, 1H 45%) 7.70 (d, J=1.59, 1H 55%) 10.82 (s, 1H 45% OH enolic)

Example 3 Preparation of the ethyl 3-amino-1,4,5,6-tetrahydropyrazolo[3,4-c]pyrrolo[1,2-a]azepine-9-carboxylate (I, wherein n is 1, R1, R2 and R4 are hydrogen, and R3 is —O—CH₂—CH₃)

To ethyl 8-cyano-9-oxo-6,7,8,9-tetrahydro-5H-pyrrolo[1,2-a]azepine-2-carboxylate (12 g, 49 mmol) in ethanol a solution of hydrazine monohydrate (6.5 g, 130 mmol) and acetic acid (9 g, 150 mmol) was added. The reaction was refluxed for 62 hours and concentrated under reduced pressure. The residue was dissolved in ethyl acetate and washed with water and NH3. The organic phase was dried on Na2SO4. 10 g of a pale yellow solid were obtained (yield 78%).

HPLC (Method 2): m/z 261.3 [M+H]+@ Rt=3.13 min. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.25 (t, J=7.1 Hz, 3H) 2.54 (t, J=6.3 Hz, 2H), 4.17 (q, J=7.2 Hz, 2H), 4.10-4.23 (m, 2H), 4.44 (br. s., 1H), 6.82 (d, J=1.8 Hz, 1H), 7.43 (d, J=2.0 Hz, 1H), 11.70 (br. s., 1H).

Example 4 Preparation of compound ethyl 3-[(trifluoroacetyl)amino]-1,4,5,6-tetrahydropyrazolo[3,4-c]pyrrolo[1,2-a]azepine-9-carboxylate (I, wherein n is 1, R1 is —COCF3, R2 and R4 are hydrogen, and R3 is —O—CH₂—CH₃)

To the compound ethyl 3-amino-1,4,5,6-tetrahydropyrazolo[3,4-c]pyrrolo[1,2-a]azepine-9-carboxylate (5 g, 19.2 mmol) in DCM, was added TEA (11 g, 110 mmol) and TFAA (21 g 100 mmol). The reaction mixture was stirred at room temperature for 3 hours and then concentrated in vacuo. To the residue diluted NH3 and MeOH were added and stirred for 1 hour. The solution was then concentrated. 100 mL of water was added and extracted with ethylacetate (3×100 mL). The organic phase was dried with anhydrous sodium sulphate to obtain a pale yellow solid (6.5 g, 92%).

LCMS (HPLC Method 2): m/z 357 [M+H]+ @ Rt 4.76 min (100% by ELS detection).

1H NMR (400 MHz, DMSO-D6) δ ppm 1.26 (t, J=7.1 Hz, 3H) 1.94-2.05 (m, 2H), 2.54-2.60 (m, 2H), 4.16-4.21 (m, 2H), 4.21-4.24 (m, 2H), 7.02 (d, J=2.0 Hz, 1H), 7.53 (d, J=1.8 Hz, 1H), 11.27 (s, 1H), 12.96 (br. s., 1H).

Preparation 9 Preparation of solid supported 3-amino-1,4,5,6-tetrahydropyrazolo[3,4-c]pyrrolo[1,2-a]azepine-9-carboxylic acid (XVII, wherein n is 1)

To polystyrene trityl chloride resin (Aldrich, loading 1.73 mmol/g) swelled in DCM a solution of ethyl 3-[(trifluoroacetyl)amino]-1,4,5,6-tetrahydropyrazolo[3,4-c]pyrrolo[1,2-a]azepine-9-carboxylate (1.5 eq) and TEA (2 eq) in DCM (10 ml/g) was added. The mixture was shaken for 24 hrs at room temperature. The resin was filtered off, washed with DMF (3×), DCM (3×), MeOH (3×), DCM, MeOH, DCM, MeOH, DCM (3×) and the unreacted chlorides were capped washing the resin with a solution of TEA/MeOH/DCM (1:2:7) (2×). Then the resin was washed with DCM (3×), MeOH (3×), DCM (3×) and dried under vacuum. Usually loading is over 90%: Calculated loading with increase of weight was 1.00 mmol/g The resin was then used in the next step.

The resin obtained from the first step was then treated with a solution of NaOH (40 eq), H2O (1 ml/12 mmol NaOH), THF (2 ml/12 mmol NaOH) and minimal amount of MeOH to give a homogeneous solution.

The reaction was left shaking for 72 hrs at 50 C.°. Then was filtered off and washed sequentially with DMF (3×), MeOH (3×), Water, MeOH, DCM, MeOH, DCM (3×).

After a check cleavage (40% TFA in DCM room temperature for 30 min) the LCMS (HPLC Method 2) m/z 233 [M+H]+@ Rt 1.15 min (100% by ELS detection), the title compound was obtained.

Example 6 Preparation A5-M1-B36 (Entry 443, Table III)

To the 3-amino-4,5-dihydro-1H-pyrazolo[4,3-g]indolizine-8-carboxylic acid bond on resin (XVII, prepared as described under preparation 6), suspended in a solution of DCM/DMF 1:1 v/v, 1.5 eq of EDC, 1.5 eq of HOBT, 5 eq of TEA and 5 eq of allylamine were added. The suspension was left shaking for 24 hours at room temperature. The resin was filtered off, washed with DMF (3×), DCM (3×), MeOH (3×), DCM, MeOH, DCM, MeOH, DCM (3×). After cleavage (TFA/DCM 40%) the product was found in LCMS 90% pure.

To the resultant 3-amino-N-prop-2-en-1-yl-4,5-dihydro-1H-pyrazolo[4,3-g]indolizine-8-carboxamide bond resin (loading 1 mmol/g) (XVIII) suspended in DCM, 5 eq of 2-chloro-benzoyl chloride, and 5.1 eq. of Pyridine were added. The suspension was left shaking over night. The resin was filtered off, washed with DMF (3×), DCM (3×), MeOH (3×), DCM, MeOH, DCM, MeOH, DCM (3×). The resultant 3-{bis[(2-chlorophenyl)carbonyl]amino}-N-prop-2-en-1-yl-4,5-dihydro-1H-pyrazolo[4,3-g]indolizine-8-carboxamide obtained but not isolated (XIX), was suspended in a solution of NaOH 1N in DMF (1:4 v/v) and was left shaking over night at room temperature. Then washed with DMF (3×), MeOH (3×), water, MeOH, DCM, MeOH, DCM (3×). After cleavage (TFA/DCM 40%) the title product was recovered and analyzed.

LCMS (HPLC Method 1A) m/z 392 [M+H]+@ Rt 2.72 min (100% by UV:MS:CLND detection).

Example 7 Preparation A42-M2-B42 (Entry 1187, Table III)

To the 3-amino-1,4,5,6-tetrahydropyrazolo[3,4-c]pyrrolo[1,2-a]azepine-9-carboxylic acid bond on resin (XVII, prepared as described under preparation 9), suspended in a solution of DCM/DMF 1:1 v/v, 1.5 eq of EDC, 1.5 eq of HOBT, 5 eq of TEA and 5 eq of piperidine were added. The suspension was left shaking for 24 hours at room temperature. The resin was filtered off, washed with DMF (3×), DCM (3×), MeOH (3×), DCM, MeOH, DCM, MeOH, DCM (3×). After a check cleavage (TFA/DCM 40%) the product was found in LCMS 90% pure.

To the resultant (3-amino-1,4,5,6-tetrahydropyrazolo[3,4-c]pyrrolo[1,2-a]azepin-9-yl)(piperidin-1-yl)methanone bond resin (loading 1 mmol/g) (XVIII) suspended in DCM, 5 eq of ethanesulphonyl chloride, and 5.1 eq. of Pyridine were added. The suspension was left shaking 24 hours at room temperature. The resin was filtered off, washed with DMF (3×), DCM (3×), MeOH (3×), DCM, MeOH, DCM, MeOH, DCM (3×). A mixture of desiderate compound and the bis-sulphonil derivative was detected.

To the resultant mixture of compounds resin (loading 1 mmol/g) a solution of 0.1M TBAF in THF was added and was shaken for 35 hours at room temperature. after that time the resin was washed off with DMF 3×, MeOH, DMF, MeOH, DCM, MeOH, DCM 3×. After cleavage (TFA/DCM 40%) the title product was recovered and analyzed.

LCMS (HPLC Method 1A) m/z 396 [M+H]+@ Rt 2.68 min (100% by UV:MS:CLND detection).

Example 8 Preparation A47-M2-B27 (Entry 1526, Table III)

To the 3-amino-1,4,5,6-tetrahydropyrazolo[3,4-c]pyrrolo[1,2-a]azepine-9-carboxylic acid bond on resin (XVII, prepared as described under preparation 9), suspended in a solution of DCM/DMF 1:1 v/v, 1.5 eq of EDC, 1.5 eq of HOBT, 5 eq of TEA and 5 eq of racemic butan-2-amine were added. The suspension was left shaking for 24 hours at room temperature. The resin was filtered off, washed with DMF (3×), DCM (3×), MeOH (3×), DCM, MeOH, DCM, MeOH, DCM (3×). After a check cleavage (TFA/DCM 40%) the product was found in LCMS 90% pure.

To the resultant 3-amino-N-(butan-2-yl)-1,4,5,6-tetrahydropyrazolo[3,4-c]pyrrolo[1,2-a]azepine-9-carboxamide bond resin (loading 1 mmol/g) (XVIII), swollen in DCM, was added TEA (10 eq), and 1-isocyanato-2-methoxybenzene (10 eq) and left shaking over night at room temperature. The resin was filtered off, washed with DMF (3×), DCM (3×), MeOH (3×), DCM, MeOH, DCM, MeOH, DCM (3×). After cleavage (TFA/DCM 40%) the title product was recovered and analyzed.

LCMS (HPLC Method 1A) m/z 437 [M+H]+@ Rt 3.42 min (100% by UV:MS:CLND detection).

Example 9 Preparation A1-M1-B1 (Entry 1, Table III)

To the ethyl 3-amino-4,5-dihydro-1H-pyrazolo[4,3-g]indolizine-8-carboxylate (prepared as described under Example 1) dissolved in a solution of THF, 5 eq of TEA and later on 2.5 eq of benzoyl chloride were added. The suspension was left shaking for 6 hours at room temperature. A LCMS reveal a poli-acetylation. The solvent was evaporated and the residue was then diluted with water and extracted with EtOAc (2×). The combined organic layers were dried over Na₂SO₄, the solvent evaporated under vacuum and the product has not been isolated. To the poli-acetylated mixture obtained from the first step a solution 2N NaOH was add. The suspension was heated to 60° C. until a limpid solution was obtained. Ethyl ether was then added and the phase separated. HCl 2N was then added to the water solution until neutrality was reached. The formed precipitate and was separated and dried under vacuum. The 3-[(phenylcarbonyl)amino]-4,5-dihydro-1H-pyrazolo[4,3-g]indolizine-8-carboxylic acid was recovered.

LCMS (HPLC Method 2) m/z 323 [M+1-1]+@ Rt 1.35 min (100% by ELS detection). 1H NMR (DMSO-d6, 400 MHz): δ ppm: 2.62 (t, J=6.7 Hz, 2H), 4.13 (t, J=6.7 Hz, 2H), 6.65 (d, J=1.2 Hz, 1H), 7.31 (d, J=8.2 Hz, 2H), 7.43 (d, J=1.7 Hz, 1H), 7.59 (t, J=7.19 Hz, 1H), 8.01 (d, J=8.6 Hz, 2H), 10.51 (s, 1H), 11.81 (br. s., 1H) 12.88 (br. s., 1H).

To the resultant carboxylic acid derived, 2 eq of EDC and 3 eq of HOBT.NH4 were dissolved in DMF and left shaken over night at room temperature. Then water and EtOAc were added, the layer separated and the water was extracted with ethyl acetate a second time. The organic layer were combined, dried and evaporated under vacuum. The title compound was purified with preparative HPLC.

LCMS m/z 339 [M+NH4]+@ Rt 2.87 min. 1H NMR (DMSO-d6,400 MHz): δ ppm: 1H NMR (DMSO-d6,400 MHz): δ ppm=2.86 (t, J=6.8 Hz, 2H), 4.08 (t, J=6.7 Hz, 2H), 6.69 (d, J=1.6 Hz, 1H), 6.77 (br. S, 1H), 7.34 (br. s, 1H), 7.45 (d, J=1.5 Hz, 1H), 7.51-7.57 (m, 2H), 7.62 (t, J=7.3 Hz, 1H), 8.02 (d, J=7.3 Hz, 2H), 10.54 (s, 1H).

Following the procedure described in examples 1 to 9 and by using any proper reactant as per the process of the invention, the following compounds of table III were also prepared.

TABLE III HPLC HPLC RT Entry Compound method min [M + H]+ 1 A1-M1-B1 2 2.87 322 2 A2-M1-B1 2 2.97 336 3 A3-M1-B1 2 2.18 286 4 A1-M1-B2 2 2.45 407 5 A1-M1-B3 1A 1.91 405 6 A1-M1-B4 2 4.08 426 7 A1-M1-B5 2 3.98 404 8 A1-M1-B6 1A 2.54 350 9 A4-M1-B7 1A 2.52 372 10 A5-M1-B8 1A 2.85 410 11 A6-M1-B9 2 4.28 432 12 A7-M1-B10 2 3.63 384 13 A8-M1-B11 1B 6.6 452 14 A9-M1-B11 1B 6.1 424 15 A10-M1-B11 1B 7.13 454 16 A11-M1-B11 1B 6.43 478 17 A12-M1-B11 1B 6.43 478 18 A13-M1-B11 1B 6.7 428 19 A14-M1-B12 1B 5.62 440 20 A15-M1-B12 1B 5.7 454 21 A12-M1-B12 1B 5.34 470 22 A13-M1-B12 1B 5.63 420 23 A14-M1-B13 1B 6.19 474 24 A15-M1-B13 1B 6.26 488 25 A8-M1-B13 1B 6.09 478 26 A9-M1-B13 1B 5.53 450 27 A15-M1-B11 1B 6.74 462 28 A8-M1-B12 1B 5.49 444 29 A9-M1-B12 1B 4.84 416 30 A10-M1-B12 1B 6.24 446 31 A11-M1-B12 1B 5.29 470 32 A10-M1-B13 1B 6.71 480 33 A11-M1-B13 1B 5.9 504 34 A12-M1-B13 1B 5.94 504 35 A13-M1-B13 1B 6.22 454 36 A14-M1-B14 1B 3.31 447 37 A15-M1-B14 1B 3.3 461 38 A8-M1-B14 1B 3.12 451 39 A9-M1-B14 1B 2.65 423 40 A10-M1-B14 1B 3.86 453 41 A11-M1-B14 1B 3.02 477 42 A12-M1-B14 1B 3.06 477 43 A13-M1-B14 1B 3.18 427 44 A14-M1-B15 1B 5.55 456 45 A15-M1-B15 1B 5.62 470 46 A8-M1-B15 1B 5.42 460 47 A9-M1-B15 1B 4.75 432 48 A10-M1-B15 1B 6.15 462 49 A11-M1-B15 1B 5.21 486 50 A12-M1-B15 1B 5.26 486 51 A13-M1-B15 1B 5.55 436 52 A14-M1-B16 1B 5.28 432 53 A15-M1-B16 1B 5.35 446 54 A8-M1-B16 1B 5.13 436 55 A13-M1-B16 1B 5.26 412 56 A9-M1-B16 1B 4.41 408 57 A10-M1-B16 1B 5.94 438 58 A11-M1-B16 1B 4.93 462 59 A12-M1-B16 1B 4.97 462 60 A14-M1-B11 1B 6.67 448 61 A16-M1-B10 2 2.52 462 62 A16-M1-B17 2 2.82 476 63 A16-M1-B18 2 2 434 64 A16-M1-B19 2 2.3 448 65 A1-M1-B20 2 4.35 404 66 A1-M1-B21 2 4.53 472 67 A1-M1-B22 2 3.92 442 68 A1-M1-B23 2 4.9 438 69 A17-M1-B24 1A 2.08 449 70 A18-M1-B24 1A 2.39 453 71 A3-M1-B24 1A 1.67 383 72 A19-M1-B24 1A 2.5 447 73 A20-M1-B24 1A 1.96 437 74 A11-M1-B24 1A 1.96 463 75 A21-M1-B24 1A 2.04 433 76 A22-M1-B24 1A 2.03 449 77 A4-M1-B24 1A 1.92 399 78 A6-M1-B24 1A 2.17 449 79 A23-M1-B24 1A 1.52 387 80 A24-M1-B24 1A 2.58 447 81 A25-M1-B24 1A 2.86 461 82 A26-M1-B24 1A 2.26 455 83 A27-M1-B24 1A 1.7 385 84 A28-M1-B24 1A 2.07 437 85 A29-M1-B24 1A 1.46 357 86 A8-M1-B24 1A 2.08 437 87 A30-M1-B24 1A 2.37 451 88 A17-M1-B25 1A 2.18 443 89 A31-M1-B25 1A 2.06 456 90 A18-M1-B25 1A 2.51 447 91 A3-M1-B25 1A 1.75 377 92 A19-M1-B25 1A 2.58 441 93 A20-M1-B25 1A 2.07 431 94 A32-M1-B25 1A 1.67 414 95 A11-M1-B25 1A 2.08 457 96 A21-M1-B25 1A 2.14 427 97 A24-M1-B25 1A 2.67 441 98 A26-M1-B25 1A 2.37 449 99 A33-M1-B25 1A 1.95 393 100 A5-M1-B25 1A 2.12 447 101 A27-M1-B25 1A 1.79 379 102 A28-M1-B25 1A 2.2 431 103 A29-M1-B25 1A 1.52 351 104 A1-M1-B25 1A 2.07 413 105 A8-M1-B25 1A 2.2 431 106 A17-M1-B26 1A 2.32 443 107 A31-M1-B26 1A 2.19 456 108 A18-M1-B26 1A 2.65 447 109 A3-M1-B26 1A 1.87 377 110 A19-M1-B26 1A 2.73 441 111 A20-M1-B26 1A 2.19 431 112 A32-M1-B26 1A 1.78 414 113 A11-M1-B26 1A 2.2 457 114 A21-M1-B26 1A 2.29 427 115 A22-M1-B26 1A 2.29 443 116 A6-M1-B26 1A 2.4 443 117 A24-M1-B26 1A 2.83 441 118 A26-M1-B26 1A 2.55 449 119 A33-M1-B26 1A 2.09 393 120 A5-M1-B26 1A 2.25 447 121 A34-M1-B26 1A 1.76 365 122 A27-M1-B26 1A 1.91 379 123 A28-M1-B26 1A 2.33 431 124 A1-M1-B26 1A 2.18 413 125 A8-M1-B26 1A 2.35 431 126 A17-M1-B27 1A 3.01 408 127 A31-M1-B27 1A 2.89 421 128 A18-M1-B27 1A 3.37 412 129 A3-M1-B27 1A 2.6 342 130 A19-M1-B27 1A 3.39 406 131 A20-M1-B27 1A 2.92 396 132 A32-M1-B27 1A 2.43 379 133 A21-M1-B27 1A 3.03 392 134 A6-M1-B27 1A 3.1 408 135 A23-M1-B27 1A 2.34 346 136 A24-M1-B27 1A 3.46 406 137 A25-M1-B27 1A 3.69 420 138 A26-M1-B27 1A 3.27 414 139 A35-M1-B27 1A 3.32 406 140 A33-M1-B27 1A 2.83 358 141 A5-M1-B27 1A 2.99 412 142 A28-M1-B27 1A 3.06 396 143 A1-M1-B27 1A 2.92 378 144 A8-M1-B27 1A 3.08 396 145 A30-M1-B27 1A 3.36 410 146 A17-M1-B28 1A 3.11 420 147 A31-M1-B28 1A 3.02 433 148 A18-M1-B28 1A 3.45 424 149 A3-M1-B28 1A 2.73 354 150 A19-M1-B28 1A 3.48 418 151 A20-M1-B28 1A 3.04 408 152 A32-M1-B28 1A 2.58 391 153 A11-M1-B28 1A 3.04 434 154 A21-M1-B28 1A 3.14 404 155 A4-M1-B28 1A 3.08 370 156 A6-M1-B28 1A 3.21 420 157 A23-M1-B28 1A 2.48 358 158 A24-M1-B28 1A 3.55 418 159 A26-M1-B28 1A 3.37 426 160 A35-M1-B28 1A 3.4 418 161 A36-M1-B28 1A 3.15 438 162 A33-M1-B28 1A 2.94 370 163 A5-M1-B28 1A 3.1 424 164 A28-M1-B28 1A 3.16 408 165 A29-M1-B28 1A 2.44 328 166 A1-M1-B28 1A 3.03 390 167 A8-M1-B28 1A 3.19 408 168 A30-M1-B28 1A 3.46 422 169 A17-M1-B29 1A 2.12 423 170 A18-M1-B29 1A 2.44 427 171 A3-M1-B29 1A 1.69 357 172 A20-M1-B29 1A 2.01 411 173 A32-M1-B29 1A 1.63 394 174 A11-M1-B29 1A 2.03 437 175 A21-M1-B29 1A 2.07 407 176 A22-M1-B29 1A 2.1 423 177 A4-M1-B29 1A 1.98 373 178 A6-M1-B29 1A 2.23 423 179 A24-M1-B29 1A 2.62 421 180 A26-M1-B29 1A 2.32 429 181 A33-M1-B29 1A 1.91 373 182 A27-M1-B29 1A 1.75 359 183 A28-M1-B29 1A 2.13 411 184 A1-M1-B29 1A 2 393 185 A8-M1-B29 1A 2.13 411 186 A17-M1-B8 1A 2.87 406 187 A18-M1-B8 1A 3.24 410 188 A3-M1-B8 1A 2.44 340 189 A19-M1-B8 1A 3.27 404 190 A20-M1-B8 1A 2.79 394 191 A32-M1-B8 1A 2.3 377 192 A11-M1-B8 1A 2.79 420 193 A21-M1-B8 1A 2.88 390 194 A22-M1-B8 1A 2.85 406 195 A4-M1-B8 1A 2.79 356 196 A6-M1-B8 1A 2.97 406 197 A24-M1-B8 1A 3.35 404 198 A25-M1-B8 1A 3.57 418 199 A26-M1-B8 1A 3.14 412 200 A35-M1-B8 1A 3.17 404 201 A36-M1-B8 1A 2.92 424 202 A33-M1-B8 1A 2.68 356 203 A34-M1-B8 1A 2.32 328 204 A27-M1-B8 1A 2.51 342 205 A28-M1-B8 1A 2.93 394 206 A8-M1-B8 1A 2.95 394 207 A30-M1-B8 1A 3.23 408 208 A17-M1-B10 1A 2.82 394 209 A31-M1-B10 1A 2.67 407 210 A18-M1-B10 1A 3.18 398 211 A3-M1-B10 1A 2.37 328 212 A19-M1-B10 1A 3.23 392 213 A20-M1-B10 1A 2.72 382 214 A32-M1-B10 1A 2.22 365 215 A11-M1-B10 1A 2.73 408 216 A22-M1-B10 1A 2.78 394 217 A6-M1-B10 1A 2.92 394 218 A24-M1-B10 1A 3.31 392 219 A25-M1-B10 1A 3.55 406 220 A26-M1-B10 1A 3.08 400 221 A35-M1-B10 1A 3.13 392 222 A36-M1-B10 1A 2.86 412 223 A33-M1-B10 1A 2.6 344 224 A5-M1-B10 1A 2.78 398 225 A27-M1-B10 1A 2.44 330 226 A28-M1-B10 1A 2.87 382 227 A1-M1-B10 1A 2.71 364 228 A8-M1-B10 1A 2.88 382 229 A30-M1-B10 1A 3.17 396 230 A17-M1-B17 1A 3.07 408 231 A31-M1-B17 1A 2.95 421 232 A18-M1-B17 1A 3.41 412 233 A3-M1-B17 1A 2.65 342 234 A19-M1-B17 1A 3.43 406 235 A20-M1-B17 1A 2.97 396 236 A32-M1-B17 1A 2.5 379 237 A11-M1-B17 1A 2.97 422 238 A21-M1-B17 1A 3.07 392 239 A4-M1-B17 1A 2.98 358 240 A6-M1-B17 1A 3.15 408 241 A24-M1-B17 1A 3.5 406 242 A25-M1-B17 1A 3.72 420 243 A26-M1-B17 1A 3.33 414 244 A36-M1-B17 1A 3.1 426 245 A33-M1-B17 1A 2.88 358 246 A5-M1-B17 1A 3.04 412 247 A27-M1-B17 1A 2.7 344 248 A28-M1-B17 1A 3.11 396 249 A1-M1-B17 1A 2.96 378 250 A8-M1-B17 1A 3.13 396 251 A30-M1-B17 1A 3.4 410 252 A17-M1-B30 1A 2.7 392 253 A31-M1-B30 1A 2.52 405 254 A19-M1-B30 1A 3.11 390 255 A20-M1-B30 1A 2.58 380 256 A32-M1-B30 1A 2.08 363 257 A21-M1-B30 1A 2.68 376 258 A22-M1-B30 1A 2.65 392 259 A4-M1-B30 1A 2.58 342 260 A24-M1-B30 1A 3.19 390 261 A25-M1-B30 1A 3.45 404 262 A26-M1-B30 1A 2.96 398 263 A35-M1-B30 1A 3.01 390 264 A36-M1-B30 1A 2.72 410 265 A33-M1-B30 1A 2.46 342 266 A5-M1-B30 1A 2.65 396 267 A28-M1-B30 1A 2.73 380 268 A1-M1-B30 1A 2.57 362 269 A8-M1-B30 1A 2.74 380 270 A30-M1-B30 1A 3.06 394 271 A17-M1-B3 1A 2.04 435 272 A31-M1-B3 1A 1.93 448 273 A18-M1-B3 1A 2.38 439 274 A3-M1-B3 1A 1.62 369 275 A37-M1-B3 1A 2.14 448 276 A19-M1-B3 1A 2.47 433 277 A20-M1-B3 1A 1.92 423 278 A32-M1-B3 1A 1.55 406 279 A11-M1-B3 1A 1.94 449 280 A21-M1-B3 1A 2.01 419 281 A22-M1-B3 1A 2 435 282 A4-M1-B3 1A 1.88 385 283 A6-M1-B3 1A 2.13 435 284 A24-M1-B3 1A 2.55 433 285 A25-M1-B3 1A 2.85 447 286 A26-M1-B3 1A 2.23 441 287 A36-M1-B3 1A 2.07 453 288 A34-M1-B3 1A 1.53 357 289 A27-M1-B3 1A 1.65 371 290 A28-M1-B3 1A 2.04 423 291 A29-M1-B3 1A 1.41 343 292 A8-M1-B3 1A 2.05 423 293 A30-M1-B3 1A 2.39 437 294 A17-M1-B7 1A 2.63 422 295 A31-M1-B7 1A 2.46 435 296 A3-M1-B7 1A 2.17 356 297 A19-M1-B7 1A 3.06 420 298 A20-M1-B7 1A 2.52 410 299 A32-M1-B7 1A 2.04 393 300 A11-M1-B7 1A 2.54 436 301 A21-M1-B7 1A 2.62 406 302 A22-M1-B7 1A 2.6 422 303 A6-M1-B7 1A 2.74 422 304 A24-M1-B7 1A 3.13 420 305 A25-M1-B7 1A 3.39 434 306 A26-M1-B7 1A 2.89 428 307 A35-M1-B7 1A 2.95 420 308 A36-M1-B7 1A 2.67 440 309 A33-M1-B7 1A 2.42 372 310 A5-M1-B7 1A 2.58 426 311 A34-M1-B7 1A 2.06 344 312 A27-M1-B7 1A 2.23 358 313 A28-M1-B7 1A 2.68 410 314 A29-M1-B7 1A 1.89 330 315 A8-M1-B7 1A 2.69 410 316 A30-M1-B7 1A 3 424 317 A17-M1-B31 1A 2.24 463 318 A31-M1-B31 1A 2.13 476 319 A18-M1-B31 1A 2.51 467 320 A3-M1-B31 1A 1.84 397 321 A19-M1-B31 1A 2.63 461 322 A20-M1-B31 1A 2.11 451 323 A32-M1-B31 1A 1.76 434 324 A11-M1-B31 1A 2.14 477 325 A21-M1-B31 1A 2.22 447 326 A22-M1-B31 1A 2.2 463 327 A4-M1-B31 1A 2.11 413 328 A24-M1-B31 1A 2.71 461 329 A26-M1-B31 1A 2.43 469 330 A33-M1-B31 1A 2.04 413 331 A5-M1-B31 1A 2.17 467 332 A27-M1-B31 1A 1.88 399 333 A28-M1-B31 1A 2.26 451 334 A29-M1-B31 1A 1.62 371 335 A1-M1-B31 1A 2.13 433 336 A8-M1-B31 1A 2.26 451 337 A17-M1-B32 1A 2.11 463 338 A31-M1-B32 1A 2 476 339 A18-M1-B32 1A 2.41 467 340 A37-M1-B32 1A 2.21 476 341 A19-M1-B32 1A 2.52 461 342 A20-M1-B32 1A 2 451 343 A32-M1-B32 1A 1.63 434 344 A11-M1-B32 1A 2.03 477 345 A21-M1-B32 1A 2.09 447 346 A4-M1-B32 1A 1.98 413 347 A6-M1-B32 1A 2.2 463 348 A24-M1-B32 1A 2.6 461 349 A25-M1-B32 1A 2.88 475 350 A26-M1-B32 1A 2.3 469 351 A35-M1-B32 1A 2.4 461 352 A36-M1-B32 1A 2.13 481 353 A33-M1-B32 1A 1.89 413 354 A5-M1-B32 1A 2.02 467 355 A27-M1-B32 1A 1.75 399 356 A28-M1-B32 1A 2.12 451 357 A1-M1-B32 1A 2 433 358 A8-M1-B32 1A 2.12 451 359 A30-M1-B32 1A 2.44 465 360 A17-M1-B33 1A 2.62 410 361 A31-M1-B33 1A 2.44 423 362 A3-M1-B33 1A 2.15 344 363 A19-M1-B33 1A 3.05 408 364 A20-M1-B33 1A 2.51 398 365 A32-M1-B33 1A 2.01 381 366 A11-M1-B33 1A 2.51 424 367 A21-M1-B33 1A 2.61 394 368 A22-M1-B33 1A 2.59 410 369 A4-M1-B33 1A 2.5 360 370 A24-M1-B33 1A 3.13 408 371 A25-M1-B33 1A 3.39 422 372 A26-M1-B33 1A 2.89 416 373 A35-M1-B33 1A 2.93 408 374 A36-M1-B33 1A 2.65 428 375 A33-M1-B33 1A 2.39 360 376 A5-M1-B33 1A 2.57 414 377 A27-M1-B33 1A 2.22 346 378 A28-M1-B33 1A 2.66 398 379 A1-M1-B33 1A 2.5 380 380 A8-M1-B33 1A 2.67 398 381 A30-M1-B33 1A 3 412 382 A17-M1-B34 1A 2.16 503 383 A31-M1-B34 1A 2.05 516 384 A18-M1-B34 1A 2.48 507 385 A3-M1-B34 1A 1.77 437 386 A19-M1-B34 1A 2.57 501 387 A20-M1-B34 1A 2.05 491 388 A32-M1-B34 1A 1.7 474 389 A11-M1-B34 1A 2.08 517 390 A21-M1-B34 1A 2.14 487 391 A22-M1-B34 1A 2.14 503 392 A4-M1-B34 1A 2.04 453 393 A6-M1-B34 1A 2.26 503 394 A24-M1-B34 1A 2.63 501 395 A25-M1-B34 1A 2.9 515 396 A26-M1-B34 1A 2.36 509 397 A35-M1-B34 1A 2.44 501 398 A36-M1-B34 1A 2.19 521 399 A33-M1-B34 1A 1.95 453 400 A5-M1-B34 1A 2.11 507 401 A27-M1-B34 1A 1.81 439 402 A28-M1-B34 1A 2.18 491 403 A29-M1-B34 1A 1.57 411 404 A8-M1-B34 1A 2.15 491 405 A30-M1-B34 1A 2.49 505 406 A17-M1-B35 1A 2.29 498 407 A31-M1-B35 1A 2.18 511 408 A18-M1-B35 1A 2.6 502 409 A37-M1-B35 1A 2.38 511 410 A19-M1-B35 1A 2.65 496 411 A32-M1-B35 1A 1.83 469 412 A11-M1-B35 1A 2.19 512 413 A22-M1-B35 1A 2.25 498 414 A4-M1-B35 1A 2.17 448 415 A6-M1-B35 1A 2.38 498 416 A25-M1-B35 1A 3.01 510 417 A26-M1-B35 1A 2.48 504 418 A35-M1-B35 1A 2.55 496 419 A36-M1-B35 1A 2.32 516 420 A5-M1-B35 1A 2.24 502 421 A27-M1-B35 1A 1.94 434 422 A28-M1-B35 1A 2.31 486 423 A29-M1-B35 1A 1.69 406 424 A1-M1-B35 1A 2.18 468 425 A8-M1-B35 1A 2.31 486 426 A30-M1-B35 1A 2.63 500 427 A17-M1-B36 1A 2.76 392 428 A31-M1-B36 1A 2.6 405 429 A18-M1-B36 1A 3.13 396 430 A3-M1-B36 1A 2.29 326 431 A19-M1-B36 1A 3.17 390 432 A32-M1-B36 1A 2.15 363 433 A11-M1-B36 1A 2.66 406 434 A21-M1-B36 1A 2.77 376 435 A22-M1-B36 1A 2.73 392 436 A6-M1-B36 1A 2.85 392 437 A24-M1-B36 1A 3.26 390 438 A25-M1-B36 1A 3.5 404 439 A26-M1-B36 1A 3.03 398 440 A35-M1-B36 1A 3.08 390 441 A36-M1-B36 1A 2.8 410 442 A33-M1-B36 1A 2.54 342 443 A5-M1-B36 1A 2.72 396 444 A34-M1-B36 1A 2.17 314 445 A27-M1-B36 1A 2.35 328 446 A28-M1-B36 1A 2.81 380 447 A1-M1-B36 1A 2.64 362 448 A8-M1-B36 1A 2.81 380 449 A30-M1-B36 1A 3.13 394 450 A17-M1-B37 1A 2.05 449 451 A31-M1-B37 1A 1.94 462 452 A18-M1-B37 1A 2.35 453 453 A3-M1-B37 1A 1.64 383 454 A19-M1-B37 1A 2.43 447 455 A20-M1-B37 1A 1.93 437 456 A32-M1-B37 1A 1.57 420 457 A11-M1-B37 1A 1.96 463 458 A21-M1-B37 1A 2.02 433 459 A22-M1-B37 1A 2.04 449 460 A4-M1-B37 1A 1.9 399 461 A6-M1-B37 1A 2.14 449 462 A24-M1-B37 1A 2.56 447 463 A25-M1-B37 1A 2.78 461 464 A26-M1-B37 1A 2.24 455 465 A36-M1-B37 1A 2.05 467 466 A33-M1-B37 1A 1.84 399 467 A5-M1-B37 1A 1.98 453 468 A27-M1-B37 1A 1.68 385 469 A28-M1-B37 1A 2.05 437 470 A29-M1-B37 1A 1.45 357 471 A8-M1-B37 1A 2.05 437 472 A30-M1-B37 1A 2.37 451 473 A17-M1-B38 1A 2.97 438 474 A31-M1-B38 1A 2.85 451 475 A3-M1-B38 1A 2.56 372 476 A19-M1-B38 1A 3.37 436 477 A20-M1-B38 1A 2.88 426 478 A32-M1-B38 1A 2.4 409 479 A11-M1-B38 1A 2.88 452 480 A21-M1-B38 1A 2.98 422 481 A22-M1-B38 1A 2.95 438 482 A4-M1-B38 1A 2.9 388 483 A6-M1-B38 1A 3.07 438 484 A24-M1-B38 1A 3.44 436 485 A25-M1-B38 1A 3.66 450 486 A26-M1-B38 1A 3.24 444 487 A35-M1-B38 1A 3.27 436 488 A36-M1-B38 1A 3.02 456 489 A5-M1-B38 1A 2.95 442 490 A27-M1-B38 1A 2.62 374 491 A28-M1-B38 1A 3.03 426 492 A1-M1-B38 1A 2.88 408 493 A8-M1-B38 1A 3.05 426 494 A30-M1-B38 1A 3.33 440 495 A17-M1-B39 1A 3.09 408 496 A31-M1-B39 1A 2.99 421 497 A3-M1-B39 1A 2.7 342 498 A19-M1-B39 1A 3.46 406 499 A20-M1-B39 1A 3 396 500 A32-M1-B39 1A 2.53 379 501 A11-M1-B39 1A 3.01 422 502 A21-M1-B39 1A 3.11 392 503 A22-M1-B39 1A 3.06 408 504 A4-M1-B39 1A 3.04 358 505 A6-M1-B39 1A 3.19 408 506 A24-M1-B39 1A 3.54 406 507 A25-M1-B39 1A 3.75 420 508 A26-M1-B39 1A 3.36 414 509 A35-M1-B39 1A 3.38 406 510 A36-M1-B39 1A 3.13 426 511 A33-M1-B39 1A 2.92 358 512 A5-M1-B39 1A 3.07 412 513 A34-M1-B39 1A 2.57 330 514 A27-M1-B39 1A 2.75 344 515 A28-M1-B39 1A 3.15 396 516 A1-M1-B39 1A 3 378 517 A8-M1-B39 1A 3.16 396 518 A30-M1-B39 1A 3.43 410 519 A17-M1-B40 1A 2.09 463 520 A31-M1-B40 1A 1.97 476 521 A3-M1-B40 1A 1.68 397 522 A19-M1-B40 1A 2.49 461 523 A20-M1-B40 1A 1.96 451 524 A32-M1-B40 1A 1.62 434 525 A11-M1-B40 1A 2 477 526 A21-M1-B40 1A 2.07 447 527 A22-M1-B40 1A 2.07 463 528 A4-M1-B40 1A 1.94 413 529 A6-M1-B40 1A 2.18 463 530 A24-M1-B40 1A 2.57 461 531 A25-M1-B40 1A 2.85 475 532 A26-M1-B40 1A 2.29 469 533 A35-M1-B40 1A 2.37 461 534 A36-M1-B40 1A 2.12 481 535 A33-M1-B40 1A 1.87 413 536 A5-M1-B40 1A 2.02 467 537 A34-M1-B40 1A 1.6 385 538 A27-M1-B40 1A 1.73 399 539 A28-M1-B40 1A 2.1 451 540 A29-M1-B40 1A 1.49 371 541 A1-M1-B40 1A 1.97 433 542 A8-M1-B40 1A 2.11 451 543 A30-M1-B40 1A 2.42 465 544 A17-M1-B41 1A 2.92 406 545 A31-M1-B41 1A 2.78 419 546 A18-M1-B41 1A 3.28 410 547 A3-M1-B41 1A 2.49 340 548 A19-M1-B41 1A 3.31 404 549 A20-M1-B41 1A 2.83 394 550 A32-M1-B41 1A 2.33 377 551 A11-M1-B41 1A 2.82 420 552 A21-M1-B41 1A 2.93 390 553 A22-M1-B41 1A 2.88 406 554 A4-M1-B41 1A 2.85 356 555 A6-M1-B41 1A 3.02 406 556 A24-M1-B41 1A 3.39 404 557 A25-M1-B41 1A 3.61 418 558 A26-M1-B41 1A 3.19 412 559 A35-M1-B41 1A 3.22 404 560 A33-M1-B41 1A 2.72 356 561 A5-M1-B41 1A 2.89 410 562 A27-M1-B41 1A 2.56 342 563 A28-M1-B41 1A 2.98 394 564 A1-M1-B41 1A 2.82 376 565 A30-M1-B41 1A 3.27 408 566 A17-M1-B42 1A 3.14 420 567 A18-M1-B42 1A 3.5 424 568 A19-M1-B42 1A 3.51 418 569 A32-M1-B42 1A 2.6 391 570 A11-M1-B42 1A 3.06 434 571 A22-M1-B42 1A 3.11 420 572 A4-M1-B42 1A 3.09 370 573 A24-M1-B42 1A 3.58 418 574 A25-M1-B42 1A 3.79 432 575 A26-M1-B42 1A 3.41 426 576 A35-M1-B42 1A 3.43 418 577 A36-M1-B42 1A 3.18 438 578 A5-M1-B42 1A 3.12 424 579 A34-M1-B42 1A 2.63 342 580 A27-M1-B42 1A 2.81 356 581 A28-M1-B42 1A 3.21 408 582 A1-M1-B42 1A 3.06 390 583 A8-M1-B42 1A 3.22 408 584 A30-M1-B42 1A 3.48 422 585 A17-M1-B6 1A 2.66 380 586 A31-M1-B6 1A 2.49 393 587 A18-M1-B6 1A 3.04 384 588 A3-M1-B6 1A 2.19 314 589 A19-M1-B6 1A 3.09 378 590 A20-M1-B6 1A 2.55 368 591 A32-M1-B6 1A 2.04 351 592 A11-M1-B6 1A 2.55 394 593 A6-M1-B6 1A 2.76 380 594 A24-M1-B6 1A 3.17 378 595 A25-M1-B6 1A 3.43 392 596 A26-M1-B6 1A 2.92 386 597 A35-M1-B6 1A 2.98 378 598 A36-M1-B6 1A 2.69 398 599 A33-M1-B6 1A 2.42 330 600 A5-M1-B6 1A 2.62 384 601 A28-M1-B6 1A 2.7 368 602 A8-M1-B6 1A 2.71 368 603 A30-M1-B6 1A 3.04 382 604 A17-M1-B43 1A 2.16 449 605 A18-M1-B43 1A 2.47 453 606 A19-M1-B43 1A 2.58 447 607 A32-M1-B43 1A 1.68 420 608 A11-M1-B43 1A 2.05 463 609 A21-M1-B43 1A 2.13 433 610 A22-M1-B43 1A 2.14 449 611 A6-M1-B43 1A 2.26 449 612 A24-M1-B43 1A 2.65 447 613 A26-M1-B43 1A 2.35 455 614 A33-M1-B43 1A 1.94 399 615 A5-M1-B43 1A 2.1 453 616 A28-M1-B43 1A 2.18 437 617 A1-M1-B43 1A 2.05 419 618 A8-M1-B43 1A 2.17 437 619 A38-M1-B41 3 4.82 444 620 A39-M1-B8 3 5.21 418 621 A39-M1-B34 3 4.52 515 622 A14-M2-B11 2 6.05 462 623 A15-M2-B11 2 5.97 476 624 A8-M2-B11 2 6 466 625 A9-M2-B11 2 5.27 438 626 A14-M2-B12 2 5.03 454 627 A15-M2-B12 2 4.93 468 628 A9-M2-B12 2 4.27 430 629 A16-M2-B12 2 3.45 538 630 A9-M2-B13 2 4.67 464 631 A14-M2-B15 2 4.9 470 632 A8-M2-B15 2 4.77 474 633 A9-M2-B15 2 4.18 446 634 A16-M2-B15 2 3.4 554 635 A14-M2-B19 2 3.93 378 636 A8-M2-B19 2 3.87 382 637 A9-M2-B19 2 3.08 354 638 A16-M2-B19 2 2.53 462 639 A26-M2-B43 1A 2.43 469 640 A17-M2-B24 1A 2.145 463 641 A19-M2-B24 1A 2.55 461 642 A32-M2-B24 1A 1.635 434 643 A11-M2-B24 1A 2.045 477 644 A4-M2-B24 1A 1.99 413 645 A6-M2-B24 1A 2.25 463 646 A24-M2-B24 1A 2.615 461 647 A25-M2-B24 1A 2.91 475 648 A28-M2-B24 1A 2.18 451 649 A29-M2-B24 1A 1.505 371 650 A8-M2-B24 1A 2.18 451 651 A30-M2-B24 1A 2.495 465 652 A17-M2-B25 1A 2.24 457 653 A18-M2-B25 1A 2.59 461 654 A3-M2-B25 1A 1.82 391 655 A19-M2-B25 1A 2.67 455 656 A20-M2-B25 1A 2.14 445 657 A32-M2-B25 1A 1.725 428 658 A21-M2-B25 1A 2.21 441 659 A4-M2-B25 1A 2.11 407 660 A6-M2-B25 1A 2.34 457 661 A26-M2-B25 1A 2.48 463 662 A33-M2-B25 1A 2.04 407 663 A34-M2-B25 1A 1.715 379 664 A28-M2-B25 1A 2.265 445 665 A1-M2-B25 1A 2.13 427 666 A8-M2-B25 1A 2.27 445 667 A17-M2-B26 1A 2.4 457 668 A31-M2-B26 1A 2.285 470 669 A18-M2-B26 1A 2.76 461 670 A3-M2-B26 1A 1.95 391 671 A19-M2-B26 1A 2.84 455 672 A20-M2-B26 1A 2.31 445 673 A32-M2-B26 1A 1.855 428 674 A11-M2-B26 1A 2.31 471 675 A21-M2-B26 1A 2.39 441 676 A6-M2-B26 1A 2.51 457 677 A24-M2-B26 1A 2.905 455 678 A26-M2-B26 1A 2.645 463 679 A33-M2-B26 1A 2.18 407 680 A5-M2-B26 1A 2.36 461 681 A28-M2-B26 1A 2.44 445 682 A1-M2-B26 1A 2.285 427 683 A8-M2-B26 1A 2.445 445 684 A17-M2-B27 1A 3.09 422 685 A31-M2-B27 1A 2.96 435 686 A18-M2-B27 1A 3.42 426 687 A19-M2-B27 1A 3.45 420 688 A20-M2-B27 1A 3.02 410 689 A32-M2-B27 1A 2.51 393 690 A11-M2-B27 1A 2.99 436 691 A22-M2-B27 1A 3.05 422 692 A6-M2-B27 1A 3.17 422 693 A24-M2-B27 1A 3.53 420 694 A25-M2-B27 1A 3.75 434 695 A26-M2-B27 1A 3.35 428 696 A35-M2-B27 1A 3.37 420 697 A36-M2-B27 1A 3.11 440 698 A5-M2-B27 1A 3.08 426 699 A27-M2-B27 1A 2.73 358 700 A28-M2-B27 1A 3.14 410 701 A1-M2-B27 1A 2.99 392 702 A8-M2-B27 1A 3.15 410 703 A30-M2-B27 1A 3.41 424 704 A17-M2-B28 1A 3.18 434 705 A31-M2-B28 1A 3.085 447 706 A18-M2-B28 1A 3.52 438 707 A19-M2-B28 1A 3.54 432 708 A20-M2-B28 1A 3.13 422 709 A32-M2-B28 1A 2.63 405 710 A11-M2-B28 1A 3.1 448 711 A21-M2-B28 1A 3.19 418 712 A22-M2-B28 1A 3.14 434 713 A24-M2-B28 1A 3.61 432 714 A25-M2-B28 1A 3.82 446 715 A26-M2-B28 1A 3.44 440 716 A35-M2-B28 1A 3.46 432 717 A33-M2-B28 1A 3.04 384 718 A5-M2-B28 1A 3.18 438 719 A28-M2-B28 1A 3.245 422 720 A1-M2-B28 1A 3.09 404 721 A8-M2-B28 1A 3.25 422 722 A30-M2-B28 1A 3.51 436 723 A17-M2-B29 1A 2.18 437 724 A3-M2-B29 1A 1.76 371 725 A19-M2-B29 1A 2.59 435 726 A32-M2-B29 1A 1.675 408 727 A11-M2-B29 1A 2.09 451 728 A26-M2-B29 1A 2.4 443 729 A28-M2-B29 1A 2.21 425 730 A8-M2-B29 1A 2.205 425 731 A17-M2-B8 1A 2.95 420 732 A31-M2-B8 1A 2.815 433 733 A3-M2-B8 1A 2.52 354 734 A19-M2-B8 1A 3.33 418 735 A20-M2-B8 1A 2.88 408 736 A32-M2-B8 1A 2.37 391 737 A11-M2-B8 1A 2.86 434 738 A21-M2-B8 1A 2.95 404 739 A22-M2-B8 1A 2.91 420 740 A4-M2-B8 1A 2.86 370 741 A24-M2-B8 1A 3.4 418 742 A25-M2-B8 1A 3.63 432 743 A26-M2-B8 1A 3.22 426 744 A35-M2-B8 1A 3.24 418 745 A36-M2-B8 1A 2.98 438 746 A33-M2-B8 1A 2.78 370 747 A5-M2-B8 1A 2.94 424 748 A27-M2-B8 1A 2.58 356 749 A28-M2-B8 1A 3.01 408 750 A1-M2-B8 1A 2.85 390 751 A8-M2-B8 1A 3.02 408 752 A30-M2-B8 1A 3.295 422 753 A17-M2-B10 1A 2.895 408 754 A31-M2-B10 1A 2.74 421 755 A18-M2-B10 1A 3.27 412 756 A19-M2-B10 1A 3.3 406 757 A20-M2-B10 1A 2.82 396 758 A32-M2-B10 1A 2.28 379 759 A11-M2-B10 1A 2.8 422 760 A24-M2-B10 1A 3.37 406 761 A26-M2-B10 1A 3.17 414 762 A35-M2-B10 1A 3.2 406 763 A33-M2-B10 1A 2.72 358 764 A5-M2-B10 1A 2.88 412 765 A28-M2-B10 1A 2.95 396 766 A8-M2-B10 1A 2.96 396 767 A30-M2-B10 1A 3.26 410 768 A17-M2-B17 1A 3.1 422 769 A31-M2-B17 1A 2.99 435 770 A18-M2-B17 1A 3.455 426 771 A3-M2-B17 1A 2.71 356 772 A32-M2-B17 1A 2.55 393 773 A11-M2-B17 1A 3.03 436 774 A21-M2-B17 1A 3.12 406 775 A22-M2-B17 1A 3.07 422 776 A4-M2-B17 1A 3.055 372 777 A6-M2-B17 1A 3.195 422 778 A24-M2-B17 1A 3.54 420 779 A26-M2-B17 1A 3.37 428 780 A35-M2-B17 1A 3.38 420 781 A36-M2-B17 1A 3.13 440 782 A5-M2-B17 1A 3.1 426 783 A27-M2-B17 1A 2.76 358 784 A28-M2-B17 1A 3.17 410 785 A8-M2-B17 1A 3.18 410 786 A30-M2-B17 1A 3.45 424 787 A17-M2-B30 1A 2.79 406 788 A31-M2-B30 1A 2.61 419 789 A18-M2-B30 1A 3.16 410 790 A19-M2-B30 1A 3.2 404 791 A32-M2-B30 1A 2.15 377 792 A11-M2-B30 1A 2.67 420 793 A4-M2-B30 1A 2.67 356 794 A6-M2-B30 1A 2.86 406 795 A24-M2-B30 1A 3.27 404 796 A25-M2-B30 1A 3.53 418 797 A26-M2-B30 1A 3.05 412 798 A35-M2-B30 1A 3.09 404 799 A33-M2-B30 1A 2.58 356 800 A27-M2-B30 1A 2.37 342 801 A28-M2-B30 1A 2.84 394 802 A30-M2-B30 1A 3.135 408 803 A17-M2-B3 1A 2.12 449 804 A31-M2-B3 1A 1.99 462 805 A18-M2-B3 1A 2.42 453 806 A3-M2-B3 1A 1.69 383 807 A37-M2-B3 1A 2.24 462 808 A19-M2-B3 1A 2.52 447 809 A32-M2-B3 1A 1.61 420 810 A11-M2-B3 1A 2.03 463 811 A21-M2-B3 1A 2.075 433 812 A24-M2-B3 1A 2.61 447 813 A25-M2-B3 1A 2.87 461 814 A26-M2-B3 1A 2.315 455 815 A33-M2-B3 1A 1.92 399 816 A5-M2-B3 1A 2.05 453 817 A34-M2-B3 1A 1.59 371 818 A27-M2-B3 1A 1.715 385 819 A28-M2-B3 1A 2.13 437 820 A29-M2-B3 1A 1.47 357 821 A1-M2-B3 1A 2.01 419 822 A8-M2-B3 1A 2.125 437 823 A17-M2-B7 1A 2.715 436 824 A31-M2-B7 1A 2.54 449 825 A18-M2-B7 1A 3.08 440 826 A19-M2-B7 1A 3.125 434 827 A11-M2-B7 1A 2.61 450 828 A21-M2-B7 1A 2.7 420 829 A24-M2-B7 1A 3.21 434 830 A25-M2-B7 1A 3.46 448 831 A26-M2-B7 1A 2.99 442 832 A35-M2-B7 1A 3.02 434 833 A36-M2-B7 1A 2.74 454 834 A33-M2-B7 1A 2.51 386 835 A5-M2-B7 1A 2.67 440 836 A34-M2-B7 1A 2.13 358 837 A27-M2-B7 1A 2.31 372 838 A28-M2-B7 1A 2.77 424 839 A29-M2-B7 1A 1.97 344 840 A8-M2-B7 1A 2.78 424 841 A30-M2-B7 1A 3.09 438 842 A17-M2-B31 1A 2.32 477 843 A31-M2-B31 1A 2.19 490 844 A18-M2-B31 1A 2.59 481 845 A3-M2-B31 1A 1.89 411 846 A19-M2-B31 1A 2.67 475 847 A20-M2-B31 1A 2.21 465 848 A32-M2-B31 1A 1.815 448 849 A11-M2-B31 1A 2.22 491 850 A4-M2-B31 1A 2.17 427 851 A6-M2-B31 1A 2.385 477 852 A23-M2-B31 1A 1.75 415 853 A24-M2-B31 1A 2.77 475 854 A26-M2-B31 1A 2.53 483 855 A5-M2-B31 1A 2.24 481 856 A34-M2-B31 1A 1.795 399 857 A28-M2-B31 1A 2.335 465 858 A8-M2-B31 1A 2.34 465 859 A17-M2-B32 1A 2.18 477 860 A31-M2-B32 1A 2.05 490 861 A18-M2-B32 1A 2.49 481 862 A3-M2-B32 1A 1.76 411 863 A37-M2-B32 1A 2.27 490 864 A19-M2-B32 1A 2.575 475 865 A32-M2-B32 1A 1.685 448 866 A11-M2-B32 1A 2.08 491 867 A21-M2-B32 1A 2.16 461 868 A4-M2-B32 1A 2.04 427 869 A6-M2-B32 1A 2.27 477 870 A23-M2-B32 1A 1.63 415 871 A24-M2-B32 1A 2.64 475 872 A25-M2-B32 1A 2.905 489 873 A26-M2-B32 1A 2.39 483 874 A35-M2-B32 1A 2.44 475 875 A36-M2-B32 1A 2.21 495 876 A5-M2-B32 1A 2.13 481 877 A28-M2-B32 1A 2.19 465 878 A1-M2-B32 1A 2.06 447 879 A8-M2-B32 1A 2.2 465 880 A17-M2-B33 1A 2.705 424 881 A31-M2-B33 1A 2.54 437 882 A3-M2-B33 1A 2.24 358 883 A19-M2-B33 1A 3.13 422 884 A20-M2-B33 1A 2.62 412 885 A32-M2-B33 1A 2.085 395 886 A11-M2-B33 1A 2.61 438 887 A21-M2-B33 1A 2.705 408 888 A22-M2-B33 1A 2.66 424 889 A4-M2-B33 1A 2.59 374 890 A6-M2-B33 1A 2.795 424 891 A24-M2-B33 1A 3.215 422 892 A25-M2-B33 1A 3.47 436 893 A26-M2-B33 1A 2.99 430 894 A35-M2-B33 1A 3.03 422 895 A36-M2-B33 1A 2.73 442 896 A33-M2-B33 1A 2.51 374 897 A5-M2-B33 1A 2.67 428 898 A27-M2-B33 1A 2.3 360 899 A1-M2-B33 1A 2.59 394 900 A8-M2-B33 1A 2.78 412 901 A30-M2-B33 1A 3.085 426 902 A17-M2-B34 1A 2.25 517 903 A31-M2-B34 1A 2.11 530 904 A18-M2-B34 1A 2.535 521 905 A3-M2-B34 1A 1.83 451 906 A19-M2-B34 1A 2.63 515 907 A20-M2-B34 1A 2.15 505 908 A32-M2-B34 1A 1.745 488 909 A11-M2-B34 1A 2.13 531 910 A21-M2-B34 1A 2.195 501 911 A22-M2-B34 1A 2.2 517 912 A4-M2-B34 1A 2.085 467 913 A6-M2-B34 1A 2.33 517 914 A24-M2-B34 1A 2.685 515 915 A26-M2-B34 1A 2.43 523 916 A35-M2-B34 1A 2.5 515 917 A36-M2-B34 1A 2.255 535 918 A33-M2-B34 1A 2.055 467 919 A27-M2-B34 1A 1.855 453 920 A28-M2-B34 1A 2.255 505 921 A1-M2-B34 1A 2.115 487 922 A8-M2-B34 1A 2.265 505 923 A30-M2-B34 1A 2.555 519 924 A17-M2-B35 1A 2.36 512 925 A31-M2-B35 1A 2.25 525 926 A18-M2-B35 1A 2.68 516 927 A3-M2-B35 1A 1.95 446 928 A37-M2-B35 1A 2.44 525 929 A19-M2-B35 1A 2.73 510 930 A20-M2-B35 1A 2.27 500 931 A32-M2-B35 1A 1.875 483 932 A11-M2-B35 1A 2.27 526 933 A4-M2-B35 1A 2.235 462 934 A6-M2-B35 1A 2.435 512 935 A24-M2-B35 1A 2.81 510 936 A26-M2-B35 1A 2.57 518 937 A35-M2-B35 1A 2.63 510 938 A36-M2-B35 1A 2.395 530 939 A28-M2-B35 1A 2.39 500 940 A1-M2-B35 1A 2.265 482 941 A8-M2-B35 1A 2.39 500 942 A30-M2-B35 1A 2.69 514 943 A17-M2-B36 1A 2.83 406 944 A31-M2-B36 1A 2.67 419 945 A18-M2-B36 1A 3.205 410 946 A27-M2-B43 1A 1.87 399 947 A19-M2-B36 1A 3.245 404 948 A20-M2-B36 1A 2.755 394 949 A32-M2-B36 1A 2.215 377 950 A22-M2-B36 1A 2.8 406 951 A4-M2-B36 1A 2.74 356 952 A6-M2-B36 1A 2.925 406 953 A28-M2-B43 1A 2.27 451 954 A24-M2-B36 1A 3.33 404 955 A25-M2-B36 1A 3.565 418 956 A26-M2-B36 1A 3.115 412 957 A35-M2-B36 1A 3.14 404 958 A33-M2-B36 1A 2.63 356 959 A5-M2-B36 1A 2.82 410 960 A27-M2-B36 1A 2.44 342 961 A28-M2-B36 1A 2.89 394 962 A29-M2-B36 1A 2.07 314 963 A1-M2-B36 1A 2.73 376 964 A8-M2-B36 1A 2.895 394 965 A30-M2-B36 1A 3.2 408 966 A17-M2-B37 1A 2.15 463 967 A31-M2-B37 1A 476 968 A18-M2-B37 1A 2.445 467 969 A19-M2-B37 1A 2.545 461 970 A20-M2-B37 1A 2.03 451 971 A32-M2-B37 1A 1.62 434 972 A11-M2-B37 1A 477 973 A21-M2-B37 1A 2.095 447 974 A4-M2-B37 1A 1.965 413 975 A6-M2-B37 1A 2.225 463 976 A24-M2-B37 1A 2.605 461 977 A25-M2-B37 1A 2.89 475 978 A26-M2-B37 1A 2.335 469 979 A35-M2-B37 1A 2.42 461 980 A36-M2-B37 1A 2.15 481 981 A33-M2-B37 1A 1.93 413 982 A5-M2-B37 1A 2.08 467 983 A27-M2-B37 1A 1.735 399 984 A28-M2-B37 1A 2.13 451 985 A29-M2-B37 1A 1.485 371 986 A1-M2-B37 1A 2.01 433 987 A8-M2-B37 1A 2.135 451 988 A17-M2-B38 1A 3.02 452 989 A31-M2-B38 1A 2.88 465 990 A18-M2-B38 1A 3.37 456 991 A32-M2-B38 1A 2.44 423 992 A11-M2-B38 1A 2.94 466 993 A21-M2-B38 1A 3.035 436 994 A22-M2-B38 1A 2.98 452 995 A4-M2-B38 1A 2.94 402 996 A26-M2-B38 1A 3.29 458 997 A35-M2-B38 1A 3.31 450 998 A36-M2-B38 1A 3.06 470 999 A5-M2-B38 1A 3.02 456 1000 A34-M2-B38 1A 2.48 374 1001 A27-M2-B38 1A 2.66 388 1002 A28-M2-B38 1A 3.08 440 1003 A8-M2-B38 1A 3.09 440 1004 A30-M2-B38 1A 3.37 454 1005 A17-M2-B39 1A 3.14 422 1006 A31-M2-B39 1A 3.02 435 1007 A18-M2-B39 1A 3.49 426 1008 A3-M2-B39 1A 2.76 356 1009 A19-M2-B39 1A 3.52 420 1010 A20-M2-B39 1A 3.09 410 1011 A32-M2-B39 1A 2.585 393 1012 A11-M2-B39 1A 3.055 436 1013 A22-M2-B39 1A 3.115 422 1014 A4-M2-B39 1A 3.1 372 1015 A6-M2-B39 1A 3.24 422 1016 A23-M2-B39 1A 2.53 360 1017 A24-M2-B39 1A 3.6 420 1018 A25-M2-B39 1A 3.81 434 1019 A26-M2-B39 1A 3.41 428 1020 A35-M2-B39 1A 3.44 420 1021 A36-M2-B39 1A 3.18 440 1022 A33-M2-B39 1A 3 372 1023 A5-M2-B39 1A 3.14 426 1024 A27-M2-B39 1A 2.82 358 1025 A28-M2-B39 1A 3.22 410 1026 A1-M2-B39 1A 3.07 392 1027 A8-M2-B39 1A 3.22 410 1028 A30-M2-B39 1A 3.48 424 1029 A19-M2-B40 1A 2.59 475 1030 A20-M2-B40 1A 2.08 465 1031 A32-M2-B40 1A 1.66 448 1032 A11-M2-B40 1A 2.07 491 1033 A21-M2-B40 1A 2.12 461 1034 A4-M2-B40 1A 2.005 427 1035 A24-M2-B40 1A 2.64 475 1036 A25-M2-B40 1A 2.89 489 1037 A26-M2-B40 1A 2.355 483 1038 A35-M2-B40 1A 2.43 475 1039 A36-M2-B40 1A 2.18 495 1040 A5-M2-B40 1A 2.11 481 1041 A27-M2-B40 1A 1.8 413 1042 A28-M2-B40 1A 2.165 465 1043 A1-M2-B40 1A 2.06 447 1044 A8-M2-B40 1A 2.175 465 1045 A30-M2-B40 1A 2.49 479 1046 A17-M2-B41 1A 2.98 420 1047 A18-M2-B41 1A 3.34 424 1048 A19-M2-B41 1A 3.38 418 1049 A32-M2-B41 1A 2.4 391 1050 A11-M2-B41 1A 2.895 434 1051 A21-M2-B41 1A 2.995 404 1052 A24-M2-B41 1A 3.445 418 1053 A25-M2-B41 1A 3.67 432 1054 A33-M2-B41 1A 2.81 370 1055 A5-M2-B41 1A 2.99 424 1056 A28-M2-B41 1A 3.055 408 1057 A1-M2-B41 1A 2.89 390 1058 A17-M2-B42 1A 3.18 434 1059 A31-M2-B42 1A 3.065 447 1060 A37-M2-B42 1A 3.24 447 1061 A19-M2-B42 1A 3.54 432 1062 A20-M2-B42 1A 3.13 422 1063 A32-M2-B42 1A 2.63 405 1064 A11-M2-B42 1A 3.095 448 1065 A21-M2-B42 1A 3.19 418 1066 A4-M2-B42 1A 3.13 384 1067 A6-M2-B42 1A 3.27 434 1068 A24-M2-B42 1A 3.6 432 1069 A26-M2-B42 1A 3.44 440 1070 A34-M2-B42 1A 2.68 356 1071 A28-M2-B42 1A 3.24 422 1072 A1-M2-B42 1A 3.09 404 1073 A8-M2-B42 1A 3.25 422 1074 A1-M2-B43 1A 2.125 433 1075 A17-M2-B6 1A 2.75 394 1076 A3-M2-B6 1A 2.27 328 1077 A19-M2-B6 1A 3.17 392 1078 A20-M2-B6 1A 2.67 382 1079 A32-M2-B6 1A 2.11 365 1080 A11-M2-B6 1A 2.63 408 1081 A22-M2-B6 1A 2.7 394 1082 A4-M2-B6 1A 2.63 344 1083 A6-M2-B6 1A 2.83 394 1084 A24-M2-B6 1A 3.25 392 1085 A26-M2-B6 1A 3.02 400 1086 A33-M2-B6 1A 2.54 344 1087 A5-M2-B6 1A 2.72 398 1088 A28-M2-B6 1A 2.8 382 1089 A8-M2-B43 1A 2.255 451 1090 A17-M2-B43 1A 2.235 463 1091 A31-M2-B43 1A 2.115 476 1092 A18-M2-B43 1A 2.58 467 1093 A3-M2-B43 1A 1.81 397 1094 A19-M2-B43 1A 2.625 461 1095 A20-M2-B43 1A 2.145 451 1096 A32-M2-B43 1A 1.725 434 1097 A11-M2-B43 1A 2.14 477 1098 A6-M2-B43 1A 2.34 463 1099 A24-M2-B43 1A 2.705 461 1100 A38-M2-B41 3 5.02 458 1101 A39-M2-B8 3 5.28 432 1102 A39-M2-B34 3 4.71 529 1103 A45-M2-B24 1A 1.51 407 1104 A41-M2-B24 1A 1.94 469 1105 A42-M2-B24 1A 1.59 421 1106 A43-M2-B24 1A 2.31 501 1107 A45-M2-B26 1A 1.74 401 1108 A42-M2-B26 1A 1.84 415 1109 A44-M2-B26 1A 2.43 499 1110 A45-M2-B27 1A 2.46 366 1111 A42-M2-B27 1A 2.56 380 1112 A43-M2-B27 1A 3.33 460 1113 A44-M2-B27 1A 3.16 464 1114 A41-M2-B28 1A 3.07 440 1115 A43-M2-B28 1A 3.43 472 1116 A44-M2-B28 1A 3.27 476 1117 A45-M2-B29 1A 1.535 381 1118 A42-M2-B29 1A 1.64 395 1119 A44-M2-B29 1A 2.17 479 1120 A45-M2-B8 1A 2.32 364 1121 A41-M2-B8 1A 2.805 426 1122 A42-M2-B8 1A 2.42 378 1123 A43-M2-B8 1A 3.18 458 1124 A44-M2-B8 1A 3.01 462 1125 A45-M2-B10 1A 2.23 352 1126 A42-M2-B10 1A 2.35 366 1127 A43-M2-B10 1A 3.13 446 1128 A44-M2-B10 1A 2.97 450 1129 A45-M2-B17 1A 2.505 366 1130 A41-M2-B17 1A 2.98 428 1131 A42-M2-B17 1A 2.62 380 1132 A43-M2-B17 1A 3.35 460 1133 A44-M2-B17 1A 3.195 464 1134 A45-M2-B30 1A 2.08 350 1135 A45-M2-B3 1A 1.47 393 1136 A41-M2-B3 1A 1.91 455 1137 A42-M2-B3 1A 1.56 407 1138 A45-M2-B7 1A 2.03 380 1139 A42-M2-B7 1A 2.13 394 1140 A43-M2-B7 1A 2.92 474 1141 A44-M2-B7 1A 2.76 478 1142 A45-M2-B31 1A 1.69 421 1143 A44-M2-B31 1A 2.29 519 1144 A45-M2-B32 1A 1.56 421 1145 A41-M2-B32 1A 1.98 483 1146 A42-M2-B32 1A 1.64 435 1147 A43-M2-B32 1A 2.325 515 1148 A44-M2-B32 1A 2.16 519 1149 A45-M2-B33 1A 2.01 368 1150 A41-M2-B33 1A 2.53 430 1151 A42-M2-B33 1A 2.125 382 1152 A44-M2-B33 1A 2.75 466 1153 A41-M2-B34 1A 2.03 523 1154 A42-M2-B34 1A 1.705 475 1155 A44-M2-B34 1A 2.21 559 1156 A45-M2-B35 1A 1.775 456 1157 A41-M2-B35 1A 2.205 518 1158 A42-M2-B35 1A 1.865 470 1159 A43-M2-B35 1A 2.55 550 1160 A44-M2-B35 1A 2.385 554 1161 A45-M2-B36 1A 2.14 350 1162 A41-M2-B36 1A 2.68 412 1163 A43-M2-B36 1A 3.08 444 1164 A44-M2-B36 1A 2.89 448 1165 A45-M2-B37 1A 1.5 407 1166 A41-M2-B37 1A 1.93 469 1167 A42-M2-B37 1A 1.57 421 1168 A43-M2-B37 1A 2.265 501 1169 A44-M2-B37 1A 2.1 505 1170 A45-M2-B38 1A 2.39 396 1171 A41-M2-B38 1A 2.89 458 1172 A42-M2-B38 1A 2.505 410 1173 A43-M2-B38 1A 3.27 490 1174 A44-M2-B38 1A 3.11 494 1175 A41-M2-B39 1A 3.035 428 1176 A42-M2-B39 1A 2.64 380 1177 A43-M2-B39 1A 3.39 460 1178 A44-M2-B39 1A 3.23 464 1179 A45-M2-B40 1A 1.545 421 1180 A41-M2-B40 1A 1.95 483 1181 A42-M2-B40 1A 1.63 435 1182 A43-M2-B40 1A 2.27 515 1183 A44-M2-B40 1A 2.13 519 1184 A45-M2-B41 1A 2.35 364 1185 A41-M2-B41 1A 2.855 426 1186 A45-M2-B42 1A 2.59 378 1187 A42-M2-B42 1A 2.68 392 1188 A44-M2-B42 1A 3.26 476 1189 A44-M2-B6 1A 2.78 436 1190 A40-M1-B11 2 5.73 488 1191 A41-M1-B24 1A 1.83 455 1192 A42-M1-B24 1A 1.51 407 1193 A43-M1-B24 1A 2.165 487 1194 A44-M1-B24 1A 1.98 491 1195 A45-M1-B25 1A 1.51 387 1196 A42-M1-B25 1A 1.605 401 1197 A45-M1-B26 1A 1.63 387 1198 A42-M1-B26 1A 1.73 401 1199 A44-M1-B26 1A 2.3 485 1200 A45-M1-B27 1A 2.33 352 1201 A41-M1-B27 1A 2.87 414 1202 A42-M1-B27 1A 2.46 366 1203 A43-M1-B27 1A 3.24 446 1204 A44-M1-B27 1A 3.05 450 1205 A45-M1-B28 1A 2.47 364 1206 A41-M1-B28 1A 2.985 426 1207 A42-M1-B28 1A 2.6 378 1208 A43-M1-B28 1A 3.34 458 1209 A44-M1-B28 1A 3.155 462 1210 A42-M1-B29 1A 1.55 381 1211 A44-M1-B29 1A 2.05 465 1212 A45-M1-B8 1A 2.185 350 1213 A41-M1-B8 1A 2.71 412 1214 A42-M1-B8 1A 2.32 364 1215 A43-M1-B8 1A 3.09 444 1216 A44-M1-B8 1A 2.9 448 1217 A45-M1-B10 1A 2.1 338 1218 A41-M1-B10 1A 2.66 400 1219 A42-M1-B10 1A 2.225 352 1220 A43-M1-B10 1A 3.045 432 1221 A44-M1-B10 1A 2.85 436 1222 A45-M1-B17 1A 2.395 352 1223 A41-M1-B17 1A 2.9 414 1224 A42-M1-B17 1A 2.515 366 1225 A43-M1-B17 1A 3.275 446 1226 A44-M1-B17 1A 3.1 450 1227 A45-M1-B30 1A 1.955 336 1228 A42-M1-B30 1A 2.09 350 1229 A43-M1-B30 1A 2.9 430 1230 A44-M1-B30 1A 2.7 434 1231 A41-M1-B3 1A 1.8 441 1232 A42-M1-B3 1A 1.465 393 1233 A43-M1-B3 1A 2.135 473 1234 A44-M1-B3 1A 1.94 477 1235 A45-M1-B7 1A 1.91 366 1236 A41-M1-B7 1A 2.45 428 1237 A42-M1-B7 1A 2.03 380 1238 A43-M1-B7 1A 2.835 460 1239 A44-M1-B7 1A 2.63 464 1240 A44-M1-B31 1A 2.18 505 1241 A45-M1-B32 1A 1.485 407 1242 A41-M1-B32 1A 1.89 469 1243 A42-M1-B32 1A 1.56 421 1244 A43-M1-B32 1A 2.21 501 1245 A44-M1-B32 1A 2.045 505 1246 A41-M1-B33 1A 2.425 416 1247 A42-M1-B33 1A 2.02 368 1248 A43-M1-B33 1A 2.82 448 1249 A44-M1-B33 1A 2.62 452 1250 A41-M1-B34 1A 1.96 509 1251 A43-M1-B34 1A 2.29 541 1252 A44-M1-B34 1A 2.11 545 1253 A45-M1-B35 1A 1.7 442 1254 A41-M1-B35 1A 2.12 504 1255 A42-M1-B35 1A 1.785 456 1256 A43-M1-B35 1A 2.46 536 1257 A44-M1-B35 1A 2.28 540 1258 A45-M1-B36 1A 2.01 336 1259 A41-M1-B36 1A 2.595 398 1260 A42-M1-B36 1A 2.15 350 1261 A43-M1-B36 1A 2.98 430 1262 A44-M1-B36 1A 2.77 434 1263 A41-M1-B37 1A 1.82 455 1264 A42-M1-B37 1A 1.5 407 1265 A43-M1-B37 1A 2.18 487 1266 A44-M1-B37 1A 1.965 491 1267 A45-M1-B38 1A 2.29 382 1268 A41-M1-B38 1A 2.83 444 1269 A42-M1-B38 1A 2.41 396 1270 A43-M1-B38 1A 3.2 476 1271 A44-M1-B38 1A 3.01 480 1272 A45-M1-B39 1A 2.42 352 1273 A41-M1-B39 1A 2.95 414 1274 A42-M1-B39 1A 2.56 366 1275 A43-M1-B39 1A 3.315 446 1276 A44-M1-B39 1A 3.13 450 1277 A45-M1-B40 1A 1.47 407 1278 A41-M1-B40 1A 1.865 469 1279 A42-M1-B40 1A 1.55 421 1280 A43-M1-B40 1A 2.2 501 1281 A44-M1-B40 1A 2.005 505 1282 A45-M1-B41 1A 2.225 350 1283 A41-M1-B41 1A 2.765 412 1284 A42-M1-B41 1A 2.355 364 1285 A43-M1-B41 1A 3.135 444 1286 A44-M1-B41 1A 2.955 448 1287 A45-M1-B42 1A 2.49 364 1288 A41-M1-B42 1A 3 426 1289 A42-M1-B42 1A 2.6 378 1290 A44-M1-B42 1A 3.19 462 1291 A41-M1-B6 1A 2.48 386 1292 A42-M1-B6 1A 2.04 338 1293 A43-M1-B6 1A 2.88 418 1294 A44-M1-B6 1A 2.67 422 1295 A42-M1-B43 1A 1.61 407 1296 A44-M1-B43 1A 2.09 491 1297 A46-M1-B24 1A 2.085 434 1298 A47-M1-B24 1A 2.27 464 1299 A48-M1-B24 1A 2.365 448 1300 A49-M1-B24 1A 2.165 466 1301 A50-M1-B24 1A 1.715 442 1302 A51-M1-B24 1A 1.985 414 1303 A52-M1-B24 1A 1.465 372 1304 A53-M1-B24 1A 1.58 416 1305 A54-M1-B25 1A 2.445 434 1306 A48-M1-B25 1A 2.495 442 1307 A49-M1-B25 1A 2.285 460 1308 A50-M1-B25 1A 1.815 436 1309 A51-M1-B25 1A 2.12 408 1310 A52-M1-B25 1A 1.535 366 1311 A53-M1-B25 1A 1.66 410 1312 A54-M1-B26 1A 2.655 434 1313 A46-M1-B26 1A 2.4 428 1314 A47-M1-B26 1A 2.57 458 1315 A48-M1-B26 1A 2.7 442 1316 A49-M1-B26 1A 2.495 460 1317 A50-M1-B26 1A 1.96 436 1318 A51-M1-B26 1A 2.3 408 1319 A52-M1-B26 1A 1.66 366 1320 A53-M1-B26 1A 1.79 410 1321 A54-M1-B27 1A 3.43 399 1322 A46-M1-B27 1A 3.19 393 1323 A47-M1-B27 1A 3.295 423 1324 A48-M1-B27 1A 3.455 407 1325 A49-M1-B27 1A 3.295 425 1326 A50-M1-B27 1A 2.68 401 1327 A51-M1-B27 1A 3.125 373 1328 A52-M1-B27 1A 2.345 331 1329 A53-M1-B27 1A 2.485 375 1330 A54-M1-B28 1A 3.53 411 1331 A46-M1-B28 1A 3.3 405 1332 A47-M1-B28 1A 3.38 435 1333 A48-M1-B28 1A 3.55 419 1334 A49-M1-B28 1A 3.39 437 1335 A50-M1-B28 1A 2.805 413 1336 A51-M1-B28 1A 3.24 385 1337 A52-M1-B28 1A 2.475 343 1338 A53-M1-B28 1A 2.625 387 1339 A54-M1-B29 1A 2.39 414 1340 A47-M1-B29 1A 2.295 438 1341 A48-M1-B29 1A 2.415 422 1342 A49-M1-B29 1A 2.225 440 1343 A50-M1-B29 1A 1.76 416 1344 A51-M1-B29 1A 2.045 388 1345 A53-M1-B29 1A 1.62 390 1346 A54-M1-B8 1A 3.27 397 1347 A46-M1-B8 1A 3.05 391 1348 A48-M1-B8 1A 3.305 405 1349 A49-M1-B8 1A 3.125 423 1350 A50-M1-B8 1A 2.52 399 1351 A51-M1-B8 1A 2.95 371 1352 A52-M1-B8 1A 2.185 329 1353 A53-M1-B8 1A 2.33 373 1354 A46-M1-B10 1A 2.98 379 1355 A47-M1-B10 1A 3.15 409 1356 A48-M1-B10 1A 3.26 393 1357 A49-M1-B10 1A 3.1 411 1358 A50-M1-B10 1A 2.46 387 1359 A51-M1-B10 1A 2.905 359 1360 A52-M1-B10 1A 2.11 317 1361 A53-M1-B10 1A 2.265 361 1362 A54-M1-B17 1A 3.45 399 1363 A46-M1-B17 1A 3.23 393 1364 A47-M1-B17 1A 3.32 423 1365 A48-M1-B17 1A 3.475 407 1366 A49-M1-B17 1A 3.305 425 1367 A50-M1-B17 1A 2.72 401 1368 A51-M1-B17 1A 3.15 373 1369 A53-M1-B17 1A 2.53 375 1370 A47-M1-B30 1A 2.97 407 1371 A48-M1-B30 1A 3.135 391 1372 A49-M1-B30 1A 2.945 409 1373 A50-M1-B30 1A 2.315 385 1374 A51-M1-B30 1A 2.75 357 1375 A52-M1-B30 1A 1.97 315 1376 A53-M1-B30 1A 2.125 359 1377 A54-M1-B3 1A 2.29 426 1378 A46-M1-B3 1A 2.06 420 1379 A47-M1-B3 1A 2.205 450 1380 A48-M1-B3 1A 2.345 434 1381 A49-M1-B3 1A 2.13 452 1382 A50-M1-B3 1A 1.68 428 1383 A51-M1-B3 1A 1.95 400 1384 A52-M1-B3 1A 1.415 358 1385 A53-M1-B3 1A 1.54 402 1386 A54-M1-B7 1A 3.02 413 1387 A46-M1-B7 1A 2.79 407 1388 A48-M1-B7 1A 3.065 421 1389 A49-M1-B7 1A 2.87 439 1390 A50-M1-B7 1A 2.25 415 1391 A51-M1-B7 1A 2.67 387 1392 A52-M1-B7 1A 1.92 345 1393 A53-M1-B7 1A 2.07 389 1394 A54-M1-B31 1A 2.52 454 1395 A46-M1-B31 1A 2.28 448 1396 A47-M1-B31 1A 2.43 478 1397 A48-M1-B31 1A 2.525 462 1398 A49-M1-B31 1A 2.345 480 1399 A50-M1-B31 1A 1.89 456 1400 A51-M1-B31 1A 2.2 428 1401 A52-M1-B31 1A 1.63 386 1402 A53-M1-B31 1A 1.74 430 1403 A54-M1-B32 1A 2.38 454 1404 A46-M1-B32 1A 2.14 448 1405 A47-M1-B32 1A 2.31 478 1406 A48-M1-B32 1A 2.415 462 1407 A52-M1-B32 1A 1.515 386 1408 A53-M1-B32 1A 1.635 430 1409 A54-M1-B33 1A 3.03 401 1410 A47-M1-B33 1A 2.89 425 1411 A48-M1-B33 1A 3.06 409 1412 A49-M1-B33 1A 2.86 427 1413 A50-M1-B33 1A 2.24 403 1414 A51-M1-B33 1A 2.67 375 1415 A52-M1-B33 1A 1.91 333 1416 A53-M1-B33 1A 2.06 377 1417 A54-M1-B34 1A 2.405 494 1418 A47-M1-B34 1A 2.34 518 1419 A48-M1-B34 1A 2.47 502 1420 A49-M1-B34 1A 2.28 520 1421 A50-M1-B34 1A 1.84 496 1422 A51-M1-B34 1A 2.1 468 1423 A52-M1-B34 1A 1.58 426 1424 A53-M1-B34 1A 1.69 470 1425 A54-M1-B35 1A 2.61 489 1426 A48-M1-B35 1A 2.625 497 1427 A49-M1-B35 1A 2.46 515 1428 A50-M1-B35 1A 1.97 491 1429 A51-M1-B35 1A 2.285 463 1430 A52-M1-B35 1A 1.705 421 1431 A53-M1-B35 1A 1.82 465 1432 A47-M1-B36 1A 3.06 407 1433 A48-M1-B36 1A 3.21 391 1434 A49-M1-B36 1A 3.03 409 1435 A50-M1-B36 1A 2.39 385 1436 A51-M1-B36 1A 2.85 357 1437 A52-M1-B36 1A 2.03 315 1438 A53-M1-B36 1A 2.18 359 1439 A54-M1-B37 1A 2.305 440 1440 A47-M1-B37 1A 2.26 464 1441 A48-M1-B37 1A 2.35 448 1442 A49-M1-B37 1A 2.17 466 1443 A50-M1-B37 1A 1.705 442 1444 A51-M1-B37 1A 1.975 414 1445 A52-M1-B37 1A 1.45 372 1446 A53-M1-B37 1A 1.57 416 1447 A54-M1-B38 1A 3.39 429 1448 A46-M1-B38 1A 3.14 423 1449 A48-M1-B38 1A 3.4 437 1450 A49-M1-B38 1A 3.24 455 1451 A50-M1-B38 1A 2.615 431 1452 A51-M1-B38 1A 3.065 403 1453 A52-M1-B38 1A 2.29 361 1454 A53-M1-B38 1A 2.425 405 1455 A54-M1-B39 1A 3.51 399 1456 A46-M1-B39 1A 3.27 393 1457 A47-M1-B39 1A 3.365 423 1458 A48-M1-B39 1A 3.53 407 1459 A49-M1-B39 1A 3.36 425 1460 A50-M1-B39 1A 2.78 401 1461 A51-M1-B39 1A 3.22 373 1462 A52-M1-B39 1A 2.43 331 1463 A53-M1-B39 1A 2.57 375 1464 A54-M1-B40 1A 2.34 454 1465 A47-M1-B40 1A 2.27 478 1466 A48-M1-B40 1A 2.41 462 1467 A49-M1-B40 1A 2.185 480 1468 A50-M1-B40 1A 1.74 456 1469 A51-M1-B40 1A 2.015 428 1470 A52-M1-B40 1A 1.495 386 1471 A53-M1-B40 1A 1.605 430 1472 A54-M1-B41 1A 3.335 397 1473 A46-M1-B41 1A 3.095 391 1474 A47-M1-B41 1A 3.195 421 1475 A48-M1-B41 1A 3.36 405 1476 A49-M1-B41 1A 3.19 423 1477 A50-M1-B41 1A 2.575 399 1478 A51-M1-B41 1A 3.025 371 1479 A52-M1-B41 1A 2.23 329 1480 A53-M1-B41 1A 2.38 373 1481 A54-M1-B42 1A 3.53 411 1482 A46-M1-B42 1A 3.32 405 1483 A48-M1-B42 1A 3.56 419 1484 A49-M1-B42 1A 3.39 437 1485 A50-M1-B42 1A 2.8 413 1486 A51-M1-B42 1A 3.25 385 1487 A52-M1-B42 1A 2.485 343 1488 A53-M1-B42 1A 2.62 387 1489 A46-M1-B6 1A 2.81 365 1490 A47-M1-B6 1A 2.94 395 1491 A48-M1-B6 1A 3.1 379 1492 A49-M1-B6 1A 2.91 397 1493 A50-M1-B6 1A 2.29 373 1494 A51-M1-B6 1A 2.72 345 1495 A52-M1-B6 1A 1.93 303 1496 A53-M1-B6 1A 2.08 347 1497 A54-M1-B43 1A 2.415 440 1498 A48-M1-B43 1A 2.475 448 1499 A49-M1-B43 1A 2.275 466 1500 A51-M1-B43 1A 2.095 414 1501 A53-M1-B43 1A 1.665 416 1502 A54-M2-B24 1A 2.405 454 1503 A46-M2-B24 1A 2.21 448 1504 A47-M2-B24 1A 2.36 478 1505 A48-M2-B24 1A 2.48 462 1506 A49-M2-B24 1A 2.265 480 1507 A50-M2-B24 1A 1.81 456 1508 A51-M2-B24 1A 2.095 428 1509 A52-M2-B24 1A 1.54 386 1510 A53-M2-B24 1A 1.66 430 1511 A54-M2-B25 1A 2.545 448 1512 A48-M2-B25 1A 2.61 456 1513 A49-M2-B25 1A 2.4 474 1514 A51-M2-B25 1A 2.23 422 1515 A52-M2-B25 1A 1.62 380 1516 A54-M2-B26 1A 2.825 448 1517 A46-M2-B26 1A 2.56 442 1518 A47-M2-B26 1A 2.68 472 1519 A48-M2-B26 1A 2.85 456 1520 A49-M2-B26 1A 2.65 474 1521 A50-M2-B26 1A 2.07 450 1522 A51-M2-B26 1A 2.46 422 1523 A52-M2-B26 1A 1.76 380 1524 A54-M2-B27 1A 3.6 413 1525 A46-M2-B27 1A 3.34 407 1526 A47-M2-B27 1A 3.42 437 1527 A48-M2-B27 1A 3.59 421 1528 A49-M2-B27 1A 3.44 439 1529 A50-M2-B27 1A 2.82 415 1530 A51-M2-B27 1A 3.31 387 1531 A52-M2-B27 1A 2.49 345 1532 A53-M2-B27 1A 2.625 389 1533 A54-M2-B28 1A 3.71 425 1534 A46-M2-B28 1A 3.44 419 1535 A47-M2-B28 1A 3.51 449 1536 A48-M2-B28 1A 3.69 433 1537 A49-M2-B28 1A 3.54 451 1538 A50-M2-B28 1A 2.94 427 1539 A51-M2-B28 1A 3.42 399 1540 A52-M2-B28 1A 2.63 357 1541 A54-M2-B29 1A 2.45 428 1542 A46-M2-B29 1A 2.25 422 1543 A47-M2-B29 1A 2.4 452 1544 A48-M2-B29 1A 2.53 436 1545 A50-M2-B29 1A 1.86 430 1546 A51-M2-B29 1A 2.145 402 1547 A53-M2-B29 1A 1.71 404 1548 A54-M2-B8 1A 3.43 411 1549 A46-M2-B8 1A 3.185 405 1550 A47-M2-B8 1A 3.26 435 1551 A48-M2-B8 1A 3.425 419 1552 A49-M2-B8 1A 3.25 437 1553 A50-M2-B8 1A 2.645 413 1554 A51-M2-B8 1A 3.11 385 1555 A52-M2-B8 1A 2.33 343 1556 A53-M2-B8 1A 2.47 387 1557 A54-M2-B10 1A 3.4 399 1558 A46-M2-B10 1A 3.13 393 1559 A47-M2-B10 1A 3.22 423 1560 A48-M2-B10 1A 3.41 407 1561 A49-M2-B10 1A 3.225 425 1562 A50-M2-B10 1A 2.6 401 1563 A51-M2-B10 1A 3.08 373 1564 A52-M2-B10 1A 2.25 331 1565 A53-M2-B10 1A 2.4 375 1566 A54-M2-B17 1A 3.61 413 1567 A46-M2-B17 1A 3.355 407 1568 A47-M2-B17 1A 3.415 437 1569 A48-M2-B17 1A 3.605 421 1570 A49-M2-B17 1A 3.435 439 1571 A50-M2-B17 1A 2.83 415 1572 A51-M2-B17 1A 3.32 387 1573 A52-M2-B17 1A 2.52 345 1574 A53-M2-B17 1A 2.65 389 1575 A46-M2-B30 1A 3 391 1576 A47-M2-B30 1A 3.08 421 1577 A48-M2-B30 1A 3.27 405 1578 A49-M2-B30 1A 3.08 423 1579 A50-M2-B30 1A 2.445 399 1580 A51-M2-B30 1A 2.92 371 1581 A46-M2-B3 1A 2.14 434 1582 A48-M2-B3 1A 2.46 448 1583 A49-M2-B3 1A 2.22 466 1584 A50-M2-B3 1A 1.77 442 1585 A51-M2-B3 1A 2.07 414 1586 A52-M2-B3 1A 1.495 372 1587 A53-M2-B3 1A 1.62 416 1588 A54-M2-B7 1A 3.16 427 1589 A46-M2-B7 1A 2.9 421 1590 A47-M2-B7 1A 3 451 1591 A48-M2-B7 1A 3.19 435 1592 A49-M2-B7 1A 2.985 453 1593 A50-M2-B7 1A 2.36 429 1594 A51-M2-B7 1A 2.83 401 1595 A53-M2-B7 1A 2.18 403 1596 A47-M2-B31 1A 2.49 492 1597 A49-M2-B31 1A 2.445 494 1598 A50-M2-B31 1A 1.97 470 1599 A51-M2-B31 1A 2.28 442 1600 A52-M2-B31 1A 1.7 400 1601 A53-M2-B31 1A 1.83 444 1602 A54-M2-B32 1A 2.48 468 1603 A51-M2-B32 1A 2.16 442 1604 A54-M2-B33 1A 3.16 415 1605 A46-M2-B33 1A 2.9 409 1606 A47-M2-B33 1A 3 439 1607 A48-M2-B33 1A 3.19 423 1608 A49-M2-B33 1A 3 441 1609 A50-M2-B33 1A 2.37 417 1610 A51-M2-B33 1A 2.82 389 1611 A52-M2-B33 1A 2.025 347 1612 A53-M2-B33 1A 2.17 391 1613 A54-M2-B34 1A 2.495 508 1614 A46-M2-B34 1A 2.29 502 1615 A47-M2-B34 1A 2.42 532 1616 A48-M2-B34 1A 2.57 516 1617 A49-M2-B34 1A 2.355 534 1618 A50-M2-B34 1A 1.9 510 1619 A51-M2-B34 1A 2.2 482 1620 A52-M2-B34 1A 1.645 440 1621 A53-M2-B34 1A 1.755 484 1622 A54-M2-B35 1A 2.73 503 1623 A46-M2-B35 1A 2.49 497 1624 A47-M2-B35 1A 2.61 527 1625 A48-M2-B35 1A 2.765 511 1626 A49-M2-B35 1A 2.58 529 1627 A50-M2-B35 1A 2.07 505 1628 A51-M2-B35 1A 2.415 477 1629 A52-M2-B35 1A 1.8 435 1630 A53-M2-B35 1A 1.91 479 1631 A47-M2-B36 1A 3.155 421 1632 A48-M2-B36 1A 3.35 405 1633 A49-M2-B36 1A 3.15 423 1634 A50-M2-B36 1A 2.515 399 1635 A51-M2-B36 1A 3 371 1636 A52-M2-B36 1A 2.17 329 1637 A53-M2-B36 1A 2.315 373 1638 A46-M2-B37 1A 2.17 448 1639 A47-M2-B37 1A 2.33 478 1640 A48-M2-B37 1A 2.445 462 1641 A49-M2-B37 1A 2.27 480 1642 A50-M2-B37 1A 1.785 456 1643 A51-M2-B37 1A 2.07 428 1644 A52-M2-B37 1A 1.525 386 1645 A53-M2-B37 1A 1.64 430 1646 A54-M2-B38 1A 3.54 443 1647 A46-M2-B38 1A 3.27 437 1648 A47-M2-B38 1A 3.35 467 1649 A48-M2-B38 1A 3.53 451 1650 A49-M2-B38 1A 3.36 469 1651 A50-M2-B38 1A 2.73 445 1652 A51-M2-B38 1A 3.23 417 1653 A52-M2-B38 1A 2.42 375 1654 A53-M2-B38 1A 2.56 419 1655 A54-M2-B39 1A 3.66 413 1656 A46-M2-B39 1A 3.41 407 1657 A47-M2-B39 1A 3.47 437 1658 A48-M2-B39 1A 3.66 421 1659 A49-M2-B39 1A 3.5 439 1660 A50-M2-B39 1A 2.895 415 1661 A51-M2-B39 1A 3.38 387 1662 A52-M2-B39 1A 2.57 345 1663 A53-M2-B39 1A 2.71 389 1664 A54-M2-B40 1A 2.45 468 1665 A46-M2-B40 1A 2.21 462 1666 A47-M2-B40 1A 2.35 492 1667 A48-M2-B40 1A 2.51 476 1668 A49-M2-B40 1A 2.32 494 1669 A50-M2-B40 1A 1.83 470 1670 A51-M2-B40 1A 2.13 442 1671 A52-M2-B40 1A 1.57 400 1672 A53-M2-B40 1A 1.685 444 1673 A54-M2-B41 1A 3.5 411 1674 A46-M2-B41 1A 3.245 405 1675 A47-M2-B41 1A 3.31 435 1676 A49-M2-B41 1A 3.325 437 1677 A50-M2-B41 1A 2.7 413 1678 A51-M2-B41 1A 3.19 385 1679 A52-M2-B41 1A 2.375 343 1680 A53-M2-B41 1A 2.51 387 1681 A54-M2-B42 1A 3.68 425 1682 A46-M2-B42 1A 3.43 419 1683 A47-M2-B42 1A 3.49 449 1684 A48-M2-B42 1A 3.67 433 1685 A49-M2-B42 1A 3.5 451 1686 A50-M2-B42 1A 2.905 427 1687 A52-M2-B42 1A 2.605 357 1688 A53-M2-B42 1A 2.73 401 1689 A54-M2-B6 1A 3.22 385 1690 A47-M2-B6 1A 3.06 409 1691 A48-M2-B43 1A 2.56 462 1692 A48-M2-B6 1A 3.25 393 1693 A49-M2-B6 1A 3.045 411 1694 A49-M2-B43 1A 2.37 480 1695 A51-M2-B6 1A 2.88 359 1696 A52-M2-B43 1A 1.63 386 1697 A53-M2-B6 1A 2.21 361 1698 A47-M2-B43 1A 2.44 478

Example 10 Preparation of the 2,4-dimethyl-N-[1-methyl-8-(pyrrolidin-1-ylcarbonyl)-4,5-dihydro-1H-pyrazolo[4,3-g]indolizin-3-yl]benzamide (I)

After dissolving the compound 2,4-dimethyl-N-[8-(pyrrolidin-1-ylcarbonyl)-4,5-dihydro-1H-pyrazolo[4,3-g]indolizin-3-yl]benzamide (A35-M1-B8, Entry 200, Table III), obtained as described in the example 9, in dichloromethane 2 equivalent of methyl iodide were added. After four hours of stirring at room temperature, water was added and the phases were separated. The organic layer was dried over Na₂SO₄ and the crude was purified through preparative HPLC. LCMS m/z 418 [M+H]+@ Rt 2.87 min.

1H NMR (DMSO-d6, 401 MHz): δ ppm=1.76-1.96 (m, 4H), 2.32 (s, 3H), 2.39 (s, 3H), 2.86 (t, J=6.6 Hz, 2H), 3.40-3.72 (m, 4H), 4.09 (t, J=6.4 Hz, 2H), 4.19 (s, 3H), 6.65 (br. s., 1H), 7.04-7.14 (m, 2H), 7.39 (br. s., 1H), 7.40 (br. s., 1H), 10.54 (br. s., 1H).

The two possible tautomers were not isolated. 

The invention claimed is:
 1. A compound of formula (I):

wherein n is 1; R1, R2 and R4, each independently one from the other, are selected from the group consisting of —R^(a), —COR^(a), —CONHR^(a), —SO₂R^(a) and —COOR^(a); R3 is a group —NR^(a)R^(b) or —OR^(a); wherein R^(a) and R^(b), the same or different, are each independently hydrogen or a group optionally substituted, selected from straight or branched C₁-C₆ alkyl, straight or branched C₂-C₆ alkenyl, straight or branched C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, cycloalkyl C₁-C₆ alkyl, heterocyclyl, heterocyclyl C₁-C₆ alkyl, aryl, aryl C₁-C₆ alkyl, heteroaryl and heteroaryl C₁-C₆ alkyl or, taken together with the nitrogen atom to which they are bonded, R^(a) and R^(b), may form an optionally substituted 3 to 8 membered heterocycle, optionally containing one additional heteroatom or heteroatomic group selected from S, O, N or NH, and pharmaceutically acceptable salts thereof.
 2. A compound of formula (I) according to claim 1 wherein: R1 is a group —CONHR^(a) wherein R^(a) is hydrogen or a group optionally substituted selected from straight or branched C₁-C₆ alkyl, straight or branched C₂-C₆ alkenyl, aryl and aryl C₁-C₆ alkyl.
 3. A compound of formula (I) according to claim 1 wherein: R1 is a group —COR^(a) wherein R^(a) is hydrogen or a group optionally substituted selected from straight or branched C₁-C₆ alkyl, straight or branched C₂-C₆ alkenyl, aryl and aryl C₁-C₆ alkyl.
 4. A compound of formula (I) according to claim 1 wherein: R1 is a group —SO₂R^(a) wherein R^(a) is hydrogen or a group optionally substituted selected from straight or branched C₁-C₆ alkyl, straight or branched C₂-C₆ alkenyl, aryl and aryl C₁-C₆ alkyl.
 5. A compound of formula (I) according to claim 1 wherein: R2 is hydrogen.
 6. A compound of formula (I) according to claim 1 wherein: R3 is a group —NR^(a)R^(b) wherein both of R^(a) and R^(b) are hydrogen or one of them is a hydrogen and the remaining one of R^(a) or R^(b) is a group optionally substituted selected from straight or branched C₁-C₆ alkyl, straight or branched C₂-C₆ alkenyl, aryl and aryl C₁-C₆ alkyl.
 7. A compound of formula (I) according to claim 1 wherein: R4 is hydrogen.
 8. A compound of formula (I) according to claim 1 wherein R1 and R2, each independently one from the other, are a substituent denoted by any of codes A1-A54 and R3 is a substituent denoted by any of codes B1-B43 listed below, wherein the compounds have the formula:

wherein substituents A and B are: FRAGMENT CODE

A1

A2

A3

A4

A5

A6

A7

A8

A9

A10

A11

A12

A13

A14

A15

A16

A17

A18

A19

A20

A21

A22

A23

A24

A25

A26

A27

A28

A29

A30

A31

A32

A33

A34

A35

A36

A37

A38

A39

A40

A41

A42

A43

A44

A45

A46

A47

A48

A49

A50

A51

A52

A53

A54

B1

B2

B3

B4

B5

B6

B7

B8

B9

B10

B11

B12

B13

B14

B15

B16

B17

B18

B19

B20

B21

B22

B23

B24

B25

B26

B27

B28

B29

B30

B31

B32

B33

B34

B35

B36

B37

B38

B39

B40

B41

B42

B43


9. A process for preparing a compound of formula (I) as defined in claim 1 characterized in that the process comprises the following steps: a) reaction of the compound of formula (II):

with an alcohol of formula (III): R^(a′)—OH  (III) wherein R^(a′) is straight or branched C₁-C₆ alkyl group; b) acylation by Friedel-Craft reaction of the resultant compound of formula (IV):

wherein R^(a′) is as defined above; c) reaction of the resultant compound of formula (V):

wherein R^(a′) is as defined above, with a suitable alcohol of formula (III) as defined above; d) alkylation of the resultant compound of formula (VI):

wherein both R^(a′), each independently one from the other, are as defined above, with a suitable halo-cyanoalkane of formula (XXI):

wherein n is 1; e) intramolecular condensation of the resultant compound of formula (VII):

wherein n is as defined above and both R^(a′), each independently one from the other, are as defined above; f) treatment with hydrazine, or an hydrazine salt thereof, of the resultant compound of formula (VIII):

wherein n and R^(a′) are as defined above, to give the compound of formula (I):

wherein n is 1; R1, R2 and R4 are hydrogen and R3 is —OR^(a′), wherein R^(a′) is a straight or branched C₁-C₆ alkyl group; optionally separating the resultant compound of formula (I) into the single isomers; and/or converting the resultant compound of formula (I) into a different compound of formula (I) by replacing the group —OR^(a′) with a different group which R3 represents, and/or by introducing the R4 group, and/or by derivatizing the amino moiety, and/or by removing the R4 group, and/or converting it into a pharmaceutically acceptable salt if desired.
 10. A process according to claim 9, characterized in that the compound of formula (I)

wherein n is 1; R1, R2 and R4 are hydrogen, and R3 is OR^(a′), wherein R^(a′) is straight or branched C₁-C₆ alkyl group, is optionally converted into a different compound of formula (I) according to one or more of the following reactions: g) replacing the group —OR^(a′) with a different group which R3 represents, according to any one of the following reactions: g.1) hydrolysis under basic condition to give the corresponding compound of formula (I) wherein R3 is OH, optionally followed by the coupling of the resultant compound with an amine of formula (IX): HNR^(a)R^(b)  (IX) wherein R^(a) and R^(b), the same or different, are each independently hydrogen or a group optionally substituted selected from straight or branched C₁-C₆ alkyl, straight or branched C₂-C₆ alkenyl, straight or branched C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, cycloalkyl C₁-C₆ alkyl, heterocyclyl, heterocyclyl C₁-C₆ alkyl, aryl, aryl C₁-C₆ alkyl, heteroaryl and heteroaryl C₁-C₆ alkyl or, taken together with the nitrogen atom to which they are bonded, R^(a) and R^(b) may form an optionally substituted 3 to 8 membered heterocycle, optionally containing one additional heteroatom or heteroatomic group selected from S, O, N or NH, to give the corresponding compound of formula (I) wherein R3 is —NR^(a)R^(b), and R^(a) and R^(b) are as defined above, or g.2) transesterification by reactions with a compound of formula (III) as defined in claim 9, to give the corresponding compound of formula (I) wherein R3 is OR^(a′) and R^(a′) is a different C₁-C₆ alkyl, or g.3) coupling with an amine of formula (IX): HNR^(a)R^(b)  (IX) wherein R^(a) and R^(b) are as defined above, to give the corresponding compound of formula (I) wherein R3 is —NR^(a)R^(b) and R^(a) and R^(b) are as defined above; or h) introducing the group R4 into the resultant compound of formula (I):

wherein n is as defined above and R3 is a group —NR^(a)R^(b) or —OR^(a), and R1, R2 and R4 are hydrogen, according to any one of the following reactions: h.1) coupling with an equivalent of an halide of formula (X): R^(a)Z  (X) wherein R^(a) is as defined above but not hydrogen and Z is a halogen, to give the corresponding compound of formula (I) wherein R4 is R^(a), and R^(a) is as defined above but not hydrogen, or h.2) coupling with an equivalent of an acyl halide of formula (XI): R^(a)COZ  (XI) wherein R^(a) and Z are as defined above, to give the corresponding compound of formula (I) wherein R4 is —COR^(a) and R^(a) is as defined above, or h.3) coupling with an equivalent of an alkoxycarbonyl halide of formula (XII): R^(a)OCOZ  (XII) wherein R^(a) and Z are as defined above, to give the corresponding compound of formula (I) wherein R4 is —OCOR^(a) and R^(a) is as defined above, or h.4) coupling with an equivalent of a sulfonyl halide of formula (XIII): R^(a)SO₂Z  (XIII) wherein R^(a) and Z are as defined above, to give the corresponding compound of formula (I) wherein R4 is —SO₂R^(a) and R^(a) is as defined above, or h.5) coupling with an equivalent of an isocyanate of formula (XIV): R^(a)NCO  (XIV) wherein R^(a) is as defined above, to give the corresponding compound of formula (I) wherein R4 is —CONHR^(a) and R^(a) is as defined above; or i) derivatizing the amino moiety of the resultant compound of formula (I):

wherein n is 1 and R3 is a group —NR^(a)R^(b) or —OR^(a); wherein R^(a) and R^(b), the same or different, are each independently hydrogen or a group optionally substituted, selected from straight or branched C₁-C₆ alkyl, straight or branched C₂-C₆ alkenyl, straight or branched C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, cycloalkyl C₁-C₆ alkyl, heterocyclyl, heterocyclyl C₁-C₆ alkyl, aryl, aryl C₁-C₆ alkyl, heteroaryl and heteroaryl C₁-C₆ alkyl or, taken together with the nitrogen atom to which they are bonded, R^(a) and R^(b), may form an optionally substituted 3 to 8 membered heterocycle, optionally containing one additional heteroatom or heteroatomic group selected from S, O, N or NH, and R1, R2 and R4 are hydrogen, according to any one of the following reactions: i.1) coupling with an equivalent of an acyl halide of formula (XI): R^(a)COZ  (XI) wherein R^(a) is as defined above and Z is a halogen, to give the corresponding compound of formula (I) wherein one of R1 or R2 is hydrogen and the other one is —COR^(a) and R^(a) is as defined above, or i.2) coupling with an equivalent of an alkoxycarbonyl halide of formula (XII): R^(a)OCOZ  (XII) wherein R^(a) and Z are as defined above, to give the corresponding compound of formula (I) wherein one of R1 or R2 is hydrogen and the other one is —OCOR^(a) and R^(a) is as defined above, or i.3) coupling with an equivalent of a sulfonyl halide of formula (XIII): R^(a)SO₂Z  (XIII) wherein R^(a) and Z are as defined above, to give the corresponding compound of formula (I) wherein one of R1 or R2 is hydrogen and the other one is —SO₂R^(a) and R^(a) is as defined above, or i.4) coupling with an equivalent of an isocyanate of formula (XIV): R^(a)NCO  (XIV) wherein R^(a) is as defined above, to give the corresponding compound of formula (I) wherein one of R1 or R2 is hydrogen and the other one is —CONHR^(a) and R^(a) is as defined above, or i.5) coupling with an equivalent of a carbonyl compound of formula (XV): R^(a)COR^(b)  (XV) wherein R^(a) and R^(b) are as defined above, to give the corresponding compound of formula (I) wherein one of R1 or R2 is hydrogen and the other one is —COR^(a) and R^(a) is as defined above; or j) further derivatizing the amino moiety of the resultant compound of formula (I):

wherein n and R3 are as defined above; one of R1 and R2 is hydrogen and the other is selected from the group consisting of —R^(a), —COR^(a), —CONHR^(a), —SO₂R^(a) and —COOR^(a), but not hydrogen, and R4 is selected from the group consisting of —R^(a), —COR^(a), —CONHR^(a), —SO₂R^(a) and —COOR^(a) but not hydrogen, according to any one of the reactions described under steps i.1 to i.5) above; or k) removing the group R4 from the resultant compound of formula (I):

wherein n, R1, R2 and R3 are as defined above and R4 is as defined above but not hydrogen, by treatment with a basic solution, to obtain the corresponding compound wherein R4 is hydrogen; optionally separating the resultant compound of formula (I) into the single isomers, and/or converting the resultant compound of formula (I) into a pharmaceutically acceptable salt.
 11. A process for preparing a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt thereof, which process comprises the following steps: l) acylation of the alkoxycarbonyl derivative of formula (I) wherein n is as defined in claim 1; R1, R2 and R4 are hydrogen, and R^(a′) is straight or branched C₁-C₆ alkyl group, with trifluoroacetic anhydride; m) removal from the resultant compound of formula (I) of the trifluoroacetyl group in position 1 or 2 of the pyrazolo ring; n) loading of the resultant compound of formula (I) trifluoroacetylated in position 3 onto a resin as suitable solid support; o) hydrolyzing under acid or basic conditions the resultant compound of formula (XVI)

wherein n is as defined in claim 1, R^(a′) is as defined above and the resin is a polystyrenic resin selected from the group consisting of Br-Wang resin, Trityl resin, Cl-trityl resin, Merriefield resin, MAMP resin, isocianate resin and derivatives thereof; p) coupling the carboxyl group of the resultant compound of formula (XVII):

wherein n and the resin are as defined above, with an amine of formula (IX) HNR^(a)R^(b)  (IX) to give the corresponding compound of formula (I) wherein R3 is —NR^(a)R^(b) wherein R^(a) and R^(b), the same or different, are each independently hydrogen or a group optionally substituted selected from straight or branched C₁-C₆ alkyl, straight or branched C₂-C₆ alkenyl, straight or branched C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, cycloalkyl C₁-C₆ alkyl, heterocyclyl, heterocyclyl C₁-C₆ alkyl, aryl, aryl C₁-C₆ alkyl, heteroaryl and heteroaryl C₁-C₆ alkyl or, taken together with the nitrogen atom to which they are bonded, R^(a) and R^(b) may form an optionally substituted 3 to 8 membered heterocycle, optionally containing one additional heteroatom or heteroatomic group selected from S, O, N or NH, to give the corresponding compound of formula (I) wherein R3 is —NR^(a)R^(b), and R^(a) and R^(b) are as defined above; q) derivatizing the amino moiety in position 3 of resultant compound of formula (XVIII):

wherein n and the resin are as defined above, with an amine of formula (IX) as defined above; r) cleaving the resin from the resultant compound of formula (XIX):

so as to obtain the desired compounds of formula I, optionally converting the resultant compound of formula (I) into a different compound of formula (I) and/or converting it into a pharmaceutically acceptable salt if desired.
 12. Two or more compounds of formula (I):

wherein n is 1; R1, R2 and R4, each independently one from the other, are selected from the group consisting of —COR^(a), —CONHR^(a), —SO₂R^(a) and —COOR^(a); R3 is a group —NR^(a)R^(b) or —OR^(a); wherein R^(a) and R^(b), the same or different, are each independently hydrogen or a group optionally substituted, selected from straight or branched C₁-C₆ alkyl, straight or branched C₂-C₆ alkenyl, straight or branched C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, cycloalkyl C₁-C₆ alkyl, heterocyclyl, heterocyclyl C₁-C₆ alkyl, aryl, aryl C₁-C₆ alkyl, heteroaryl and heteroaryl C₁-C₆ alkyl or, taken together with the nitrogen atom to which they are bonded, R^(a) and R^(b), may form an optionally substituted 3 to 8 membered heterocycle, optionally containing one additional heteroatom or heteroatomic group selected from S, O, N or NH, and pharmaceutically acceptable salts thereof.
 13. Two or more compounds according to claim 12 wherein the compounds have the formula:

wherein substituents A and B are: FRAGMENT CODE

A1

A2

A3

A4

A5

A6

A7

A8

A9

A10

A11

A12

A13

A14

A15

A16

A17

A18

A19

A20

A21

A22

A23

A24

A25

A26

A27

A28

A29

A30

A31

A32

A33

A34

A35

A36

A37

A38

A39

A40

A41

A42

A43

A44

A45

A46

A47

A48

A49

A50

A51

A52

A53

A54

FRAGMENT CODE

B1

B2

B3

B4

B5

B6

B7

B8

B9

B10

B11

B12

B13

B14

B15

B16

B17

B18

B19

B20

B21

B22

B23

B24

B25

B26

B27

B28

B29

B30

B31

B32

B33

B34

B35

B36

B37

B38

B39

B40

B41

B42

B43

and wherein the compounds are among those listed herein below: Entry Compound 622 A14-M2-B11 623 A15-M2-B11 624 A8-M2-B11 625 A9-M2-B11 626 A14-M2-B12 627 A15-M2-B12 628 A9-M2-B12 629 A16-M2-B12 630 A9-M2-B13 631 A14-M2-B15 632 A8-M2-B15 633 A9-M2-B15 634 A16-M2-B15 635 A14-M2-B19 636 A8-M2-B19 637 A9-M2-B19 638 A16-M2-B19 639 A26-M2-B43 640 A17-M2-B24 641 A19-M2-B24 642 A32-M2-B24 643 A11-M2-B24 644 A4-M2-B24 645 A6-M2-B24 646 A24-M2-B24 647 A25-M2-B24 648 A28-M2-B24 649 A29-M2-B24 650 A8-M2-B24 651 A30-M2-B24 652 A17-M2-B25 653 A18-M2-B25 654 A3-M2-B25 655 A19-M2-B25 656 A20-M2-B25 657 A32-M2-B25 658 A21-M2-B25 659 A4-M2-B25 660 A6-M2-B25 661 A26-M2-B25 662 A33-M2-B25 663 A34-M2-B25 664 A28-M2-B25 665 A1-M2-B25 666 A8-M2-B25 667 A17-M2-B26 668 A31-M2-B26 669 A18-M2-B26 670 A3-M2-B26 671 A19-M2-B26 672 A20-M2-B26 673 A32-M2-B26 674 A11-M2-B26 675 A21-M2-B26 676 A6-M2-B26 677 A24-M2-B26 678 A26-M2-B26 679 A33-M2-B26 680 A5-M2-B26 681 A28-M2-B26 682 A1-M2-B26 683 A8-M2-B26 684 A17-M2-B27 685 A31-M2-B27 686 A18-M2-B27 687 A19-M2-B27 688 A20-M2-B27 689 A32-M2-B27 690 A11-M2-B27 691 A22-M2-B27 692 A6-M2-B27 693 A24-M2-B27 694 A25-M2-B27 695 A26-M2-B27 696 A35-M2-B27 697 A36-M2-B27 698 A5-M2-B27 699 A27-M2-B27 700 A28-M2-B27 701 A1-M2-B27 702 A8-M2-B27 703 A30-M2-B27 704 A17-M2-B28 705 A31-M2-B28 706 A18-M2-B28 707 A19-M2-B28 708 A20-M2-B28 709 A32-M2-B28 710 A11-M2-B28 711 A21-M2-B28 712 A22-M2-B28 713 A24-M2-B28 714 A25-M2-B28 715 A26-M2-B28 716 A35-M2-B28 717 A33-M2-B28 718 A5-M2-B28 719 A28-M2-B28 720 A1-M2-B28 721 A8-M2-B28 722 A30-M2-B28 723 A17-M2-B29 724 A3-M2-B29 725 A19-M2-B29 726 A32-M2-B29 727 A11-M2-B29 728 A26-M2-B29 729 A28-M2-B29 730 A8-M2-B29 731 A17-M2-B8 732 A31-M2-B8 733 A3-M2-B8 734 A19-M2-B8 735 A20-M2-B8 736 A32-M2-B8 737 A11-M2-B8 738 A21-M2-B8 739 A22-M2-B8 740 A4-M2-B8 741 A24-M2-B8 742 A25-M2-B8 743 A26-M2-B8 744 A35-M2-B8 745 A36-M2-B8 746 A33-M2-B8 747 A5-M2-B8 748 A27-M2-B8 749 A28-M2-B8 750 A1-M2-B8 751 A8-M2-B8 752 A30-M2-B8 753 A17-M2-B10 754 A31-M2-B10 755 A18-M2-B10 756 A19-M2-B10 757 A20-M2-B10 758 A32-M2-B10 759 A11-M2-B10 760 A24-M2-B10 761 A26-M2-B10 762 A35-M2-B10 763 A33-M2-B10 764 A5-M2-B10 765 A28-M2-B10 766 A8-M2-B10 767 A30-M2-B10 768 A17-M2-B17 769 A31-M2-B17 770 A18-M2-B17 771 A3-M2-B17 772 A32-M2-B17 773 A11-M2-B17 774 A21-M2-B17 775 A22-M2-B17 776 A4-M2-B17 777 A6-M2-B17 778 A24-M2-B17 779 A26-M2-B17 780 A35-M2-B17 781 A36-M2-B17 782 A5-M2-B17 783 A27-M2-B17 784 A28-M2-B17 785 A8-M2-B17 786 A30-M2-B17 787 A17-M2-B30 788 A31-M2-B30 789 A18-M2-B30 790 A19-M2-B30 791 A32-M2-B30 792 A11-M2-B30 793 A4-M2-B30 794 A6-M2-B30 795 A24-M2-B30 796 A25-M2-B30 797 A26-M2-B30 798 A35-M2-B30 799 A33-M2-B30 800 A27-M2-B30 801 A28-M2-B30 802 A30-M2-B30 803 A17-M2-B3 804 A31-M2-B3 805 A18-M2-B3 806 A3-M2-B3 807 A37-M2-B3 808 A19-M2-B3 809 A32-M2-B3 810 A11-M2-B3 811 A21-M2-B3 812 A24-M2-B3 813 A25-M2-B3 814 A26-M2-B3 815 A33-M2-B3 816 A5-M2-B3 817 A34-M2-B3 818 A27-M2-B3 819 A28-M2-B3 820 A29-M2-B3 821 A1-M2-B3 822 A8-M2-B3 823 A17-M2-B7 824 A31-M2-B7 825 A18-M2-B7 826 A19-M2-B7 827 A11-M2-B7 828 A21-M2-B7 829 A24-M2-B7 830 A25-M2-B7 831 A26-M2-B7 832 A35-M2-B7 833 A36-M2-B7 834 A33-M2-B7 835 A5-M2-B7 836 A34-M2-B7 837 A27-M2-B7 838 A28-M2-B7 839 A29-M2-B7 840 A8-M2-B7 841 A30-M2-B7 842 A17-M2-B31 843 A31-M2-B31 844 A18-M2-B31 845 A3-M2-B31 846 A19-M2-B31 847 A20-M2-B31 848 A32-M2-B31 849 A11-M2-B31 850 A4-M2-B31 851 A6-M2-B31 852 A23-M2-B31 853 A24-M2-B31 854 A26-M2-B31 855 A5-M2-B31 856 A34-M2-B31 857 A28-M2-B31 858 A8-M2-B31 859 A17-M2-B32 860 A31-M2-B32 861 A18-M2-B32 862 A3-M2-B32 863 A37-M2-B32 864 A19-M2-B32 865 A32-M2-B32 866 A11-M2-B32 867 A21-M2-B32 868 A4-M2-B32 869 A6-M2-B32 870 A23-M2-B32 871 A24-M2-B32 872 A25-M2-B32 873 A26-M2-B32 874 A35-M2-B32 875 A36-M2-B32 876 A5-M2-B32 877 A28-M2-B32 878 A1-M2-B32 879 A8-M2-B32 880 A17-M2-B33 881 A31-M2-B33 882 A3-M2-B33 883 A19-M2-B33 884 A20-M2-B33 885 A32-M2-B33 886 A11-M2-B33 887 A21-M2-B33 888 A22-M2-B33 889 A4-M2-B33 890 A6-M2-B33 891 A24-M2-B33 892 A25-M2-B33 893 A26-M2-B33 894 A35-M2-B33 895 A36-M2-B33 896 A33-M2-B33 897 A5-M2-B33 898 A27-M2-B33 899 A1-M2-B33 900 A8-M2-B33 901 A30-M2-B33 902 A17-M2-B34 903 A31-M2-B34 904 A18-M2-B34 905 A3-M2-B34 906 A19-M2-B34 907 A20-M2-B34 908 A32-M2-B34 909 A11-M2-B34 910 A21-M2-B34 911 A22-M2-B34 912 A4-M2-B34 913 A6-M2-B34 914 A24-M2-B34 915 A26-M2-B34 916 A35-M2-B34 917 A36-M2-B34 918 A33-M2-B34 919 A27-M2-B34 920 A28-M2-B34 921 A1-M2-B34 922 A8-M2-B34 923 A30-M2-B34 924 A17-M2-B35 925 A31-M2-B35 926 A18-M2-B35 927 A3-M2-B35 928 A37-M2-B35 929 A19-M2-B35 930 A20-M2-B35 931 A32-M2-B35 932 A11-M2-B35 933 A4-M2-B35 934 A6-M2-B35 935 A24-M2-B35 936 A26-M2-B35 937 A35-M2-B35 938 A36-M2-B35 939 A28-M2-B35 940 A1-M2-B35 941 A8-M2-B35 942 A30-M2-B35 943 A17-M2-B36 944 A31-M2-B36 945 A18-M2-B36 946 A27-M2-B43 947 A19-M2-B36 948 A20-M2-B36 949 A32-M2-B36 950 A22-M2-B36 951 A4-M2-B36 952 A6-M2-B36 953 A28-M2-B43 954 A24-M2-B36 955 A25-M2-B36 956 A26-M2-B36 957 A35-M2-B36 958 A33-M2-B36 959 A5-M2-B36 960 A27-M2-B36 961 A28-M2-B36 962 A29-M2-B36 963 A1-M2-B36 964 A8-M2-B36 965 A30-M2-B36 966 A17-M2-B37 967 A31-M2-B37 968 A18-M2-B37 969 A19-M2-B37 970 A20-M2-B37 971 A32-M2-B37 972 A11-M2-B37 973 A21-M2-B37 974 A4-M2-B37 975 A6-M2-B37 976 A24-M2-B37 977 A25-M2-B37 978 A26-M2-B37 979 A35-M2-B37 980 A36-M2-B37 981 A33-M2-B37 982 A5-M2-B37 983 A27-M2-B37 984 A28-M2-B37 985 A29-M2-B37 986 A1-M2-B37 987 A8-M2-B37 988 A17-M2-B38 989 A31-M2-B38 990 A18-M2-B38 991 A32-M2-B38 992 A11-M2-B38 993 A21-M2-B38 994 A22-M2-B38 995 A4-M2-B38 996 A26-M2-B38 997 A35-M2-B38 998 A36-M2-B38 999 A5-M2-B38 1000 A34-M2-B38 1001 A27-M2-B38 1002 A28-M2-B38 1003 A8-M2-B38 1004 A30-M2-B38 1005 A17-M2-B39 1006 A31-M2-B39 1007 A18-M2-B39 1008 A3-M2-B39 1009 A19-M2-B39 1010 A20-M2-B39 1011 A32-M2-B39 1012 A11-M2-B39 1013 A22-M2-B39 1014 A4-M2-B39 1015 A6-M2-B39 1016 A23-M2-B39 1017 A24-M2-B39 1018 A25-M2-B39 1019 A26-M2-B39 1020 A35-M2-B39 1021 A36-M2-B39 1022 A33-M2-B39 1023 A5-M2-B39 1024 A27-M2-B39 1025 A28-M2-B39 1026 A1-M2-B39 1027 A8-M2-B39 1028 A30-M2-B39 1029 A19-M2-B40 1030 A20-M2-B40 1031 A32-M2-B40 1032 A11-M2-B40 1033 A21-M2-B40 1034 A4-M2-B40 1035 A24-M2-B40 1036 A25-M2-B40 1037 A26-M2-B40 1038 A35-M2-B40 1039 A36-M2-B40 1040 A5-M2-B40 1041 A27-M2-B40 1042 A28-M2-B40 1043 A1-M2-B40 1044 A8-M2-B40 1045 A30-M2-B40 1046 A17-M2-B41 1047 A18-M2-B41 1048 A19-M2-B41 1049 A32-M2-B41 1050 A11-M2-B41 1051 A21-M2-B41 1052 A24-M2-B41 1053 A25-M2-B41 1054 A33-M2-B41 1055 A5-M2-B41 1056 A28-M2-B41 1057 A1-M2-B41 1058 A17-M2-B42 1059 A31-M2-B42 1060 A37-M2-B42 1061 A19-M2-B42 1062 A20-M2-B42 1063 A32-M2-B42 1064 A11-M2-B42 1065 A21-M2-B42 1066 A4-M2-B42 1067 A6-M2-B42 1068 A24-M2-B42 1069 A26-M2-B42 1070 A34-M2-B42 1071 A28-M2-B42 1072 A1-M2-B42 1073 A8-M2-B42 1074 A1-M2-B43 1075 A17-M2-B6 1076 A3-M2-B6 1077 A19-M2-B6 1078 A20-M2-B6 1079 A32-M2-B6 1080 A11-M2-B6 1081 A22-M2-B6 1082 A4-M2-B6 1083 A6-M2-B6 1084 A24-M2-B6 1085 A26-M2-B6 1086 A33-M2-B6 1087 A5-M2-B6 1088 A28-M2-B6 1089 A8-M2-B43 1090 A17-M2-B43 1091 A31-M2-B43 1092 A18-M2-B43 1093 A3-M2-B43 1094 A19-M2-B43 1095 A20-M2-B43 1096 A32-M2-B43 1097 A11-M2-B43 1098 A6-M2-B43 1099 A24-M2-B43 1100 A38-M2-B41 1101 A39-M2-B8 1102 A39-M2-B34 1103 A45-M2-B24 1104 A41-M2-B24 1105 A42-M2-B24 1106 A43-M2-B24 1107 A45-M2-B26 1108 A42-M2-B26 1109 A44-M2-B26 1110 A45-M2-B27 1111 A42-M2-B27 1112 A43-M2-B27 1113 A44-M2-B27 1114 A41-M2-B28 1115 A43-M2-B28 1116 A44-M2-B28 1117 A45-M2-B29 1118 A42-M2-B29 1119 A44-M2-B29 1120 A45-M2-B8 1121 A41-M2-B8 1122 A42-M2-B8 1123 A43-M2-B8 1124 A44-M2-B8 1125 A45-M2-B10 1126 A42-M2-B10 1127 A43-M2-B10 1128 A44-M2-B10 1129 A45-M2-B17 1130 A41-M2-B17 1131 A42-M2-B17 1132 A43-M2-B17 1133 A44-M2-B17 1134 A45-M2-B30 1135 A45-M2-B3 1136 A41-M2-B3 1137 A42-M2-B3 1138 A45-M2-B7 1139 A42-M2-B7 1140 A43-M2-B7 1141 A44-M2-B7 1142 A45-M2-B31 1143 A44-M2-B31 1144 A45-M2-B32 1145 A41-M2-B32 1146 A42-M2-B32 1147 A43-M2-B32 1148 A44-M2-B32 1149 A45-M2-B33 1150 A41-M2-B33 1151 A42-M2-B33 1152 A44-M2-B33 1153 A41-M2-B34 1154 A42-M2-B34 1155 A44-M2-B34 1156 A45-M2-B35 1157 A41-M2-B35 1158 A42-M2-B35 1159 A43-M2-B35 1160 A44-M2-B35 1161 A45-M2-B36 1162 A41-M2-B36 1163 A43-M2-B36 1164 A44-M2-B36 1165 A45-M2-B37 1166 A41-M2-B37 1167 A42-M2-B37 1168 A43-M2-B37 1169 A44-M2-B37 1170 A45-M2-B38 1171 A41-M2-B38 1172 A42-M2-B38 1173 A43-M2-B38 1174 A44-M2-B38 1175 A41-M2-B39 1176 A42-M2-B39 1177 A43-M2-B39 1178 A44-M2-B39 1179 A45-M2-B40 1180 A41-M2-B40 1181 A42-M2-B40 1182 A43-M2-B40 1183 A44-M2-B40 1184 A45-M2-B41 1185 A41-M2-B41 1186 A45-M2-B42 1187 A42-M2-B42 1188 A44-M2-B42 1189 A44-M2-B6 1502 A54-M2-B24 1503 A46-M2-B24 1504 A47-M2-B24 1505 A48-M2-B24 1506 A49-M2-B24 1507 A50-M2-B24 1508 A51-M2-B24 1509 A52-M2-B24 1510 A53-M2-B24 1511 A54-M2-B25 1512 A48-M2-B25 1513 A49-M2-B25 1514 A51-M2-B25 1515 A52-M2-B25 1516 A54-M2-B26 1517 A46-M2-B26 1518 A47-M2-B26 1519 A48-M2-B26 1520 A49-M2-B26 1521 A50-M2-B26 1522 A51-M2-B26 1523 A52-M2-B26 1524 A54-M2-B27 1525 A46-M2-B27 1526 A47-M2-B27 1527 A48-M2-B27 1528 A49-M2-B27 1529 A50-M2-B27 1530 A51-M2-B27 1531 A52-M2-B27 1532 A53-M2-B27 1533 A54-M2-B28 1534 A46-M2-B28 1535 A47-M2-B28 1536 A48-M2-B28 1537 A49-M2-B28 1538 A50-M2-B28 1539 A51-M2-B28 1540 A52-M2-B28 1541 A54-M2-B29 1542 A46-M2-B29 1543 A47-M2-B29 1544 A48-M2-B29 1545 A50-M2-B29 1546 A51-M2-B29 1547 A53-M2-B29 1548 A54-M2-B8 1549 A46-M2-B8 1550 A47-M2-B8 1551 A48-M2-B8 1552 A49-M2-B8 1553 A50-M2-B8 1554 A51-M2-B8 1555 A52-M2-B8 1556 A53-M2-B8 1557 A54-M2-B10 1558 A46-M2-B10 1559 A47-M2-B10 1560 A48-M2-B10 1561 A49-M2-B10 1562 A50-M2-B10 1563 A51-M2-B10 1564 A52-M2-B10 1565 A53-M2-B10 1566 A54-M2-B17 1567 A46-M2-B17 1568 A47-M2-B17 1569 A48-M2-B17 1570 A49-M2-B17 1571 A50-M2-B17 1572 A51-M2-B17 1573 A52-M2-B17 1574 A53-M2-B17 1575 A46-M2-B30 1576 A47-M2-B30 1577 A48-M2-B30 1578 A49-M2-B30 1579 A50-M2-B30 1580 A51-M2-B30 1581 A46-M2-B3 1582 A48-M2-B3 1583 A49-M2-B3 1584 A50-M2-B3 1585 A51-M2-B3 1586 A52-M2-B3 1587 A53-M2-B3 1588 A54-M2-B7 1589 A46-M2-B7 1590 A47-M2-B7 1591 A48-M2-B7 1592 A49-M2-B7 1593 A50-M2-B7 1594 A51-M2-B7 1595 A53-M2-B7 1596 A47-M2-B31 1597 A49-M2-B31 1598 A50-M2-B31 1599 A51-M2-B31 1600 A52-M2-B31 1601 A53-M2-B31 1602 A54-M2-B32 1603 A51-M2-B32 1604 A54-M2-B33 1605 A46-M2-B33 1606 A47-M2-B33 1607 A48-M2-B33 1608 A49-M2-B33 1609 A50-M2-B33 1610 A51-M2-B33 1611 A52-M2-B33 1612 A53-M2-B33 1613 A54-M2-B34 1614 A46-M2-B34 1615 A47-M2-B34 1616 A48-M2-B34 1617 A49-M2-B34 1618 A50-M2-B34 1619 A51-M2-B34 1620 A52-M2-B34 1621 A53-M2-B34 1622 A54-M2-B35 1623 A46-M2-B35 1624 A47-M2-B35 1625 A48-M2-B35 1626 A49-M2-B35 1627 A50-M2-B35 1628 A51-M2-B35 1629 A52-M2-B35 1630 A53-M2-B35 1631 A47-M2-B36 1632 A48-M2-B36 1633 A49-M2-B36 1634 A50-M2-B36 1635 A51-M2-B36 1636 A52-M2-B36 1637 A53-M2-B36 1638 A46-M2-B37 1639 A47-M2-B37 1640 A48-M2-B37 1641 A49-M2-B37 1642 A50-M2-B37 1643 A51-M2-B37 1644 A52-M2-B37 1645 A53-M2-B37 1646 A54-M2-B38 1647 A46-M2-B38 1648 A47-M2-B38 1649 A48-M2-B38 1650 A49-M2-B38 1651 A50-M2-B38 1652 A51-M2-B38 1653 A52-M2-B38 1654 A53-M2-B38 1655 A54-M2-B39 1656 A46-M2-B39 1657 A47-M2-B39 1658 A48-M2-B39 1659 A49-M2-B39 1660 A50-M2-B39 1661 A51-M2-B39 1662 A52-M2-B39 1663 A53-M2-B39 1664 A54-M2-B40 1665 A46-M2-B40 1666 A47-M2-B40 1667 A48-M2-B40 1668 A49-M2-B40 1669 A50-M2-B40 1670 A51-M2-B40 1671 A52-M2-B40 1672 A53-M2-B40 1673 A54-M2-B41 1674 A46-M2-B41 1675 A47-M2-B41 1676 A49-M2-B41 1677 A50-M2-B41 1678 A51-M2-B41 1679 A52-M2-B41 1680 A53-M2-B41 1681 A54-M2-B42 1682 A46-M2-B42 1683 A47-M2-B42 1684 A48-M2-B42 1685 A49-M2-B42 1686 A50-M2-B42 1687 A52-M2-B42 1688 A53-M2-B42 1689 A54-M2-B6 1690 A47-M2-B6 1691 A48-M2-B43 1692 A48-M2-B6 1693 A49-M2-B6 1694 A49-M2-B43 1695 A51-M2-B6 1696 A52-M2-B43 1697 A53-M2-B6 1698 A47-M2-B43.


14. A method for treating a disease caused by and/or associated with a dysregulated protein kinase activity which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as defined in claim 1, wherein the disease is selected from the group consisting of breast carcinoma and ovarian carcinoma.
 15. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) as defined in claim 1 and, at least, one pharmaceutically acceptable excipient, carrier and/or diluent. 